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Abstract 
 
During the course of the studies outlined in this thesis, a new short and efficient synthesis 
of PK11195 was developed using Pd(0)-mediated reactions to effect the key carbon-carbon 
bond forming reactions.  PK11195 is a ligand that interacts with the translocator protein 
(TSPO) in the brain. During brain injury the concentration of TSPO increases, making 
TSPO an ideal and sensitive biomarker. Using single photon emission computed 
tomography along with [123I]PK11195, medical practitioners are able to visualize the 
receptor. In addition to the synthesis of PK11195, three other analogues were devised 
using the same methodology as for PK11195. Firstly, a Heck reaction was used to form the 
isoquinoline core, followed by a Suzuki reaction to couple the correct phenyl ring.  
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However, PK11195 has some limitations regarding biodistrubution, on crossing the blood 
brain barrier the ligand is not particularly selective and interacts with other receptors.  
Therefore a new class of TSPO ligands, quinoline-2-carboxamides were developed and 
tested for their binding affinity to TSPO. Two successful routes were developed to 
synthesise new iodinated quinoline-2-carboxamides.  The first route involved a two step 
condensation reaction to form the quinoline ring system and the second a 
chlorotrimethylsilane-mediated Friëdlander condensation reaction. 
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The final project of this thesis involved developments towards the total synthesis of 
crispine C.  
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1 Introduction 
 
1.1 Translocator Protein 
 
The translocator protein 18 kDa (TSPO, formerly known as the peripheral benzodiazepine 
receptor) was identified in 1977 when investigators were searching for binding sites for the 
benzodiazepine, diazepam in the rat.1,2 Benzodiazepines bind with high affinity to 
receptors concentrated in the central nervous system and these receptors were named 
GABAa receptors .3 During the same investigation Braestrup and Squires discovered that 
[3H]diazepam bound to sites other than in the central nervous system, and that 
[3H]diazepam had a high affinity to the peripheral tissues in the body including the brain, 
leading to the “peripheral benzodiazepine receptors”.4,5   
 
TSPO is found at high levels on the outer mitochondrial membrane of cells in the 
peripheral organs such as kidney, heart, lung, adrenal cortex, salivary gland, testis or 
ovaries6  as well as at low levels in the brain, primarily associated with the glial cells.7,8 
 
1.1.1 Structure and Function 
 
TSPO is an 18 kDa protein consisting of 169 amino-acids.9 It is highly hydrophobic and 
rich in tryptophan.10 The TSPO appears to be a multimeric 140-200 kDa complex1 with an 
isoquinoline binding subunit (18 kDa), a 32 kDa voltage-dependent anion channel (VDAC) 
also called mitochondrial porin and an 30 kDa adenine nucleotide (ANT) carrier in the 
outer mitochondrial membrane (Figure 1).9,11   
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Figure 1: Multimeric Complex4  Reprinted with permission from J. Med. Chem 2009, 52, 
581. Copyright 2009 American Chemical Society. 
 
Decades of study of mammalian TSPO has showed that this protein is involved in many 
physiological functions, including cholesterol transport,7,12 steroid hormone synthesis, 
7,12,13 cellular proliferation, apoptosis, mitochondrial respiration and chemotaxis.7  It is also 
implicated in a number of nervous system disorders such as cerebral ischaemia, epilepsy, 
nerve injury and neurodegenerative diseases as well as immune system diseases such as 
cancer.14   
1.1.2 TSPO and Neuroinflammation 
 
Levels of TSPO are very low in the body under normal conditions and limited to glial cells 
(astrocytes and microglia).9 Following brain injury, illness or infection, glial cells in the 
brain activate in response to the stimuli and increase TSPO receptor density.15,16 Microglial 
cells respond to any pathological event, through the production and release of 
proinflammatory cytokines such as TNF-α, interleukin-1β and nitric oxide (Figure 2). This 
process in normal brain inflammation allows the brain to respond to changes in its 
environment and dispose of damaged tissue.  However, this useful process sometimes gets 
out of balance and the neuroinflammatory process persists, which cause the overproduction 
of these cytokines, making them neurotoxic.14,17   
TSPO
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Figure 2: Function and Mechanism of TSPO18 Reprinted with permission from Progress 
in Neurobiology 2006, 80, 308. Copyright 2006 Elsevier. 
 
As TSPO concentration increases during brain injury, it makes TSPO an ideal and sensitive 
biomarker for activated microglia.9 This change makes it possible to determine the role of 
neuroinflammation in specific neurological and neurodegenerative conditions.17 These 
findings have prompted researchers to develop radioligands for TSPO, which can be used 
to visualize this receptor.15 One such ligand devised for interaction with TSPO is PK11195. 
 
1.2 TSPO Ligands 
 
Dr Leo Sternbach synthesised the first benzodiazepine, diazepam and introduced it into 
clinical medicine in 1961.3,19 Benzodiazepines are a class of drugs prescribed widely for 
their pharmacological importance in relieving anxiety and insomnia, in addition to having 
a sedative and anticonvulsant effect (Figure 3).20 After discovering that [3H]diazepam 
binds with relatively high affinity (3 nM) to both GABAa and TSPO in rat brain, other 
benzodiazepine derivatives were used to determine the difference between the two 
receptors.  It was found that the 4-chloro derivative of diazepam, Ro5-4864 binds with 
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high affinity to TSPO in rodents and low affinity to GABAa and clonazepam binds with 
high affinity to GABAa and shows low affinity to TSPO.4,21 
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Figure 3: Benzodiazepines 
 
In addition to benzodiazepines, LeFur and co-workers in 1983 detailed a new class of 
compounds called isoquinoline carboxamides (Figure 4).21 They are structurally different 
from benzodiazepines and with a higher selectivity for the TSPO than for GABAa. 
PK11195, 1-(2-chlorophenyl)isoquinoline-3-N-methyl-N-sec-butylcarboxamide, was the 
first non-benzodiazepine ligand found to bind to TSPO with nanomolar affinity, and for the 
last 20 years it is the most commonly used radioligand for this receptor.22 They 
distinguished between PK11195 and Ro5-4864, and classified PK11195 as an antagonist 
and Ro5-4864 as agonist or partial agonist for TSPO.23  
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Figure 4: Isoquinoline Carboxamides 
 
There has been a wide range of ligands developed over the years that all show high affinity 
to the TSPO binding site.  These ligands all share some common features that allow 
researchers to understand the TSPO binding domain better. The common features include a 
fused bicyclic aromatic ring system containing two electronegative boundaries and a freely 
rotating aromatic ring.20 Furthermore, many ligands also contain a third electronegative 
group surrounded by lipophilic substituents.20 
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1.2.1 Ro5-4864 
 
As mentioned above Ro5-4864 (7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-
1,4-benzodiazepin-2-one) binds to TSPO with micromolar affinity, unlike other 
benzodiazepines that bind to GABAa.  Ro5-4864 is dissimilar from its class in that it has 
no anxiolytic or anticonvulsant activity.24 This ligand has been used for many years in 
various experiments, it is however, not used for in vivo studies due to the side effects i.e. 
convulsant in rodents.25 Awad and Gavish in 1987 carried out research on the binding of 
[3H]Ro5-4864 to cerebral cortex and peripheral tissues in various species. They concluded 
that the interaction of the ligand on TSPO is highly species dependant.26 For rat kidney and 
cerebral cortex, [3H]Ro5-4864 showed nanomolar (0.05-30 nM) affinity, but in calf 
cerebral cortex and kidney, binding is negligible.20,26 Ro5-4864 binds to all the components 
in the receptor, VADC, ANT and IBP whereas PK11195 only binds to the IBP 
component.27  
 
Benzodiazepines are bicyclic heterocyclic compounds, with a benzene ring fused to a 
seven-membered ring containing two nitrogen atoms.  Van Dort and co-workers reported a 
synthesis of radioiodinated Ro5-4864 analogues to image TSPO receptor in tumors 
outlined in Scheme 1.28  
 
The first step involved the condensation of aniline-boron trichloride complex with a 
benzonitrile analogue to form the ketimine, followed by acid hydrolysis to give 2-
aminobenzophenone analogue 3.  Next the seven membered ring was formed by reaction 
with glycine ethyl ester hydrochloride to form an imine, then cyclisation gave the desired 
1,4-benzodiazepine analogue 4.  Finally N-methylation using sodium hydride and methyl 
iodide gave 5.   
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Scheme 1: Synthesis of Ro5-4864 
 
Both compounds 5a and 5b were tested for affinity for the GABAa and TSPO binding sites, 
Table 1 shows the results.  From the data, both 5a and 5b show affinity for TSPO, 
therefore substitution of chlorine for iodine makes only a slight difference to the binding 
affinity.  
 
Ligand R1 R2 TSPO  
Ki (nM) 
GABAa 
 Ki (nM) 
Ro5-4864 Cl Cl 7.3 ± 2.3 >1000 
5a I Cl 13.3 ± 4.8 >1000 
5b Cl I 13.6 ± 4.5 >1000 
 
Table 1: Binding affinity of Ro5-4864 
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1.2.2 Imidazopyridines  
 
Imidazopyridines, a group of high affinity TSPO ligands, show similar pharmacological 
action and binding properties to benzodiazepines.20 They have been shown to have the 
ability of stimulating pregnenolone formation from mitochondria and bind to both TSPO 
and GABAa.21,29 The derivative, alpidem, shows high binding across many species, making 
it a promising ligand for TSPO in humans.20 
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Figure 5: Imidazopyridine 
 
Trapani and co-workers designed new analogues of alpidem, in order to improve the 
affinity and selectivity to TSPO (Scheme 2).30,31 Acetamidoimidazo[1,2-a]pyridine 
compounds were prepared by Friedel-Crafts acylation of appropriate aromatic compounds 
with succinic anhydride to give 7. Using ethyl 1,2-dihydro-2-ethoxy-1-
quinolinecarboxylate (EEDQ) as a dehydrating agent, reaction of 7 with appropriate 
dialkylamines gave 8.  Bromination in carbon tetrachloride gave the desired 
bromoketoamides 9.  Lastly condensation of the required substituted 2-aminopyridines 10, 
with the bromoketoamides afforded the required acetamidoimidazo[1,2-a]pyridines 11. 
  17
Z
O
OH
O
Z
O
NR1R2
O
Z
O
NR1R2
O
Br
EEDQ
Br2 / CCl4
R1R2NH
N
Y
X
NH2
N
N
Y
X
O
NR1R2
Z
Z
AlCl3
DMF
6 7 8
910
11
OO O
 
 
Scheme 2: Synthesis of acetamidoimidazo[1,2-a]pyridines  
 
Table 2 shows various analogues of alpidem and their overall yields along with the binding 
affinity to TSPO.   
 
 
Table 2: Binding affinity of alpidem analogues 
 
Trapani and co-workers concluded that 2-phenylimidazo[1,2-a]-pyridine derivatives are 
potent and selective ligands for TSPO and stimulate steroidogenesis in both the brain and 
periphery.   
 
 
 
Compound X Y Z R1 R2 Yield 
(%) 
IC50 
(nM) 
Alpidem Cl H Cl C3H7 C3H7 23 7.90 
11a Cl Cl H C4H9 H 35 6.53 
11b H H Cl C3H7 H 15 6.23 
11c H H H C6H13 C6H13 15 7.72 
11d H NHCOCH3 Cl C3H7 C3H7 42 8.00 
11e H NHCOCH3 H C3H7 C3H7 40 6.59 
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1.2.3 Pyrazolopyrimidines 
 
The pyrazoloprimidine, DPA-713 (N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-
dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide) is structurally closely related to 
alpidem (Figure 6).  In 2001, Selleri and co-workers decided to synthesise compounds that 
were related to alpidem.32 Although, alpidem binds to TSPO (Ki 0.5-7 nM) and GABAa (Ki 
1-28 nM) with nanomolar affinity it was still a good starting point even though selective 
TSPO binding was required.  During the study of alpidem, it was shown that the tertiary 
acetamide moiety was important for hydrogen bond interactions to TSPO and therefore the 
group decided to keep this moiety.  They also decided to investigate the effect of para-
substituents (R) on the phenyl ring and the R1, R2, and R3 positions.  They selected the 
same substituents, H, OCH3, CH3, and Cl but alternated them around the R positions.  One 
compound to show good binding affinity to TSPO and no affinity for GABAa was DPA-
713 (Ki  4.7 nM). 
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Figure 6: Pyrazolopyrimidines 
 
James and co-workers then radiolabelled DPA-713 with carbon-11 in 2005. They 
performed in vivo studies on baboons using positron emission tomography (PET) and it 
proved to have potent and selective activity at TSPO.33 This was the first analogue of its 
class to be radiolabelled and showed promising evidence of being a good ligand for 
imaging studies. 
 
James and co-workers reported a synthesis of DPA-713 starting from commercially 
available methyl 4-methoxybenzoate 12 (Scheme 3).33 Compound 12 was reacted with 
sodium methoxide and acetonitrile at 100 °C to give aroylacetonitrile 13 in 17% yield.  
Next 13 was reacted with N,N-diethylchloroacetamide and sodium iodide in an alkaline 
solution to afford 14 in 64% yield. This was followed by the conversion of 14 to the 
pyrazole 15 by heating under reflux in ethanol with hydrazine hydrate.  The final step 
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involved the condensation of 15 with electrophilic 2,4-pentadione, then closure of the 
pyrimidine ring to form 16 in 93% yield.   
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Scheme 3: Synthesis of DPA-713 
 
1.2.4 Phenoxyphenylacetamides 
 
A more recent class of TSPO ligands described are the phenoxyphenylacetamide 
derivatives, derived by opening the diazepine ring of benzodiazepines (Figure 7).4 
DAA1106, N-(2,5-dimethoxybenzyl)-N-(4-fluoro-2-phenoxyphenyl)acetamide and 
DAA1097, N-(4-chloro-2-phenoxyphenyl)-N-(2-isopropoxybenzyl)acetamide, are selective 
and potent TSPO agonists, with high lipophilicity and anxiolytic effects.4,34 
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Figure 7: Phenoxyphenylacetamide 
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There are a number of subtle differences between DAA1106 and DAA1097, which allows 
an understanding of the TSPO binding site. DAA1097, like PK11195 activates 
steroidogenesis, whereas DAA1106 is unable to activate steroidogenesis alone. Both 
DAA1106 and DAA1097 have the capability to displace PK11195 at nanomolar 
concentrations suggesting that both ligands have the same binding domains.4 
 
Although PK11195 is the oldest and most widely used radioligand for imaging, advances 
in this field over the years have led to DAA1106 analogues which are more effective than 
PK11195.  DAA1106 analogues have been shown to have more potent in vitro binding 
affinity for TSPO and have significant selectivity against other receptors including the 
GABAa.15 PK11195 has low brain uptake, whereas DAA1106 shows higher uptake in in 
vivo studies on rodent and primate brains.15   
 
In 1999, Chaki and co-workers reported their study on binding characteristics of 
[3H]DAA1106 and demonstrated the advantages of this new ligand.35 They performed 
autoradiographic and biochemical studies in the rat brain and found that [3H]DAA1106 
binding is localized in the olfactory bulb, and structures related to cerebrospinal fluid, 
followed by the cerebellum and cerebral cortex.  Their results indicate the same binding for 
[3H]PK11195.  Furthermore, as DAA1106 is not in the same class of compounds as 
PK11195 and benzodiazepine derivatives, Chaki and co-workers postulated that DAA1106 
could have its own binding domain therefore helping to identify the molecular 
characteristics of TSPO.35 They also carried out their studies on rhesus monkeys as well as 
rats and found very little difference in affinity for mitochondrial preparations, just that the 
binding affinity in monkey was slightly lower.  This result suggested that binding for 
DAA1106 is not species dependant and that DAA1106 might also have high affinity for 
human TSPO. 
 
A derivative of DAA1106, FEDAA1106 N-(5-fluoro-2-phenoxyphenyl)-N-(2-(2-
fluoroethoxy)-5-methoxybenzyl)acetamide shows even better TSPO binding (Ki 0.078 nM) 
than DAA1106 (Ki 0.16 nM). FEDAA1106 radiolabelled with fluorine-18 and DAA1106 
with carbon-11 are used as radioligands for PET.  Wang and co-workers from University 
of Indiana, synthesised [11C]FEDAA1106 because of the ease of the radiosynthesis 
compared to fluorine-18. They successfully synthesised and radiosynthesised, 
FEDAA1106 encouraging the use of [11C]FEDAA1106 as a potential radioligand for 
imaging TSPO in the brain.14  
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They reported a synthesis starting form commercially available 2,5-
dihydroxybenzaldehyde 17, which was benzylated using benzyl bromide to give 18 in 32% 
yield (Scheme 4). Alkylation of the hydroxyl group with 1-bromo-2-fluoroethane gave 2-
fluoroethyl ether 19 in 21% yield.  Reduction of the aldehyde then gave 20 and finally 
reaction with phosphorus tribromide gave benzylic bromide 21. 
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Scheme 4: Synthesis of 21 
 
The next key intermediate formed was the acetanilide component, which was prepared 
from 1,4-difluoro-2-nitrobenzene 22. Nucleophilic aromatic substitution with phenol gave 
23 in 99% yield. Reduction of 23 with iron gave aniline 24 in 97% yield, which was then 
acetylated with acetyl chloride to give 25 in 93% yield. 
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Scheme 5: Synthesis of 25 
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To conclude the synthesis, Wang and co-workers, reacted 21 with acetanilide 25 using 
sodium hydride to give compound 26 in 71% yield. The benzyl group was then removed 
by catalytic hydrogenation with 10% Pd/C to give 27 in 66% yield. Finally O-methylation 
of 27 with methyl iodide and sodium hydride gave FEDAA1106 28 in 70% yield.  
 
OBn
O
F
O
F NH
O
O
F N
O
OBn
O
F
O
F N
O
OH
O
FO
F N
O
OCH3
O
F
NaH, DMF
71%
H2, Pd/C
THF,MeOH
66%
NaH, CH3I
DMSO
70%
21 25 26
2728
Br
 
Scheme 6: Synthesis of FEDAA1106 
 
1.3 PK11195 
 
PK11195 is the mostly widely used ligand used to image the TSPO in the brain.  It is 
involved in the inhibition of cell proliferation, induction of apoptosis, stimulates steroid 
synthesis and inhibition of immune response and inflammation.4 PK11195 does not show 
species variation and binding affinity remains high (Kd < 20 nM).36 It is also not affected 
by temperature (4 °C–25 °C) change unlike Ro5-4864, and the affinity of [3H]PK11195 in 
binding to brain cortex and olfactory bulb membranes is constant.37   
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1.3.1 Structure-Affinity Relationships 
 
PK11195 dates back to the early 1980’s from a company in France called Pharmuka 
Laboratories. The first set of analogous, the PK series started with 2-phenylquinolines.  
The first analogue 29, showed fairly good affinity to the GABAa but not to the TSPO 
(Table 3).  The N,N-diethylamide side chain was changed to a more lipophilic group, N-
methyl-N-isobutyl, which led to dramatic loss in GABAa affinity but improved TSPO 
binding.  Changing the nitrogen to a different position also improved TSPO binding, to 45 
nM.38 
 
 
N
N
O
N
N
O
N
N
O
29 30 31  
 
GABAa  IC50 (nM) 50  1000   
TSPO IC50 (nM) 360  100  45  
 
Table 3: Binding affinity of 2-phenylquinolines 
 
Subsequent studies led to the isoquinoline series, where the benzene-fused ring is moved 
towards the freely rotating aromatic ring, greatly improving selectivity.38   
 
N
Cl
N
O
32 (9 nM for TSPO)  
 
It has been well documented that o-chlorophenyl derivative PK11195 is a selective ligand 
for TSPO, from work carried out in 1983 by Le Fur and co-workers.39,40   A review article 
by Bourguignon describes the SAR for PK11195.38 As shown in table 4 the binding 
affinity varies, referring to 33 as the reference compound, if chlorine is placed on the 
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phenyl ring the affinity increases significantly.  Also changing N,N-diethyl group to a more 
lipophilic group N,N-di-n-butyl 33b, the affinity is more favourable and even better for the 
N-methyl-N-isobutyl carboxamide 33c.  By replacing the sec-butyl group on PK11195, to a 
benzyl group 33f the affinity decreases considerably. 
 
A
B
N
O
R1
R2
X
33  
 
Compound A B X R1 R2 Ki (nM) 
33 N CH H Et Et 150 
33b N CH H n-Bu n-Bu 21 
33c N CH H Me i-Bu 2 
33d N CH 2-Cl Et Et 17 
33e N CH 2-Cl Pr Pr 18 
PK11195 N CH 2-Cl Me sec-Bu 9 
33f N CH 2-Cl Me Bn 117 
33g N CH 3-Cl Et Et 9 
33h CH N H Et Et 27 
33i CH N 2-F Me i-Bu 2 
33j N N H Et Et 27 
 
Table 4: Binding affinity of PK11195 analogues 
 
While PK11195 includes a stereogenic centre in its structure, the racemate has the same 
binding affinity for TSPO as the more potent R-enantiomer.   
 
N
N
O
Cl
32  
                                         
                        Table 5: Stereoisomers of PK11195 
Stereoisomer IC50 (nM) 
R,S 9 
S 19 
R 9 
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Shah and co-workers synthesised both enantiomers of [N-methyl-11C]PK11195 (Scheme 7) 
and compared their behaviours for TSPO binding in rats.8 Previously, work with 
radiolabelled PK11195 for in vivo studies used the racemate, however, it is know that 
enantiomers can behave differently. They synthesised both enantiomers from 1-(2-
chlorophenyl)isoquinoline-3-carboxylic acid, firstly by reacting the acid with ethyl 
chloroformate, followed by addition of either R-(-)-sec-butylamine or S-(+)-sec-butylamine 
to form both the R and S enantiomers, respectively. Lastly, radiosynthesis with 
[11C]iodomethane  gave the desired radioligands 36 and 37. 
 
N
OH
O
Cl
EtOCOCl
Et3N
CH3Cl
N
O
O
Cl
OEt
O
N
N
O
Cl
11CH3 N
N
O
Cl
11CH3
2. 11CH3 I
1. S-sec-butylamine
2. 11CH3 I
1. R-sec-butylamine
34
35
36 37  
 
Scheme 7: Synthesis of PK11195 
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The group concluded that both R and S enantiomers bind in vivo to TSPO but discovered 
that more radioactivity is retained in the tissue after intravenous injection of the R-
enantiomer, indicating that it binds with higher affinity to the binding site than the S-
enantiomer. They postulated that the two enantiomers bind differently due to the 
interactions of the chiral sec-butyl groups with a lipophilic domain in the binding site. The 
methyl and ethyl groups on the R-enantiomer would interact with the lipophilic domain, 
whereas the methyl group on the S-enantiomer would be further away from the lipophilic 
domain (Figure 8).  
 
MeNR
Me
H Me
MeNR
Me
Me H
Lipophilic
domian
Lipophilic
domain
R-PK11195 S-PK11195
 
 
Figure 8: Binding of R and S enantiomers of PK11195 
 
1.3.2 X-Ray Crystal Structure of PK11195 
 
Knowing the conformation of PK11195 helps in the understanding of the binding to the 
receptor.  Kubicki and Codding carried out X-ray crystallographic studies of PK11195 and 
found that the crystal structure is highly disordered (Figure 9).41 The methylpropyl 
substituent was found in two different positions and the chloride substituent on the 
chlorophenyl fragment was found in two positions, C2’ and C6’.   
 
 
Figure 9: X-ray crystal structure of PK11195 
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1.3.3 Syntheses of PK11195 
 
In 2002, Janin and co-workers published their synthesis of 1-(2-chlorophenyl)isoquinoline 
as their contribution towards the synthesis of PK11195 as no synthesis had yet been 
published.42 They started from commercially available 2-chlorobenzoyl chloride and 
reacted it with amphetamine in acetonitrile with triethylamine to form ortho-
chlorobenzamide 38. As shown in Scheme 8, Bischler-Napieralski synthesis was used to 
form the isoquinoline core followed by dehydrogenation to the aromatised product 40.  
Firstly, sulfur in decalin was used for the aromatization but only achieved a 25% yield. 
Therefore, excess manganese oxide in benzene, was used and gave 40 in 64% yield.  The 
methyl group was then oxidised to aldehyde 41 using selenium oxide in 1,2 
dichlorobenzene in 97% yield.  Further oxidation of the aldehyde gave the carboxylic acid 
target 34.    
 
 
NH N
Cl
N
Cl
O POCl3, MeCN MnO2, benzene
SeO2
180 oC
N
Cl
N
Cl
OH
O
AgNO3
82%
Cl 37% 64%
97%
O
H
38 39 40
4134
NaOH-EtOH-H2O
 
 
Scheme 8: Synthesis of 1-(2-chlorophenyl)isoquinoline 
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The same group reported another synthesis for the 1-(2-chlorophenyl)isoquinoline-3-
carboxylic acid core for PK11195 (Scheme 9),42 this time starting from commercially 
available dihydroisoquinoline carboxylic acid 42. The acid was converted to the methyl 
ester 43, followed by aromatization using palladium over charcoal in diphenyl ether to give 
isoquinoline 44. Treatment of the isoquinoline core with phosphorus oxybromide afforded 
the brominated product in 82% yield. Bromide 45 underwent a Suzuki reaction with 2-
chlorophenylboronic acid in dimethylformamide, which gave the final product 46 in 90% 
yield.  
 
NH
O
OH
O
MeOH
H2SO4
72%
NH
O
OMe
O
N
OH
OMe
O
Pd/C
250 oC
N
OMe
O
Br
72%
 POBr3
K2CO3
82%
Cl
B(OH)2
N
Cl
O
OMe
Pd(PPh3)4
90%
K3PO4
42 43 44
45
46  
 
Scheme 9: Second synthesis of 1-(2-chlorophenyl)isoquinoline 
 
Janin and co-workers reported two different approaches for the synthesis of the 
isoquinoline core, which would facilitate the preparation of new TSPO ligands.  Their first 
synthesis was achieved in 4 steps with an overall yield of 19% and the second synthesis 
was also achieved in 4 steps but with a better overall yield of 42%.42   
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Another approach to the synthesis of PK11195 was reported by Jaing and co-workers, as 
shown in Scheme 10.43 The first half of the synthesis was developed by Manning and co-
workers44 and the second half uses the same chemistry developed by Janin and co-workers 
(Scheme 8).42 The first intermediate 49 was achieved via base catalysed coupling of 
norephedrine with 2-chlorobenzoyl chloride.  Next, condensation with phosphorus 
pentoxide in o-dichlorobenzene formed the isoquinoline ring 40.  Subsequent steps follow 
the same chemistry as Janin and co-workers to form the carboxylic acid derivative.  The 
amide coupling was achieved via the acid chloride followed by reaction with appropriate 
amines.  This approach for the synthesis of the isoquinoline core is significantly more 
efficient than the approach described by Janin and co-workers.43 
 
OH
NH3+Cl-
COCl
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H
N
O
Cl
47 48
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CH2Cl2
5% NaOH
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N
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O
34
1. SeO2, o-DCB
2. AgNO3, NaOH
    EtOH
N
Cl
N
O
1. SOCl2, CH2Cl2
    DMF (one drop)
2. amine
32  
Scheme 10: Synthesis of PK11195 
  
Later in 2002, Rahman and co-workers published their full synthesis of PK11195 and 
analogues (Scheme 11).45 The first step started with commercially available 2-
chlorobenzophenone 50, which underwent a one-pot reductive amination of the ketone to 
give 52 via imine 51.  Amine 52 was converted to amide 53 by reaction with ethyl 
diethoxyacetate. Firstly the amine was activated by conversion to the aluminium amide by 
treatment with trimethylaluminium, followed by the reaction of the aluminium amide with 
ethyl diethoxyacetate to give 53 in 66% yield.  Cyclisation of 53 using conc H2SO4 gave 
54.  The resulting alcohol was converted to triflate 55 by reaction of alcohol with 
trifluoromethanesulfonic anhydride at ambient temperature.  Finally, [11C]PK11195 was 
prepared by reaction with N-methyl-sec-butylamine and [11C]carbon monoxide in a Pd(0) 
mediated reaction. 
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Scheme 11: Synthesis of [11C]PK11195 
 
Rahman and co-workers synthesised [11C]PK11195 with the carbonyl carbon instead of the 
N-methyl group labelled because using their approach they were able to produce a broad 
range of 11C-labelled analogues of PK11195 by using different amines.  Labelling at the N-
methyl group can sometimes prove difficult depending on the amine groups used whereas 
Rahman’s way prevents this difficulty.  They also found that using their way; the specific 
radioactivity is high (393 GBq μmol–1) compared to labelling at the methyl group (20–96 
GBq μmol–1).   
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1.4 Molecular Imaging 
 
Molecular imaging is a non-invasive imaging technique used to visualise and characterise 
biochemical pathways, molecular interaction, drug pharmacokinetic and 
pharmacodynamics.46,47 A radiotracer is used along with in vivo imaging techniques such 
as Positron Emission Tomograpy (PET) and Single Photon Emission Computed 
Tomography (SPECT). A radiotracer contains a radionuclide and an organic ligand that is 
selective and has high binding affinity for the required binding site.  The ligand that is 
radiolabelled should also have low non-specific binding, good blood-brain barrier 
penetration, antagonist action and slow metabolism.48   
 
Choosing the right radionuclide to use to label the ligand is important. The half-life of the 
radionuclide is a major factor in choosing the correct isotope; half-life is defined in two 
parts, physical half-life and biological half-life. The physical half-life is the time taken for 
half the atoms to disintegrate and biological half-life depends on the excretion from the 
body.   If the half-life is short then it needs to be produced onsite and administered straight 
away. Similarly, if the half-life is too long, then it can still be in the patient after the scan is 
finished, thereby affecting the patient and other people around them.49 
 
1.4.1 PET 
 
A PET scanner is used to detect the gamma rays leaving the body after a radioactive tracer 
has been injected, providing 3D information of the binding site.  When the patient is 
injected with the radioactive tracer it travels to and binds to the required receptor. The 
radioisotope starts to decay and emits a positron (Figure 10).  The positron interacts after a 
short distance with an electron from the surrounding tissue resulting in annihilation 
producing two gamma photons of 511 KeV, emitted at 180o to each other.50  A ring of 
detectors surrounding the patient detects the photons and constructs a tomographic image 
of the required site, resulting in 3D image of the tissue.46  PET uses isotopes with short 
half-lives, e.g. carbon-11 (20.3 min), nitrogen-13 (10 min), oxygen-15 (~ 2 min) and 
fluorine-18 (109.8 min),7 these isotopes are relatively small and are already present in the 
compound. They are useful for monitoring processes that are finished within a short time 
but are less useful at imaging at later times as the radioactive isotope has significantly 
decade resulting in poor analysis.47 Due to the short half-lives of the isotopes used there 
needs to be a cyclotron on site to generate these isotopes, which can be expensive. 
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However, the PET has a great advantage with respect to sensitivity (pico- to nanomolar) 
and resolution to measure receptor density and interactions in vivo. It has gained clinical 
popularity over the years, with PET- based studies reaching 3.2 million.47,50   
 
 
 
Figure 10: Fundamental principle of PET47 Reprinted with permission from Chemical 
Reviews 2010, 110, 2858.  Copyright 2010 American Chemical Society. 
 
1.4.2 SPECT 
 
Although SPECT imaging has much lower detector efficiency and less quantitative 
accuracy than PET, it is more practical and has wider clinical applications.51 The isotopes 
that are used have longer half-lives e.g. iodine-123 (13 h) and technetium-99 (6 h), 
therefore this allows the radioisotopes to be produced away from the site of use and 
transported when required.  Due to the longer half-live, the observation time frame can be 
widened, allowing observation of biological processes in vivo over several hours or days 
after the labelled ligand has be injected.50  A disadvantage of SPECT is the use of a large 
iodine atom that affects the binding and lipophilicity of the ligand.   SPECT scanners use 
radionuclides that decay emitting single photons (gamma rays) at a range of angles.  The 
cameras rotate 360o around the patient and image reconstruction techniques are used to 
form a 3D image.49 An example of a SPECT scanner is shown in Figure 11. 
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Figure 11: SPECT Scanner 
1.4.3 Clinical Use 
Previously, the only way for medical practitioners to detect neurological and 
neurodegenerative damage to the nervous system was to carry out biopsy or post-mortems.  
However, due to advances in technology, brain damage and inflammation in 
neurodegenerative diseases can be visualised in living humans through the use of PET or 
SPECT with suitable ligands. These techniques have the potential to clarify the 
relationship between changes in the receptor with progress of certain diseases.48   The 
information would allow more effective diagnosis, analysis of progression and determine 
different approaches to take in the treatment of each individual disease.4   
 
Parkinson’s disease is one neurodegenerative disease diagnosed using a SPECT scanner.  
The images shown in Figure 12 shows the progression of Parkinson’s disease in the brain, 
the left image is that of a normal brain, image B and C shows mild Parkinson’s symptoms 
and D shows a patient with chronic Parkinson’s disease.52 
 
               A                                  B                                  C                                    D 
 
Figure 12: Brain images of the progression of Parkinson’s disease 
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1.4.4 Radiotracers for TSPO 
 
Both PET and SPECT have been used widely along with the ligand, PK11195 to image the 
TSPO receptor.  PK11195 has been labelled with tritium-3, carbon-11 and iodine-123 for 
in vitro and in vivo studies.  PK11195 was first labelled with carbon-11 by Camsonne and 
co-workers in 1984, for use with PET to investigate the use of PK11195 as a new 
radiopharmaceutical.53 They methylated the N-desmethyl analogue with [11C]iodomethane 
in 45 minutes and obtained a high specific activity of 769 Ci/mmol.  Radiolabelling of 
PK11195 led to noninvasive investigation of cardiac receptors which before was otherwise 
impossible.54 Charbonneau and co-workers were the first to successfully perform in vivo 
studies to investigate the TSPO binding sites in human and dog hearts, using Camsonne’s 
method of radiolabelling PK11195.54 
 
A few years later and after the success of [11C]-PK11195, Gildersleeve decided that a 
radioiodine labelled analogue of PK11195 might be beneficial for the use with SPECT 
imaging of TSPO.55  They synthesised [125I]PK11195 via solid-state interhalogen exchange 
(Scheme 12).  Using a vial containing 3 mm glass beads, PK11195, ammonium sulfate, 
[125I]sodium iodide and sodium hydroxide in 1:2 ethanol/water was  heated for 20 minutes.  
They achieved their synthesis in a short time and the product was obtained in 50-76% 
radiochemical yield, >94% radiochemical purity and a good specific activity of 15-17 
Ci/mmol.    
 
N
Cl
O
N
N
I125
O
N
Na125I, (NH4)2SO4
230 oC
32  
Scheme 12: Synthesis of [125I]PK11195 
 
As previously mentioned chlorine and fluorine in the ortho position exhibit high affinity 
binding for TSPO but there have been no studies on the use with bromine or iodine.  
Furthermore, the use of iodine would allow the use of SPECT imaging. Using 
iodine/SPECT would not require an on-site cyclotron. Gildersleeve reported that [125I]-
PK11195 in rat glioma had the same high specificity and affinity as PK11195 and would 
be a good tool for in vivo studies in the future.55 
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In 1996 Gildersleeve and co-workers attempted to radioiodinate PK11195 again but using 
iodine-123, however this was ineffective because of its low yield and the trouble to remove 
unreacted chlorinated material.56 Therefore, I-PK11195 and the [123I]-PK11195 were 
synthesised (Scheme 13).  The synthesis of I-PK11195 was achieved in an overall yield of 
40%. The first step was the condensation of 2-iodohippuric acid 57 with benzaldehyde 58 
to give 59 in 57% yield.  Next, aluminium trichloride-mediated rearrangement of 59 gave 
isoquinoline-3-carboxylic acid 60, followed by reaction of the acid with ethyl 
chloroformate to form the activated ester.  Finally, reaction with N-methyl-sec-butylamine 
gave 61 in 94% yield.  The radiosynthesis was carried out as before with a >60% isolated 
radiochemical yield, >99% radiochemical purity and specific activity of 233-348 
mCi/mmol. 
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Scheme 13: Synthesis of [123I]PK11195 
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1.5 Proposed research 
 
Although [123I]PK11195 is being used successfully for SPECT imaging, the syntheses of 
PK11195 are long and low yielding and not very flexible. The radiosynthesis is also not 
very effective and previous synthesis uses solid state interhalogen isotope exchange which 
suffers from low activity.  This project aims to develop a novel, more efficient synthesis of 
PK11195 and will investigate the different methods of radioiodination, in order to obtain a 
more rapid and efficient method that will give a high radiochemical yield, a high 
radiochemical purity and a high specific activity.   
 
The second part of this research is to develop a new class of TSPO ligands, quinoline-2-
carboxamides.  Despite PK11195 being the most widely used isoquinoline ligand, there are 
some limitations regarding biodistribution. On crossing the blood brain barrier the ligand is 
not particularly selective and interacts with other receptors.   
 
The aims of the PhD project were: 
 
• To develop a short efficient synthesis of PK11195 analogues (Figure 13). 
 
• Investigate new reactions for the radiosynthesis of [123I]PK11195. 
 
• Generate a small library of iodinated quinoline-2-carboxamides as new SPECT 
ligands for TSPO. 
 
• Perform binding assays to check compounds for affinity with TSPO. 
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Figure 13: Analogues of PK11195 and quinoline-2-carboxamides 
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2 Results and Discussion 
2.1 The Synthesis of PK11195 and Analogues 
 
Early syntheses of PK11195 are relatively long, inefficient and limited to the number of 
analogues that can be prepared. The first aim of this project was to devise a synthesis that 
is short and efficient but also flexible enough to prepare various analogues from a common 
intermediate. Including PK11195, three other derivatives were synthesised that could be 
radioiodinated for SPECT imaging (Figure 14). 
 
N
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Figure 14: Analogues of PK11195 
 
The same synthetic route for PK11195 was adapted to form bromo-analogue 63, which 
was then used to synthesis iodo-analogue 61 using a copper catalysed, aromatic halogen 
exchange reaction.  The last analogue that was synthesised was organostannane derivative 
64, again synthesised from the bromo-analogue.   
 
The next aim of the project was to synthesise [123I]PK11195 from the bromo and 
organostannane derivatives and investigate the best method of radioiodination. Previous 
methods are not very efficient, therefore the aim was to obtain a rapid and efficient 
synthesis of [123I]PK11195 with a high specific activity and a high isolated radiochemical 
yield.   I-PK11195 was synthesised as a standard for HPLC to check if [123I]PK11195 had 
been made successfully.   
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2.1.1 Retrosynthetic Analysis of PK11195 
 
The proposed retrosynthetic analysis of PK11195 is shown in Scheme 14.  Disconnection 
of the amide side chain leads back to carboxylic acid 34.  Further disconnection of the 2-
chlorophenyl ring gives 45, followed by functional group interconversion of the halide to a 
carbonyl group, 67.  Isoquinolin-1-one 67 can be prepared from commercially available 
methyl 2-iodobenzoate 69 and methyl 2-acetamidoacrylate 68.    
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Scheme 14: Retrosynthesis of PK11195 
 
There are two key reactions in the formation of PK11195, firstly a Heck reaction to form 
the isoquinoline core and a Suzuki reaction to couple the 2-chlorophenyl ring.   
 
2.1.2 Synthesis of PK11195 
 
As shown in Scheme 15, the synthesis of PK11195 started from commercially available 
methyl 2-iodobenzoate 69.   A one-pot procedure developed by Chattopadhyay and co-
workers,57 was used to couple 68 and 69 to give methyl isoquinolin-1-one-3-carboxylate 
67 in 65% yield.  Initially the reaction was carried out in N,N-dimethylformamide (DMF) 
but gave a poor yield of 23%.  Acetonitrile was then used improving the yield to 65%.  The 
reaction proceeds via a palladium(0) catalysed Heck type arylation of 68 and 69, to give 
intermediate 70, followed by cyclisation through nucleophilic attack of the acetamide on 
the ester carbonyl and loss of N-acetyl group to give 67.58  For the Heck reaction, 
conditions developed by Jeffery were used, involving tetrabutylammonium chloride as the 
phase transfer agent, sodium hydrogen carbonate as a base and catalytic palladium 
acetate.59 
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Scheme 15: Synthesis of methyl isoquinolin-1-one-3-carboxylate 67 
 
Palladium-catalysed coupling reaction of an alkene with an organic halide was first 
reported by Mizoroki and Heck in the 1970’s.60 The reaction is very versatile and a wide 
range of olefins and aryl species have been reported to form a new alkene bond.  Scheme 
16 shows the general transformation of a Heck reaction, where R1 can be aryl, vinyl or 
allyl and X can be a halide or triflate.  
  
R1 X
R2 Pd(II) or Pd(0)
Base
R1
R2 HX
 
Scheme 16: General Heck reaction 
 
The reaction occurs via a palladium-catalysed cycle, as shown in Scheme 17.60 Firstly 
oxidative addition takes place in which the palladium(0) inserts between the aryl halide 
bond to form complex A, followed by insertion of the alkene into Pd-R1 bond to give C.  
Subsequent β-hydride elimination yields the desired double bond D, and removes the 
palladium species. Finally the base is used to convert the palladium(II) complex back to 
palladium(0).   
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          Scheme 17: Palladium-catalysed Heck reaction 
  40
The next key stage of the synthesis involves the use of the Suzuki cross-coupling reaction.  
A Suzuki reaction is used to couple various boronic acids to aryl or vinyl halides using a 
palladium catalyst.61 In order to carry out this reaction, oxoisoquinoline 67 was initially 
converted using phosphorus(V) oxybromide to the required halide 45 in a 71% yield 
(Scheme 18).  The reaction proceeds via the enol tautomer.  The hydroxyl group attacks 
the phosphorus reagent to make an O-P bond at the same time as displacing a bromine 
atom.  The nucleophilic bromine then attacks the carbon and displaces the phosphorus 
species generating a P=O bond thereby driving the reaction to completion. 
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Scheme 18: Synthesis of 45 
 
Having formed the bromide intermediate 45, a Suzuki reaction was then used to couple 2-
chlorophenylboronic acid to compound 45 using tetrakis(triphenylphosphine)palladium(0) 
as the catalyst and potassium phosphate as the base in DMF (Scheme 19). The reaction was 
initially attempted using a co-solvent system of toluene/ethanol and sodium carbonate in 
water but was unsuccessful with a very poor yield of 9%.  Therefore, the conditions shown 
in Scheme 19 proved to be a better alternative to form 1-(2-chlorophenyl)isoquinoline-3-
carboxylate 46 in 67% yield. 
 
N
CO2Me
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CO2Me
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45 46  
Scheme 19: Synthesis of 1-(2-chlorophenyl)isoquinoline-3-carboxylate 46 
 
The reaction mechanism for the Suzuki reaction proceeds via a catalytic cycle similar to 
the Heck reaction but with another key step, transmetallation.  Shown in Scheme 20 is the 
catalytic cycle for the formation of 1-(2-chlorophenyl)isoquinoline-3-carboxylate 46.  
Initially, oxidative addition of palladium(0) complex into the aryl halide bond of 45 takes 
place to form a palladium(II) species.  The additional key step, transmetallation is slow, 
which allows the coupling of 2-chlorophenylboronic acid to 45, followed by reductive 
elimination to give required product 46 and regeneration of palladium(0).  
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Scheme 20: Suzuki reaction 
 
The second half of the synthesis required the coupling of an appropriate amine side chain.  
Hydrolysis of methyl ester 46 gave carboxylic acid 34 in excellent yield of 96% (Scheme 
21).  Coupling of the carboxylic acid 34 and an amine was initially attempted using N-
methyl-sec-butylamine using the standard coupling reagents, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) and 4-dimethylaminopyridine (DMAP). 
Coupling of N-methyl-sec-butylamine was also attempted using the acid chloride from 34. 
However, these reactions gave either the desired product in very low yield (10%) or just 
starting material.  An alternative approach used by Cappelli and co-workers proved very 
efficient.62 Reaction with oxalyl chloride to form the acid chloride and in situ reaction with 
sec-butylamine gave 71 in 90% yield.  To complete the synthesis, the secondary amide was 
converted into the required tertiary amide by N-methylation using sodium hydride and 
methyl iodide to give 32 in 84% yield.   
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Scheme 21: Completion of PK11195 32 
 
After the methylation of secondary amide 71 the NMR spectra showed the presence of 
rotamers in both proton and carbon spectra.  This occurs because the amide bond is able to 
rotate and the lone pair of electrons on the nitrogen is delocalized into the carbonyl group 
generating cis and trans isomers (Scheme 22).  The NMR spectrum shows signals for both 
the cis and trans conformations resulting in more than one peak for each proton and carbon. 
In general, rotation of the amide is so fast that there should only be one conformation but 
because rotation is slow on the NMR timescale there are two conformations. Shown in 
Figure 15 is the 1H NMR spectrum for PK11195, showing the presence of two rotamers.  
The final step completed the six step synthesis of PK11195 to give the target compound in 
a 22% overall yield.  
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Scheme 22: Cis and trans isomers of PK11195 
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Figure 15: NMR of PK11195 
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2.1.3 Synthesis of Bromo-Analogue 63 
 
 
Having established the route, the next aim was to prepare other analogues using the 
chemistry already developed.  To prepare the iodo-analogue, the bromo-derivative was 
prepared first.  This was achieved exactly the same way as PK11195, using 2-
bromophenylboronic acid to yield 72 in 60% (Scheme 23). 
 
N
CO2Me
Br
N
CO2Me
Br
45
72
B(OH)2
Br
  Pd(PPh3)4, 
K2PO4
DMF
60%  
Scheme 23: Synthesis of 72 
 
Hydrolysis of the methyl ester 72, gave carboxylic acid 73 in 91% yield.  Reaction of 
carboxylic acid 73 with oxalyl chloride followed by in situ reaction with sec-butylamine 
gave 74 in a 60% yield.   Again, completion of the synthetic route involved N-methylation 
using prior conditions to form bromo-analogue 63 in an excellent 91% yield. 
 
N
CO2Me
Br
N
CO2H
Br
N
Br
N
H
O
NaOH
EtOH/H2O
91%
72 73
74
1. (COCl)2, CH2Cl2 
    DMF (Cat).
2.
60%
N
Br
N
O
63
NaH, MeI
THF
91%
H2N
 
 
Scheme 24: Synthesis of Br-PK11195 
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2.1.4 Iodo-Analogue 61 
 
As shown in Scheme 25, the iodo-analogue was prepared using a copper-catalysed 
aromatic Finkelstein reaction, using conditions originally published by Klapars and 
Buchwald.63  Bromide 63 was reacted with sodium iodide and catalytic amounts of copper 
iodide and the diamine ligand N,N-dimethylethylenediamine at high temperature.  This 
gave iodide 61 in 63% yield.   
 
N
Br
N
O
63
N
I
N
O
61
MeHN NHMe
CuI, NaI, 
Butan-1-ol
63%
 
Scheme 25: Synthesis of 61 
 
The reaction mechanism for the halogen exchange is not fully understood.  One proposed 
mechanism as shown in Scheme 26, path A, occurs via a 4-centred transition state.64  
Another plausible mechanism is a cross coupling pathway (path B). Oxidative addition of 
the metal between the aryl halide bond, followed by ligand exchange to introduce the new 
halide.  Finally reductive elimination to give the required product. 
 
X
MY
Y
MXX
Y
M
 
Path A 
 
X M
Ln
X M
Ln
Y
Y
LnM +Y
−X
−LnM
 
Path B 
 
Scheme 26: Halogen exchange reaction 
 
Another approach to incorporate the iodide was successfully achieved by addition of the 
iodide before the coupling of the amide side chain (Scheme 27).  The copper-catalysed 
halogen exchange reaction involving bromide 72 gave the iodinated butyl ester analogue 
75 in 52% yield. Ester hydrolysis gave 60.  Reaction with sec-butyl amine followed by N-
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methylation gave the required iodo-analogue 61.   This alternative route was investigated 
as analysis of the reaction described in Scheme 25 by NMR spectroscopy proved difficult 
to follow due to the presence of rotomers.  Thus, incorporation of the iodine atom at the 
ester stage allowed clearer analysis as to when the reaction was complete and may be 
useful in generating other amide analogues of PK11195. 
 
N
CO2Me
Br
N
CO2Bu
I
N
N
O
I
1. NaI, CuI
butan-1-ol, 52%
MeHN NHMe
NaOH, EtOH
1. (COCl)2, CH2Cl2 
    DMF (cat).
sec-butylamine
2. NaH, MeI
48%
72 75
61
74%
89%
N
CO2H
I
60
Scheme 27: Synthesis of Iodo-PK11195 
 
2.1.5 Synthesis of Organostannane-Analogue 64 
 
The last target from the PK11195 series was the organostannane derivative.  Initial 
attempts using a palladium(0)-catalysed procedure developed by Katsifis and co-workers,6 
with hexabutylditin and iodo-analogue 61 were unsuccessful (Scheme 28).  Instead of 
forming the required product 77, the reduced product 76 was recovered. It was proposed 
that failure of this reaction was probably due to steric hindrance associated with the ortho-
iodo position and the bulky hexabutylditin reagent.  
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Scheme 28: First attempt of the synthesis of 64 
 
With the failure of the reaction above, another method was adopted. Homes and co-
workers were able to convert an aromatic bromide to the trimethylstannyl derivative using 
the same reaction conditions as Katsifis.65  So, instead of using the iodo-analogue, the 
bromo-analogue was used and the less bulky hexamethylditin reagent (Scheme 29).  The 
reaction gave organostannane 64 in a low 13% yield.  The reaction was very low yielding 
and not optimised at the time as the amount of 64 prepared by this method was sufficient 
for the radiosynthesis study. 
 
Pd(PPh3)4
toluene
N
N
O
Br
63
N
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SnMe3
64
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Scheme 29: Synthesis of organostanne-analogue 64 
 
2.1.6 Radiosynthesis of [123I]PK11195 
 
Our collaborator, Dr S Pimlott at the Department of Clinical Physics, carried out the 
radiosynthesis of the PK11195 analogues.  The aim was to develop the radiosynthesis of 
[123I]PK11195 in a rapid and efficient method with high specific activity and radiochemical 
yield.  
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The Br-PK11195 was radiolabelled using a solid-state interhalogen exchange reaction, a 
modification of the technique previously called solid-state isotopic exchange developed by 
Gildersleeve and co-workers.17,56  Organostannane analogue 64 was radiolabelled via 
electrophilic iododestannylation using peracetic acid or chloramine-T as an oxidant 
(Scheme 30). 
 
N
N
O
Br
63
N
N
O
SnMe3
64
N
N
O
I123
62
Halogen
exchange
Iodo-
destannylation
Na123I
Scheme 30: Radiosynthesis of [123I]PK11195 
 
With reference to table 6,17 63 was radiolabelled to give [123I]PK11195 with a slightly 
improved radiochemical yield, radiochemical purity and specific activity than using 
PK11195. However, the reaction time is also important and the reaction with Br-PK11195 
63 took more than double the time of that with PK11195.  Compared to I-PK11195 61, Br-
PK11195 63 was labelled with a reduced isolated radiochemical yield and higher specific 
activity and again the reaction time was longer. 
 
N
X
O
N
X=Cl, 32
    Br, 63
      I,  61
N
I123
O
N
Halogen 
exchange
Na123I
62
 
 Radiochemical  
yield (%) 
Isolated radiochemical 
yield (%) 
Radiochemical 
purity (%) 
Specific activity 
(Ci/μmol) 
Rxn time 
(min) 
Br 66.0±4.0  41.3±11.2  >99 1.9±0.7  45 
Cl 50-76 10-20 >94 0.26-0.91 20 
I - >60 >99 0.23-0.35 30 
 
Table 6: Halogen exchange reaction 
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The electrophilic iododestannylation technique using organostannane 64 proved to be very 
efficient (Table 7).  There was a significant increase in the radiochemical yield and isolated 
radiochemical yield compared to the halogen exchange method.  The use of chloramine-T 
as the oxidant was more beneficial as the reaction time dropped dramatically to 5 minutes 
producing [123I]PK11195 62 with an excellent specific activity of 25.5 Ci/μmol.  One of 
the most important aspects in radiolabelling a ligand is to gain high specific activity.  The 
higher the specific activity the less dosage is needed to be injected into the patient. 
 
N
SnMe3
O
N
N
I123
O
N
Iodo-
destannylation
peracetic acid or
chloramine T
64 62
Na123I, EtOH
 
Reagent Radiochemical  
yield (%) 
Isolated 
radiochemical yield 
(%) 
Radiochemical 
purity (%) 
Specific 
activity 
(Ci/μmol) 
Rxn time 
(min) 
Peracetic 
acid 
92.3±5.1  72.4±9.8  >99 8.3±0.3  25 
Chloramine 
T 
      97.6±0.3  83.9±4.1  >99 25.5±7.4  5 
 
Table 7: Electrophilic iododestannylation 
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2.2 Second Generation Quinolinecarboxamides 
 
As mentioned before, PK11195 is the mostly widely used ligand for SPECT imaging but 
has a number of limitations regarding biodistribution.  The high lipophilicity and low 
bioavailability means that on crossing the blood brain barrier the ligand is not particularly 
selective and interacts with a number of other receptors.66  In 1997, the Cappelli group 
synthesised a wide range of PK11195 derivatives and tested them for their affinity with 
TSPO.62 They discovered that the derivative quinoline-2-carboxamides had better affinity 
for TSPO and showed potential in biodistribution (i.e. they cross the blood brain barrier).  
The group then radiolabelled various analogues of quinoline-2-carboxamides with carbon-
11 for PET imaging.66 However there has been no reported synthesis of quinoline-2-
carboxamides for SPECT imaging.  Therefore, the aim of this stage of the project was to 
develop a small library of iodinated quinoline-2-carboxamides (Figure 16) and test them 
for affinity with TSPO. 
 
N
I
N
O
N
N
O
I
N
N
O
I
78 65 66  
Figure 16: Second generation quinolinecarboxamides 
 
The second generation ligands retain some of the important features that are needed to bind 
to the receptor. The quinoline and phenyl moiety are needed to bind into the lipophillic 
binding pockets in TSPO and the amide is essential for binding in the hydrophobic region 
of TSPO.  The addition of the 3-methyl substituent was to increase the rigidity of the 
compound, preventing the phenyl ring from rotating and improving binding affinity.  It 
was proposed that compounds 78 and 65 could be further modified by replacing sec-
butylamine with other amines to try and improve binding affinity.  Compound 66, with the 
iodide attached to the amide side chain was devised to probe the binding pocket of the 
amide side chain. Also the iodide would be easier to radiosynthesise as it is not hindered 
by any other part of the compound. 
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2.2.1 Retrosynthetic Route of Quinolinecarboxamide 78 
 
The proposed route to synthesis compound 78 utilises some of the chemistry used to 
synthesis PK11195. The retrosynthetic analysis of 78 is shown in Scheme 31. Firstly 
disconnection of the amide bond leads back to carboxylic acid intermediate 79, followed 
by further disconnection of the phenyl ring to give 80. Next functional group 
interconversion of the halide 80 gives hydroxyl compound, 81.  Formation of the quinoline 
carboxamide core can be prepared from commercially available aniline and diethyl 
oxalpropionate. 
 
N
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N CO2H
I
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CO2Et
N
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CO2Et
NH2 EtO2C CO2Et
O
78 79
80
818283
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Scheme 31: Reterosynthesis of 78 
 
2.2.2 Synthesis of Quinolinecarboxamide 78 
 
The first step in the synthesis of quinolinecarboxamide 78 was to prepare the quinoline 
carboxamide core.  This was achieved in two steps by condensation of aniline with diethyl 
oxalpropionate followed by acid-mediated cyclisation of the imine to form 81 in 53% yield 
(Scheme 32).67,68 This transformation is known as Combes quinoline synthesis (cf. Conrad-
Limpach reaction).67  
 
NH2
EtO2C CO2Et
O
N CO2Et
CO2Et
N
OH
CO2EtDean-Stark
PPA
120 °C
53%cyclohexane
p-TsOH
83 82 84
81
Scheme 32: Synthesis of 81 
 
  52
The reaction was carried out using Dean-Stark apparatus to remove water that was 
produced from the condensation of aniline and diethyl oxalpropionate.  Initially, the 
reaction was attempted using benzene as the solvent but this did not go to completion.  The 
reaction was repeated with increased temperature, but still did not go to completion. Next 
toluene was used with molecular sieves, to help remove water but still no improvement. A 
procedure reported by Bradbury and co-workers allowed the synthesis of imine 84, this 
was achieved using cyclohexane and catalytic amount of p-toluenesulfonic acid.67  
Although imines are normally too unstable to purify on a silica column, imine 84 was 
thought to be stable enough to column due to the conjugation from the aryl and ester 
groups. However, after completion of the column, the NMR spectrum showed only starting 
material indicating that the imine had hydrolysed on the silica column.  To overcome this, 
the imine was taken onto the next step without purification.    The next step occurs via an 
acid catalysed cyclisation using polyphosphoric acid to form quinoline compound 81 in 
53% over two steps.68   
 
Formation of the imine 84 as shown in Scheme 33, occurs via nucleophilic attack of the 
carbonyl to form intermediate 85.  Proton transfer and dehydration then gives imine 84.   
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Scheme 33: Mechanism of the formation of imine 84 
 
To conclude the formation of the quinoline ring system, the strong polyphosphoric acid 
aids the cyclisation by protonating the carbonyl group, followed by electrophilic aromatic 
substitution to form the ring (Scheme 34).  Next, regeneration of aromaticity, elimination 
of ethanol and finally keto-enol tautomerisation, formed product 81.   
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Scheme 34: Cyclisation of 84 to form 81 
 
The next stage in the synthesis uses the same chemistry already used for the formation of 
the isoquinolines.  Conversion of 81 to the bromide using phosphorus oxybromide gave 80 
in 84% yield.  A Suzuki cross coupling reaction was used to couple 2-bromophenylboronic 
acid to compound 80, using tetrakis(triphenylphosphine)palladium(0).  The reaction was 
successful and gave 91 in 75% yield.      
  
N CO2Et
OH
POBr3
84%
N CO2Et
Br
N CO2Et
Br
K3PO4
Pd(PPh3)4
B(OH)2
Br
75%
81 80 91  
Scheme 35: Synthesis of 91 
 
Completion of the synthesis of 78, involved coupling of the appropriate amine side chain 
and a copper-catalysed halogen exchange reaction to introduce the iodide moiety.  Based 
on previous work during the synthesis of PK11195 32, the iodide was introduced before 
the coupling of the amine.  Therefore, to complete the quinoline carboxamide 78, the 
copper-halogen exchange reaction was undertaken first (Scheme 36).  The reaction was 
carried out using the same conditions developed for the iodination of PK11195.  The only 
modification was a change of solvent of butanol to ethanol. This was because previously, 
the reaction at the ester stage underwent transesterification to produce the butyl ester.  This 
is not an issue but can be avoided with the use of ethanol.  Unfortunately, the reaction was 
ineffective and only starting material was recovered after five days.   
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Scheme 36: Iodination of 91 
 
Another approach was attempted but using the carboxylic acid derivative instead (Scheme 
37).  The ethanol was exchanged for dioxane and hexamethyldisilazane was added to the 
reaction mixture.  Since the carboxylic acid derivative was used, hexamethyldisilazane was 
included to convert the carboxylic acid to a more soluble trimethylsilyl ester, which could 
be cleaved during the work-up.63  Again, the reaction did not work and starting material 
was recovered.  Another attempt involved using butanol as the solvent in the reaction. 
However, this also showed no reaction and thus, this synthetic approach was abandoned. 
 
N CO2H
Br
CuI, NaI
dioxane
MeHN NHMe
N CO2H
I
X
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93 79
N CO2Et
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Scheme 37: Iodination of 93 
 
One possible explanation for the reaction not working could be due to the steric hindrance 
of the methyl substituent at position 3 of the quinoline ring which is in close proximity to 
the bromine atom.   
2.2.3 3-Iodomethylquinoline-2-carboxamides 
 
With the unsuccessful completion of quinoline carboxamide 78, the next aim was to 
synthesise other analogues, with the incorporation of the iodide atom at the 3-methyl 
position of the quinoline ring (e.g. 65).   
 
N
I
N
O
65  
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Utilising the same chemistry as before the synthesis of quinoline carboxamide 65 starts 
from condensation of aniline and diethyl oxalpropionate to form 81 (Scheme 38).  
Bromination followed by a Suzuki cross coupling reaction would give intermediate 94.  
Next coupling of the amide side chain will give compound 95 and finally bromination at 
the methyl substituent, followed by conversion to iodide would give 65. 
 
NH2
O
EtO2C CO2Et
N CO2Et
OH
N CO2Et
1. Dean-Stark
    cyclohexane
    p-TsOH
2. PPA
1. POBr3
2. K3PO4
    Pd(PPh3)4
B(OH)2
83 82
81
94
N
95
N
O
1. NaOH, MeOH
2. (COCl)2, CH2Cl2
H2N
3.
4. NaH, MeI,
 THF
1. NBS, CCl4
dibenzoyl peroxide
2. NaI, 18-crown-6
N
65
N
O
I
 
Scheme 38: Proposed synthesis of 3-iodomethylquinoline-2-carboxamides 
 
The formation of quinoline carboxamide 65, started from commercially available aniline 
and diethyl oxalpropionate as described in Scheme 32.  Condensation of aniline and diethyl 
oxalpropionate formed an imine, followed by acid mediated cyclisation which gave the 
quinoline product 81.  Bromination using phosphorus oxybromide gave 80 in 84% yield. 
Suzuki reaction using phenylboronic acid then gave 94 in an excellent 99% yield.  
Hydrolysis of the ethyl ester 94 using standard conditions afforded 96 in 92% yield.  
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Scheme 39: Synthesis of 96 
 
The first analogue of the 3-iodomethylquinoline-2-carboxamide series to be prepared, 
contained the same side chain as PK11195, N-methyl-sec-butyl amine.  The series of 
transformations involved the reaction of carboxylic acid 96 with oxalyl chloride to form 
the acid chloride and in situ reaction with sec-butyl amine which gave 97 in 70% yield.   
Methylation of 97 using methyl iodide and sodium hydride gave 95 in 82% yield.     
 
N CO2H 1. (COCl)2, CH2Cl2
    DMF (Cat),
H2N
2.
70%
N
N
H
O
N
N
O
NaH, MeI, THF
82%
96 97 95  
Scheme 40: Synthesis of 95 
 
The final stages involved bromination of 95 via a radical reaction using N-
bromosuccinimide (NBS) as the bromine source and dibenzoyl peroxide as the initiator. 
This gave bromide 98 in 45% yield. Nucleophilic substitution with sodium iodide and 18-
crown-6 gave 3-iodomethylquinoline-2-carboxamide 65 in 74% yield.5    
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Scheme 41: Completion of 3-iodomethylquinoline-2-carboxamide 65 
 
As shown in Scheme 42, the bromination occurs via a radical chain mechanism. Firstly, 
homolytic cleavage of the weak oxygen-oxygen bond in dibenzoyl peroxide forms free 
radicals. The initiator then selectively abstracts a hydrogen atom from the methyl to give a 
carbon centred radical, which can then abstract a bromide from NBS to form the required 
product. 
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Scheme 42: Radical chain mechanism 
 
Introduction of the iodide occurs via a Finkelstein-like reaction, with the 18-crown-6 
having the effect of co-ordinating the sodium cation and leaving the naked iodide anion to 
carry out an SN2 reaction with the bromide to give 65 in 74% yield.5 
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Scheme 43: Finkelstein-like reaction to give 65 
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With the successful completion of the synthesis of 65, the next stage was to introduce other 
amine side chains.  Diethylamine, benzylamine and phenylethylamine were used to replace 
sec-butylamine.  As before, the carboxylic acid 96 intermediate was reacted with oxalyl 
chloride to form the acid chloride and in situ reaction with diethylamine, benzylamine or 
phenylethylamine gave 99, 101 and 103 in good yields. However problems were 
encountered during the NBS bromination stage, resulting in very low yields or no reaction.  
This could be due to introduction of bulkier amide side chains, preventing the bromide 
from reacting with the 3-methyl group.  Instead of using NBS as the bromine source, 1,3-
dibromo-5,5-dimethyl hydantoin (DBDMH) was tried as an alternative. However, low 
yields or no reaction was observed.   
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Scheme 44: Synthesis of 100, 102 and 104 
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2.2.4 New Synthetic Route 
 
Since the initial attempt failed to brominate derivatives 99, 101 and 103, another route was 
developed to synthesise the target compounds. As shown in Scheme 45, the retrosynthetic 
analysis of 105 begins by functional group interconversion of the iodide to alcohol 106, 
followed by formation of the lactone ring to give intermediate 107.  Next cleavage of the 
carbon oxygen bond to give 108 and further disconnection of the quinoline ring gave 2-
aminobenzophenone 110 and ethyl 4-chloroacetoacetate 109 as the two starting materials.  
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Scheme 45: Retrosynthesis of 106 
 
A chlorotrimethylsilane-mediated Friëdlander condensation was used to synthesise 
quinoline 111.69 Starting from commercially available 2-aminobenzophenone and ethyl 4-
chloroacetoacetate the reaction was carried out in a Schlenk tube in DMF to give 111 in 
85% yield.    
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Scheme 46: Synthesis of 111 
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Although there are various methods for quinoline synthesis, the Friëdlander condensation 
reaction is able to produce polysubstituted quinolines in a staightforward approach.69  
Previous reaction conditions involved the use of basic or acidic catalysts, the latter being 
more effective.  More recently iodine, Lewis acids and a combination of acidic catalysts 
and microwave irradiation have been useful.  However, the use of catalysts can be very 
expensive and the use of specialised equipment limits the availability of the reaction. 
 
Shown in Scheme 47 is the general mechanism for two possible ways in which the 
Friëdlander reaction can proceed.  Starting from 2-amino substituted aromatic carbonyl 
compound 112 and ketone 113, the first step involves the formation of Schiff base 114 as 
an intermediate.  Next an intramolecular aldol reaction forms the hydroxy imine 115, 
followed by dehydration to give quinoline 116.  The second route occurs via an 
intermolecular aldol reaction to give 117, followed by loss of water to afford quinoline 
116.70 
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Scheme 47: General mechanism of the Friëdlander reaction 
  
Rayabukhin and co-workers reported a procedure for the Friëdlander synthesis of 
polysubstiuted quinolines using chlorotrimethylsilane (TMSCl).69 With the successful 
completion of a number of quinolines with high yields using TMSCl, the same reaction 
conditions were adopted for the synthesis of 111.  Shown in Scheme 48 below is the 
reaction mechanism in the presence of TMSCl.  Reaction of TMSCl generates a silyl enol 
ether 118 which attacks the electrophilic carbonyl of 2-aminobenzophenone 110 to form 
intermediate 119.  Cyclocondensation closes the ring to form an amine 121, followed by 
dehydration to give quinoline 111. 
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Scheme 48: Friëdlander synthesis 
 
The next stage was to couple the amine side chain however before this could be completed 
there were a number of reactions to be performed in order for the ester to be in position 2.  
Firstly, formation of a lactone ring using 6 M hydrochloric acid in ethanol gave 9-
phenylfuro[3,4-b]quinolin-1(3H)-one 122 in an excellent 91% yield (Scheme 49).71  
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Scheme 49: Formation of lactone 122 
 
One possible way in which the lactone ring could be formed, would be ester hydrolysis to 
form a carboxylic acid followed by attack of the lone pair on the oxygen to the carbon 
chloride bond to form the lactone ring (Scheme 50). 
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Scheme 50: Mechanism for lactone formation 
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Next the lactone was reduced using lithium aluminium hydride to achieve diol 123 in a 
moderate 67% yield.  During the reduction, small quantities of the dihydroquinoline are 
also formed.  The quinoline was reformed by treatment of the reaction mixture with 
palladium on carbon.  Regioselective oxidation with manganese dioxide gave the key 
isomeric lactone intermediate 107 in 80% yield.71   
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Scheme 51: Synthesis of 107 
 
To incorporate the desired amide side-chains, lactone 107 underwent aminolysis in the 
presence of trimethylaluminum with a series of secondary amines to afford 3-
hydroxymethylquinoline-2-carboxamides 124, 125 and 126 in reasonable yields (Scheme 
52).  The trimethylaluminium reacts with the amine to form a complex, which makes the 
amine more nucleophilic allowing the amine to attack the carbonyl forming a new C-N 
bond. 
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Scheme 52: Synthesis of 124,125 and 126 
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Completion of the synthesis was accomplished by chlorination of the hydroxymethyl group 
with thionyl chloride followed by a halogen exchange reaction with sodium iodide which 
gave 3-iodomethylquinoline-2-carboxamides in moderate yields (Scheme 53).  Formation 
of the iodide was achieved using sodium iodide as the iodide source in acetonitrile. The 
reactions went to completion within two hours to afford 127, 128 and 129.  During the 
development of this reaction, it was noted that a non-aqueous work-up was required to 
provide the iodides cleanly.  
 
N
OH
NR1R2
O
N
I
NR1R2
O
1. SOCl2, CH2Cl2
2. NaI, MeCN
125 R1=R2=CH2CH3
124 R1=CH3, R2=CH2Ph
126 R1=CH3, R2=CH2CH2Ph
127 R1=R2=CH2CH3, 56%
128 R1=CH3, R2=CH2Ph, 39%
129 R1=CH3, R2=CH2CH2Ph, 53%  
 
Scheme 53: Synthesis of 127, 128 and 129 
 
2.2.5 3- and 4-Iodobenzyl Analogues 
 
The proposed synthesis of 3- and 4-iodobenzyl analogues involves the same chemistry 
used to synthesis compound 65. Starting from aniline 83 and diethyl oxalpropionate 82, a 
number of key reactions were used to form carboxylic acid 96, followed by acid chloride 
formation and finally reaction with 3- or 4-iodobenzylamine to form 66. 
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Scheme 54: Synthesis of 3- and 4-Iodobenzyl analogues 
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 Starting from previously prepared quinoline carboxylate 96, the acid chloride was formed, 
followed by reaction with 3-iodobenzylamine to give 130 in a good 80% yield (Scheme 
55).  The final step involved methylation using standard conditions, iodomethane and 
sodium hydride to give 131 in 76% yield.  
  
 
N CO2H N
N
H
O
I1. (COCl)2, DMF
    CH2Cl2
2.
H2N
I
80%
N
N
O
I
MeI, NaH, THF
76%
96 130
131  
Scheme 55: Synthesis of 131 
The next analogue that was prepared involved the coupling of 4-iodobenzylamine. The 
reaction procedure was the same as the 3-iodobenzyl analogue 131, firstly conversion to 
the acid chloride, followed by coupling with 4-iodobenzylamine which gave 132 in 53% 
yield (Scheme 56). Finally methylation gave desired analogue 133 in 90% yield.    
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1. (COCl)2, DMF
    CH2Cl2
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H2N
53%
N
N
O
MeI, NaH, THF
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I
I
I
96 132
133  
Scheme 56: Synthesis of 133 
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2.2.6 Biological evaluations 
 
In discovering a new molecular imaging agent, it is important to identify direct binding 
interactions of the ligand to the required receptor.  The interaction between the ligand and 
receptor can be quantified in ligand binding assays.  With the successful completion of a 
new library of compounds, the next aim was to investigate the binding affinity, with the 
intent of finding an analogue that proved to have higher binding affinity for TSPO than 
PK11195.  A competition binding assay technique was used to evaluate in vitro binding 
using rat brain homogenates.   Competition binding assays test the binding affinity of new 
compound versus a labelled ligand. Once the assay was complete, competition curves were 
obtained by plotting ligand binding (counts per minute) against the log concentration of the 
competing ligand.  From the curve, the Ki of the receptor for the competing compound was 
determined.  The Ki is the equilibrium dissociation constant; it is the concentration of the 
unlabelled compound that would bind to half the binding sites at equilibrium.  
 
Firstly, the binding affinity of PK11195 was determined, in order to use it as a direct 
comparison to the new compounds. Shown below in Figure 17, is the competition binding 
curve of PK11195.  The top of the curve is a plateau at a value equal to radioligand binding 
in the presence of lower concentration of the competing unlabelled compound (i.e Totals).  
The bottom of the curve is a plateau equal to nonspecific binding i.e. binding of high 
concentrations of unlabelled ligand.72 The equilibrium point in the curve represents the Ki 
value corresponding to the concentration when half the binding sites are occupied by the 
unlabelled ligand.  The Ki value was determined from nonlinear regression analysis using 
GraphPad Prism Version 4 (GraphPad Software Inc).  The Ki can be calculated from the 
equation below developed by Cheng and Prussoff.73 
 
Figure 17: Competition binding curve of PK11195 
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After determining the Ki for PK11195 (9.8 ± 1.6 nM), the same conditions were used to 
determine the binding affinity of the new compounds.  For each compound, three 
independent experiments were carried out to determine the final Ki value.  From Table 8, it 
can be seen that two compounds from the 3-iodomethylquinoline-2-carboxamide series 
have excellent binding affinity for TSPO.  Compound 128 with the benzyl side chain was 
found to have a Ki value of 26.1 nM whilst, the diethyl analogue 127 has an even better 
binding affinity of 12.0 nM, similar to that of PK11195, the most widely used imaging 
agent.  
 
Compound 65, with the same amide side chain as PK11195 32 has low binding affinity to 
TSPO with a Ki value of 173 nM.  The last compound in the 3-iodomethylquinoline-2-
carboxamide series, compound 129 with an extra carbon in the amide position compared to 
compound 128, again has a lower binding affinity of 411 nM.   
 
The second group of analogues with the iodine incorporated into the amide side chain, 
compounds 131 and 133, show poor affinity for TSPO.  Compound 131 has a Ki value of 
455 nM while compound 133 has a significantly lower affinity. 
 
As well as determining how well the ligand binds it is also important to determine the 
ligands distribution i.e. how easily the ligand can reach its intended target in the body, and 
how long it will remain in the body in an active form once it reaches the target.   A high 
log P value means that the ligand is too lipophilic and not able to cross cell walls. A low 
log P value indicates that the ligand will be too hydrophilic and will probably not cross the 
blood brain barrier and will be eliminated from the body quickly.   The log P values for 
these compounds were determined by our collaborator Adriana A. S. Tavares from the 
Division of Clinical Neuroscience.  The log P was determined using an HPLC method 
involving C18 chromatography.  The compounds all have relatively high log P values 
which are not ideal for imaging agents.  The diethyl analogue 127 still has a high log P of 
4.76 but is comparable to other SPECT imaging agents known to cross the blood brain 
barrier. 
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Compound Ki a (nM) Log P 
N
N
O
Cl
32  
 
9.8 ± 1.6 
 
3.85 
N
N
O
I
65  
 
173 ± 35 
 
5.17 
N
N
O
I
127  
 
12.0 ± 1.3 
 
4.76 
N
N
O
I
128  
 
26.1 ± 4.7 
 
5.39 
N
N
O
I
129  
 
411 ± 62 
 
5.17 
N
N
O
I
131
 
 
455 ± 51 
 
5.03 
N
N
O
I
133
 
  
>1000 
 
5.12 
a Calculated from three independent experiments. 
Table 8: Binding affinity of quinoline-2-carboxamide analogues 
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Another set of compounds similar to 131 and 133 without the methyl substituent on the 
quinoline ring were synthesised by A. Brunet from the group and tested for binding affinity 
against TSPO.  These also showed very poor affinity for TSPO (Table 9).  Compounds 134 
and 135 have Ki values greater than 1000 nM and with high log P values rendering them 
unsuitable as imaging agents.  The final group of analogues to be tested incorporated a 
fluoride at the para-position of the phenyl ring.  Incorporation of a fluoride and iodide 
atom allows the compound to be used for both PET and SPECT imaging.  However, the 
binding affinity was again high (Ki >1000 nM). 
 
Compound Ki (nM) Log P 
N
N
O
I
134
 
 
>1000 
 
5.11 
N
N
O
I
135
 
 
>1000 
 
5.12 
N
N
O
I
F
136
 
 
 
>1000 
 
 
 
5.16 
 
 
N
N
O
I
F
137
 
 
 
>1000 
 
 
5.21 
a Calculated from three independent experiments. 
 
Table 9: Binding affinity of compounds 134, 135, 136 and 137 
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2.2.7 Space Filling Models 
 
Using a software package called Spartan by Wavefunction, Inc. space filling models were 
constructed to give an insight into the overall molecular size and shape of these compounds.  
Shown in Figure 18, are the energy minimised models of various compounds. The first 
space filling model shows I-PK11195.  The large purple atom at the back of the structure is 
the iodine atom and the red atom is the oxygen. This model proposes why I-PK11195 has 
high binding affinity to TSPO. The iodine atom does not hinder formation of the key 
hydrogen bonds when the amide side-chain binds to the receptor.   Compound 127 has 
similar attributes to PK11195, the large iodine atom is situated in the cleft of the compound 
therefore allowing the compound to bind effectively to the receptor.  Compound 133, 
however, has poor affinity due to the large iodine atom possibly blocking the amide side-
chain from binding.  
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Figure 18: Space filling models of compound 61, 127 and 133 
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2.3 Third Generation Quinoline-2-carboxamides 
 
Having learned that the larger the amide side chain the worse the binding affinity to TSPO 
was, the next step forward was to develop new compounds with shorter amide side chains.  
From the binding assay experiments, the diethyl compound 127 was shown to have the 
best affinity and therefore it was decided to use the same core structure but incorporate a 
shorter amine substituent. Also, a morpholine substituent was used to try and lower the log 
P value. 
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127 138 139  
 
Figure 19: Third generation quinoline-2-carboxamides 
 
 
The synthesis of compounds 138 and 139 followed the same synthetic route used 
previously to synthesise 3-iodomethyl-4-phenylquinoline-2-N-diethylcarboxamide 127. 
Starting from a common intermediate lactone 107, the amine was coupled to form 140.  
Introduction of the iodide was achieved by reaction of the hydroxyl group with thionyl 
chloride to form the chloride, followed by reaction with sodium iodide to give 141. 
 
N
O
O
N
NR'R
O
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N
NR'R
O
I
Al(CH3)3
NHR'R
1. SOCl2
2. NaI, MeCN
107 140 141  
Scheme 57: Synthesis of 141 
 
As shown in Scheme 58, the coupling of the appropriate amine involved aminolysis of the 
lactone ring using trimethylaluminium to afford compound 142 and 143 in good yields.  
Purification of the morpholine analogue was problematic, whilst on the silica column the 
morpholine ring was removed and the lactone intermediate 107 was reformed.  This was 
due to the fact that morpholine is a good leaving group and since the silica is acidic it helps 
promote the formation of the lactone ring.  The next stage was formation of the chloride 
derivative, which was achieved by reaction of the hydroxymethyl group with thionyl 
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chloride. With the completion of the chloride derivative, the final step involved a halogen 
exchange reaction of the chloride for the iodide.  This was carried out in the presence of 
sodium iodide in acetonitrile which gave 3-iodomethylquinoline-2-carboxamides 138 in 
15% yield and 139 in 21% yield over the two steps. 
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86%
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Scheme 58: Synthesis of 138 and 139 
 
2.3.1 Final Analogues 
 
The final series of analogues that were synthesised incorporated the iodide onto the phenyl 
ring in a similar fashion to PK11195. These compounds were of interest as they are more 
likely to be more stable than the 3-iodomethylquinoline-2-carboxamide due to the stronger 
carbon iodine bond. The synthetic route followed the same procedures developed in the 
synthesis of 4-phenyl-3-iodomethylquinoline-2-N-methyl-N-sec-butylcarboxamide 65.  
Shown in Figure 20, are the three new proposed compounds. 
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Figure 20: Final analogues 
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The proposed retrosynthetic analysis is shown in Scheme 59.  Disconnection of the amide 
side chain leads back to carboxylic acid 148.  Further disconnection of the 2-bromophenyl 
ring gives 149, followed by functional group interconversion of the halide to a hydroxyl 
group, 150.  Quinoline can be prepared from commercially available aniline 83 and diethyl 
oxalacetate 151. 
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147 148
149
15015183
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Scheme 59: Retrosynthesis of 147 
 
The quinoline carboxamide was prepared in two steps by condensation of aniline 83 with 
diethyl oxalacetate 151 to form 150 in 40% yield over two steps (Scheme 60). Bromination 
of the hydroxyl group on 150 using phosphorus oxybromide afforded 149 in an excellent 
85% yield.  Next, a Suzuki reaction using 2-bromophenylboronic acid in the presence of 
catalytic tetrakis(triphenylphosphine) palladium(0), introduced the ortho-bromophenyl ring, 
which gave 152 in a good 71% yield. The last step before the amide coupling involved 
ester hydrolysis using sodium hydroxide in methanol/water to form the carboxylic acid 
intermediate 148 in 84% yield.   
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Scheme 60: Synthesis of 148 
 
Formation of the amide side chain was carried out by incorporating diethylamine, 
dimethylamine or morpholine amine using the same reaction conditions as before.  Firstly, 
formation of the acid chloride using oxalyl chloride, followed by reaction with the required 
amine gave target compounds 153, 154 and 155 in good overall yields.  
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Scheme 61: Synthesis of 153, 154 and 155 
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Completion of the synthesis to give the final products involved a copper-catalysed 
aromatic Finkelstein reaction to exchange the bromide to the iodide.  The first compound 
to be synthesised was the dimethyl analogue 153, using the same reaction conditions 
developed by Klapers and Buchwald.63  The first attempt was unsuccessful with only 
recovery of starting material after four days. The reaction was repeated and after 5 days, 
analysis using mass spectrometry showed the presence of the desired iodide along with the 
bromide starting material.  The reaction was attempted again and heated for 7 days. This 
time, the reaction went to completion and gave iododinated compound 145 in 27% yield.  
The yield of 145 was low but it gave sufficient amounts of 145 for binding experiments. 
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Scheme 62: Iodination of 153 
 
The synthesis of the final two analogues, diethyl 144 and morpholine 146 were 
unsuccessful (Scheme 63 and 64).  The reaction was attempted using the same reaction 
conditions as for 153 and monitored over the course of 2-3 weeks.  After 3 weeks, the 
reaction was thought to have gone to completion but the mass spectrum for each analogue 
showed the presence of both bromide and iodide.  Attempts to separate the bromide and 
iodide derivatives by flash column chromatography were unsuccessful.  The reaction was 
not attempted again as after one week the reaction is not a viable method as it takes too 
long.  Increasing the size of the amide side chain adds extra bulk therefore, steric hindrance 
probably retards halogen exchange between the bromide and iodide and slows the reaction 
significantly.   
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Scheme 63: Iodination of 154 
 
  75
N
I
N
O
O
146
CuI, NaI
Butan-1-ol
NHMeMeHN
X
N
Br
N
O
O
155  
Scheme 64: Iodination of 155 
 
Due to time restraints the reactions were not modified.  However future work on these 
analogues would consist of another method of iodination.  One way in which the problem 
could be overcome would be to prepare the iodide via an organostannane derivative 
(Scheme 65).  Failing that, another approach would be to use microwave conditions, to 
increase the rate of the halogen exchange reaction. 
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Scheme 65: Synthesis of 158 
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2.3.2 Biological Evaluations 
 
The binding affinity of the small library of compounds for TSPO was carried out in vitro 
using the same conditions as previous.   Shown in Table 10 are the final binding assay 
results of four analogues that were tested.  The dimethyl analogue 138, a derivative of the 
diethyl analogue that was shown to have good affinity (Ki = 12 nM), showed poor affinity 
for TSPO.  The best result was the morpholine derivative 139 with binding affinity of Ki = 
27.8 ± 2.89 nM, however the result was still not good enough to proceed further and 
develop this into an imaging agent. 
 
 
Compound Ki (nM) Log P 
N
I
N
O
138  
 
 
>1000a 
 
 
4.50 
N
I
N
O
O
139  
 
 
27.8 ± 2.89b 
 
 
3.62 
N
I
N
O
145  
 
 
>1000a 
 
 
2.91 
N
N
O
I
159  
 
 
491.3 ± 154a,* 
 
 
4.50 
a Calculated from three independent experiments 
b Calculated from two independent experiments 
* Synthesised by Jonathan Gardiner from our group 
Table 10: Binding affinity of quinoline-2carboxamide analogues 
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2.3.3 Conclusions 
 
Two successful routes were developed to synthesise new iodinated quinoline-2-
carboxamides.  The first route involved a two step condensation reaction to form the 
quinoline ring system and the second a chlorotrimethylsilane-mediated Friëdlander 
condensation reaction.  The second half of the project determined the binding affinity of 
these compounds for TSPO.  The results showed that the diethyl analogue 127 had the best 
affinity and that compounds with large amide side chains, particulary containing the large 
iodine atom had poor affinity for TSPO.  This could be easily observed from space filling 
models which showed the relative size of the iodine atom and how this possibly prevents 
binding to the TSPO active site 
 
Whilst compound 127 has good binding affinity, the iodomethyl moiety, a well know 
alkylating group, could cause stability problems.  This therefore, led the investigation of 
iodophenyl derivatives.  However, due to poor affinity for TSPO, a new class of ligands 
need to be investigated.   
 
2.3.4. Future Work 
 
Future work for this project would be to synthesise a new class of ligands that would have 
high binding affinity to TSPO.  Okubo and co-workers reported a class of compounds 
called phenoxyphenylacetamides, that were derived by opening the diazepine ring of Ro5-
4864 (Scheme 66).74  They exhibit high and selective affinity for TSPO with an IC50 in 
nanomolar range (0.28-0.98 nM). These could also be designed with suitable log P values 
that could generate compounds with good pharmacokinetics.     
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Scheme 66: Retrosynthesis of Ro5-4864 
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As well as designing good analogues that bind well to TSPO, it would also be beneficial to 
develop analogues with multi-labelled positions which could be used for either PET or 
SPECT imaging.  This would result in more widespread use of a single ligand. 
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2.4  Synthetic Approaches Towards The First Total Synthesis 
of Crispine C 
2.4.1  Introduction 
 
Carduus Crispus L (welted thistle) is an invasive plant studied for its potential 
pharmacological activity (Figure 21). It is found in Asia and Europe and has been used in 
Chinese folk medicine for the treatment of colds, stomach ache and rheumatism.75  
Researchers have discovered that the extracts from C. crispus inhibit the growth of various 
human cancer lines in vitro and show significant cytotoxic activity.75, 76  In 2002, Zhao and 
co-workers isolated a new class of isoquinoline alkaloids from C. crispus, crispine A-E.  
Crispine A and B have pyrrolo-[2,1-a]isoquinoline skeletons whereas crispine C-E are 
isoquinoline alkaloids with guanidinyl groups (Figure 22).75  
 
 
 
Figure 21: Welted thistle 
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Figure 22: Crispine A-E 
 
  80
2.4.2 Synthesis of Crispine A 
 
Pyrrolo[2,1-a]isoquinoline alkaloid crispine A, has been synthesised by a number of 
different groups.  In 2005, Knölker and Agarwal synthesised (±)-crispine A in a short and 
direct route using a approach for the preparation of pyrrole ring that they had developed in 
their group.76  Shown in Scheme 67 is their synthesis of crispine A which  starts from 3,4-
dihydro-6,7-dimethoxyisoquinoline 163.76  Compound 163 was made by the Bischler-
Napierlski cyclisation of N-formyl-3,4-dimethoxyphenylethylamine. Next, boron 
trifluoride aided addition of 3-trimethylsilylpropargylmagnesium bromide to compound 
163 gave 164 in 61% yield and the allene 165 in 2% yield.  Oxidative cyclisation of 164 
using silver acetate to pyrrole 166 occurred in 58% yield.  Allene 165 also underwent 
oxidative cyclisation to afford pyrrole 166 in 43% yield but at 53 °C rather than at room 
temperature.  The final step involves chemoselective hydrogenation of the pyrrole ring to 
give 167 in 66% yield.  Knölker and Agarwal synthesised (±)-crispine A in three steps with 
an overall yield of 24%.   
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Scheme 67: Synthesis of crispine A 
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In 2007, King developed a three step synthesis of (±)-crispine A via an acyliminium ion 
cyclisation to afford the natural product in an overall 55% yield.77 Starting from 3,4-
dimethoxyphenacylchloride 168, compound 170 was prepared in 80% yield.  Cyclisation 
of 170 occurred using aluminium chloride in dichloromethane to afford 171 in an excellent 
87% yield. The final step involved the reduction of 171 using lithium aluminium hydride 
as the reducing reagent to give (±)-crispine A in 80% yield.  The synthesis of (±)-crispine 
A was successfully achieved in three steps with an excellent overall 55% yield, an 
improvement to the synthesis developed by Knölker and Agarwal.  
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Scheme 68: Synthesis of crispine A 
 
2.4.3 Synthesis of Crispine E 
 
The second class of alkaloids from C. crispus series is crispine C-E which contain the 
isoquinoline group with a guanidinyl unit.  Czarnocki and co-workers successfully 
synthesised (+)-crispine E using the same synthetic route they used to synthesise the  
alkaloid (+)-tryargine.78  Compound 172 was prepared in a number of steps. Firstly the 
amine group of γ-aminobutyric acid was protected using phthalic anhydride to form the N-
phthaloyl derivative.  The carboxylic acid side was then reacted with thionyl chloride to 
give the acid chloride 172.  Next, the acid chloride was reacted with 3,4-
dimethoxyphenethylamine 173 to afford amide 174 in 79% yield.  Cyclisation of 174 using 
the Bischler-Napieralski approach gave imine 175 in 91% yield.  Asymmetric transfer 
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hydrogenation was used to reduce 175 to compound 176.  Using the catalyst (S,S)-179 in a 
solution of formic acid and triethylamine gave 176 in an excellent 90% yield and 89% ee.   
 
The completion of the synthesis of crispine E, involved deprotection of the phthaloyl group 
using hydrazine in ethanol, followed by derivatisation with N,N’-bis(Boc)-S-
methylisothiourea in DMF to give Boc-protected crispine E, 177.  Finally removal of the 
Boc groups with TFA and exchange of the anion by repeated evaporation with methanolic 
HCl gave (+)-crispine E in quantitative yield.  (+)-Crispine E was completed in a good 
53% overall yield.   
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Scheme 69: Synthesis of Crispine E 
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2.4.4 Proposed Research 
 
To date there has been no reported synthesis of crispine C.  The aim of this project was to 
develop the first total synthesis of crispine C using Pd(0)-mediated reactions to effect the 
key carbon-carbon bond forming reactions. 
 
2.4.5 Retrosynthetic Analysis of Crispine C 
 
The proposed retrosynthesis of crispine C is shown in Scheme 70.  Disconnection of the 
guanidine unit of 180 would give amine 181 followed by functional group interconversion 
to give α,β-unsaturated nitrile 182.  Further disconnection of the acrylonitrile side chain 
would give a bromide, followed by functional group interconversion to the carbonyl, 183.  
Isoquinoline core 183 could be synthesised from methyl 2-iodo-4,5-dimethoxybenzoate 
185 and amidoacrylate 184 via a one-pot Heck/amide cyclisation.  Finally compound 185 
could be synthesised from 3,4-dimethoxybenzoic acid 186. 
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Scheme 70: Retrosynthesis of crispine C 
 
The key transformations in the synthesis of crispine C involves Pd(0)-mediated reactions 
similar to those developed for the preparation of PK11195 described earlier in this thesis 
(see section 2.1.2).   
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2.4.6 Synthesis of Crispine C 
 
The first step in the synthesis was to form the isoquinoline core (Scheme 71).  This was 
achieved by iodinating commercially available 3,4-dimethoxybenzoic acid with the use of 
diacetoxyiodobenzene and iodine to afford 187 in 60% yield.79  The procedure was 
developed by Kryska and Skulski.  They showed that a range of aromatic iodides could be 
prepared under mild conditions using iodine, diacetoxyiodobenzene as an oxidant in the 
presence of catalytic amounts of sulfuric acid.  The advantage of using 
diacetoxyiodobenzene as the oxidant is that it is relatively cheap, stable and very accessible 
compared to other oxidants. The resulting compound 187 was then esterified under 
standard conditions using thionyl chloride in methanol, to give 185 in an excellent 92% 
yield. 
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Scheme 71: Synthesis of 185 
 
To complete the isoquinoline core the next step involves a palladium(0) catalysed Heck 
reaction (Scheme 72).  A one-pot procedure developed by Chattopadhyay and co-workers 
allowed the coupling of 2-iodo-4,5-dimethybenzoic acid 185 with amidoacrylate 184 to 
afford 183 in 61% yield.57  The reaction works via a palladium-catalysed cycle and starts 
by oxidative addition of the palladium(0) in between the aryl halide bond of 187,  followed 
by insertion of amidoacrylate into the Pd-halide bond and lastly β-hydride elimination of 
the palladium.   
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Scheme 72: Synthesis of 183 
 
The resulting oxoquinoline 183 was converted to the bromide using phosphorus(V) 
oxybromide to give 188 in 70% (Scheme 73).  The next stage was the introduction of the 
appropriate side-chain, via a Heck reaction using acrylonitrile as the coupling partner.  The 
reaction was first attempted using tetrakis(triphenylphosphine)palladium(0) as the catalyst 
in the presence of triethylamine.80 However, the reaction was unsuccessful and only 
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starting material was recovered.  This was because, whilst heating the reaction, the 
acrylonitrile was evaporating, therefore not in the mixture for the reaction to occur.  The 
next procedure that was attempted used a method reported by Wang and co-workers. Their 
method involved the use of  palladium acetate, triphenylphosphine and silver carbonate as 
the base.81  The reaction was carried out at room temperature and reacted for 48 h but 
unfortunantely after 48 h there was no sign of any product.   
 
Another procedure reported by Deng and co-workers used Jeffery’s conditions using  
palladium acetate and tetra-n-butylammonium bromide in DMF.82  The reaction was 
carried out in a Schlenk tube in order for it to be heated to 80 °C.  This time the reaction 
did work but the reaction took three weeks to produce 189 with a very low 11% yield.  The 
last attempt involved using tributylphosphine and heating the reaction to 150 °C.  The 
reaction was slightly better taking four nights to afford 189 in a poor 13% yield.  At this 
stage it was decided more efficient route was required. 
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Scheme 73: Synthesis of 189 
 
2.4.7 New Synthetic Route 
 
A new shorter seven step approach was devised.  Instead of using Pd(0) chemistry the new 
route involves the Bischler-Napieralski approach to form the isoquinoline ring.  Shown in 
Scheme 74 is the retrosynthesis of crispine C.  Disconnection of the guanidine unit of 180 
would give amine 181.  Further disconnection of the isoquinoline ring to form amide 190, 
followed by disconnection of amide bond leads back to 173 and 191. 
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Scheme 74: Retrosynthesis of 180 
 
The first step involves the coupling of 3,4-dimethoxyphenethylamine and γ-aminobutyric 
acid.  Firstly, the γ-aminobutyric acid was protected using benzyl chloroformate in 2 M 
sodium hydroxide to afford 192 in quantitative yield.  The coupling reaction of Cbz- 
protected γ-aminobutyric acid and 3,4 dimethoxyphenethylamine 173, involved ethyl 3-(3-
dimethylaminopropyl)carbodiimide and dimethylaminopyridine as the catalyst in 
dichloromethane to afford 193 in an excellent 89% yield.83 
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Scheme 75: Synthesis of 193 
 
The coupling reaction forms a new amide bond between 3,4-dimethoxyphenethylamine 
173 and γ-aminobutyric acid 192.  Firstly EDCl reacts with γ-aminobutyric acid 192 to 
form intermediate 194. Next dimethylaminopyridine attacks the activated carbonyl to form 
new intermediate 196. The amino group of 3,4-dimethoxyphenethylamine attacks the 
DMAP amide to give 193 in a very fast reaction.84 
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Scheme 76: Amide coupling mechanism 
 
Cyclisation of N-(3,4-dimethoxyphenethyl)-4-(benzyloxycarbonylamino)butanamide 193, 
was then carried out using the Bischler-Napieralski reaction (Scheme 77).78  The reaction 
using phosphorus(V) oxychloride in dichloromethane was found to be unpredictable.  The 
reaction went to completion the first time to afford 197 in 60% yield.  However, when the 
reaction was repeated several times after, it failed.  The reaction was then repeated using 
neat phosphorus(V) oxychloride which gave imine 197 in an improved 73% yield.85   
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Scheme 77: Cyclisation of 193 
 
Shown in Scheme 78, is the mechanism for the Bischler-Napieralski reaction.  The 
mechanism involves the conversion of amide 195 to protonated imidoyl chloride 202, 
followed by electrophilic aromatic substitution to give 200. 
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Scheme 78: Mechanism for the Bischler-Napieralski reaction 
 
The next stage involves a dehydrogenation reaction to obtain the isoquinoline ring system.  
Formation of compound 201 was attempted using several different reaction conditions but 
all ended in failure.  The first procedure involved the use palladium on carbon in diphenyl 
ether at 170 °C to remove two hydrogen atoms.  However, the reaction failed and the 
starting material decomposed.86  The second attempt to effect this transformation involved 
the use of selenium dioxide.  A paper published by Bernstein and Littell used selenium 
dioxide in the presence of t-butyl alcohol and glacial acetic acid. The same reaction 
conditions were carried out on compound 197 but proved unsuccessful.87 The reaction was 
repeated without glacial acetic acid and with the addition of deactivated Raney nickel 
catalyst.87 After two hours heating the reaction under reflux no reaction was observed and 
the starting material had decomposed.   
 
The next strategy was to use the common dehydrogenating reagent 2,3-dichloro-5,6-
dicyano benzoquinone (DDQ).88 The reaction was heated under reflux in toluene overnight. 
Again this gave no reaction.  The last attempt to dehydrogenate 197, was to use manganese 
dioxide under Dean-Stark conditions.  However, the reaction reopened the ring to form 
compound 193.  Further research into methods for dehydrogenation led to a paper from 
1983 by Walker and co-workers. They reported difficulties in the dehydrogenation of 
similar isoquinoline ring systems.89 They overcame these problems by incorporating a 
leaving group and the use of the Pictet-Gams reaction which allowed more facile 
generation of the isoquinoline ring system.  A route using the Pictet-Gams reaction was 
devised to overcome problems with the dehydrogenation step. 
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Scheme 79 
 
2.4.8 Third Route, Use of the Pictet-Gams Reaction 
 
The Pictet-Gams reaction involves the addition of a good leaving group, beta to the amide.  
This allows cyclisation and aromatization in one step, by-passing the dehydrogenation 
reaction.  Before the cyclisation stage there were a number of reactions required to prepare  
amine 204.  Shown in Scheme 80, is the proposed route to the synthesis of the key 
isoquinoline intermediate 201.  Firstly formation of amine 204, followed by the coupling 
reaction to give 205 and finally the Pictet-Gams reaction to form the isoquinoline 201. 
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Scheme 80: Proposed route for the synthesis of crispine C 
 
The first step of the synthesis involves condensation of veratraldehyde and nitromethane to 
form β-nitrostyrene 206.  The reaction is a Henry Reaction which similar to an Aldol 
addition reaction and can also be referred to as the nitro Aldol reaction.  The reaction was 
heated under reflux in toluene to afford 206 in an excellent 97% yield.89   
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Scheme 81: Synthesis of 206 
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The reaction mechanism is shown below in Scheme 82.  The first step in the mechanism is 
the deprotonation of the nitromethane by the base (ammonium acetate) at the α position to 
form the corresponding resonance stabilized anion 207.  Next an aldol reaction takes place, 
between the nitromethane and the carbonyl to form intermediate 208, Protonation of the 
alkoxide to form the nitro alcohol 209, followed by elimination of water gave compound 
206. 
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Scheme 82: Mechanism of the formation of 206 
 
The next stage in the synthesis was the conversion of nitrostyrene 206 to the nitroethane 
compound 211 by the conjugate addition of the methoxide group.  This gave 211 in 84% 
yield (Scheme 83).89  Reduction of the nitro group to afford β-methoxyphenethylamine 204 
was problematic and was attempted a number of times using various reagents.  Firstly the 
reaction was attempted numerous times using lithium aluminium hydride in diethyl ether 
as the reducing agent but the reaction was very low yielding (17-34% yield).  Problems 
arose in attempting to isolate 204 during the work-up.  A second attempt using ammonium 
formate and palladium on carbon led to decomposition of the starting material.90  Another, 
reported procedure for the reduction of nitro groups involved the use of tin chloride but 
again this method returned only starting material. 
 
MeO
MeO
NO2 MeO
MeO
NO2
OMe
Na+OCH3
MeOH
84%
MeO
MeO
NH2
OMe
LiAlH4
206 211 204  
Scheme 83: Synthesis of 204 
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Due to time restraints it was thought that it would be beneficial to take the crude amine 204 
produced using the LiAlH4 procedure onto the next few steps to test whether the Pictet-
Gams reaction would successful or not, before any more time was spend on developing the 
nitro reduction stage.   
 
The next stage involved the coupling of compound 204 to Cbz-protected γ-aminobutyric 
acid 194, which gave 205 in 37% yield over two steps.  The Pictet-Gams reaction was then 
carried out neat in phosphorous oxychloride.  Although the compound was not isolated, the 
1H NMR spectrum of the crude material indicated formation of the desired compound.  
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Scheme 84: Synthesis of 201 
 
2.4.9 Conclusions 
 
The synthesis of crispine C, was first attempted using Pd(0)-mediated reactions to effect 
the key carbon-carbon bond forming reactions.  However, failure of the Heck reaction to 
couple the appropraite side-chain resulted in a new synthesis.  The new route involved the 
Bischler-Napieralski approach to form the isoquinoline core.  To complete the isoquinoline 
ring system, a dehydrogenation reaction was attempted but proved difficult.  Therefore, a 
route using the Pictet-Gams reaction was devised to overcome problems with 
dehydrogenation, allowing the cyclisation and aromatization in one step.  To date the third 
route is promising but still requires optimisation of nitro group reduction. 
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2.4.10 Future Work 
 
Future work for this project would include the modification of the nitro reduction stage to 
increase the yield. Further work would be involved in improving the purification of the 
Pictet-Gams reaction to obtain a clean compound ready for the final steps.  Shown in 
Scheme 85 would be the final steps to complete the synthesis of crispine C.  Firstly 
deprotection of the amine would give 212, followed by coupling the resulting amine with 
commercially available N,N-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine in the 
presence of Hünig’s base.  This will give the Boc-protected guinidine substituent to afford 
compound 212.  Treatment of 212 with trifluoroacetic acid will remove the Boc-protecting 
groups and complete the first total synthesis of crispine C.  
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Scheme 85: Completion of the synthesis of crispine C 
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3 Experimental 
 
3.1 Experimental 
General experimental  
All reactions were performed under an argon atmosphere unless otherwise noted. Reagents 
and starting materials were obtained from commercial sources and used as received. Dry 
solvents were purified using a PureSolv 500 MD solvent purification system. Flash column 
chromatography was carried out using Fisher matrix silica 60. Macherey-Nagel aluminium 
backed plates pre-coated with silica gel 60 (UV254) were used for thin layer 
chromatography and were visualised by staining with potassium permangante. 1H NMR 
and 13C NMR spectra were recorded on a Bruker DPX 400 spectrometer with chemical 
shift values in ppm relative to TMS (δH 0.00 and δC 0.0) or residual chloroform (δH 7.28 
and δC 77.2) as standard. Proton and carbon assignments are based on two-dimensional 
COSY and DEPT experiments, respectively. Infrared spectra were recorded using sodium 
chloride or potassium chloride plates on a JASCO FTIR 410 spectrometer or neat on the 
SHIMADZU spectrometer and mass spectra were obtained using a JEOL JMS-700 
spectrometer.  
General Procedure 1: Suzuki Coupling. To a solution of the isoquinoline bromide in 
N,N-dimethylformamide (150 mL) was added the boronic acid (1.3 equiv), potassium 
phosphate (1.30 equiv) and tetrakis(triphenylphosphine)palladium(0) (0.03 equiv) and the 
mixture heated under reflux for 24 h. An additional amount of the boronic acid (0.65 
equiv) and potassium phosphate (0.65 equiv) was added and the mixture heated under 
reflux for a further 24 h. The reaction mixture was cooled to room temperature and the 
product extracted into dichloromethane (150 mL). The organic layer was washed with 
water (3 × 20 mL) and then dried (MgSO4). The resulting solution was concentrated under 
reduced pressure to afford a dark brown oil. The product was purified by flash column 
chromatography using a graduated eluent of petroleum ether > petroleum ether/ethyl 
acetate (50:50) to give the coupled product.  
General Procedure 2: Ester Hydrolysis. To a solution of the ethyl ester in 50% aqueous 
ethanol (150 mL) was added ground sodium hydroxide (4 equiv) and the solution stirred at 
80 °C for 1.5 h. The reaction mixture was cooled to room temperature and the ethanol 
removed under reduced pressure leaving an aqueous solution. The solution was acidified 
with 1 M hydrochloric acid (20 mL) and the product extracted into dichloromethane. The 
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organic layer was washed with water (3 × 20 mL) and dried (MgSO4). The organic solvent 
was removed under reduced pressure to afford the carboxylic acid which was used without 
further purification.  
General Procedure 3: Acid Chloride Formation and Subsequent Amine Coupling. 
The carboxylic acid, dichloromethane (50 mL) and a few drops of N,N-dimethylformamide 
were cooled to 0 oC. Oxalyl chloride (1.2 equiv.) was then added and reaction heated to 50 
oC for 2 h. The solvent was removed in vacuo and excess oxalyl chloride was removed 
with toluene (3 × 20 mL). The residue was re-dissolved in dichloromethane (50.0 mL), 
cooled to 0 oC and the amine (5 equiv.) was then added and heated to 50 oC overnight. The 
reaction mixture was diluted with water, extracted with ethyl acetate, dried (MgSO4) and 
concentrated to dryness. Purification was carried out using flash column chromatography 
eluting with petroleum ether/ethyl acetate to give the desired compounds.  
General Procedure 4: Methylation of Amides. The amide, tetrahydrofuran (50 mL) and 
sodium hydride (4.2 equiv.) were stirred under argon at room temperature for 0.5 h. Methyl 
iodide (16 equiv.) was then added to the reaction mixture and heated under reflux 
overnight. The reaction mixture was quenched with water (20 mL), neutralized with 1 M 
hydrochloric acid (pH ~1) and extracted with ethyl acetate (3 × 20 mL). Purification was 
carried out using flash column chromatography eluting with petroleum ether/ethyl acetate 
to give the desired compounds.  
General Procedure 5: Aluminium Mediated Lactone Opening Using Secondary 
Amines. The amine (1.4 equiv.) was dissolved in dichloromethane (30 mL) and a 2 M 
solution of trimethylaluminium in toluene (1.3 equiv.) was added slowly to the reaction. 
After 0.25 h, 9-phenylfuro[3,4-b]quinolin-3(1H)-one 108 was added to the reaction which 
was heated under reflux for 48 h. The reaction was quenched with 1 M hydrochloric acid 
(20 mL), extracted with dichloromethane (3 × 50 mL), dried (MgSO4) and concentrated 
under vacuum. Purification was carried out by flash column chromatography eluting, with 
dichloromethane/ethyl acetate to give the desired compounds.  
General Procedure 6: Chlorination and Subsequent Iodination of the Primary 
Alcohols 
To a solution of the hydroxyl compound in dichloromethane (10 mL), thionyl chloride (22 
equiv) was added. The reaction mixture was stirred at room temperature for 3 h. The 
reaction mixture was concentrated in vacuo and the chloro analogue used without further 
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purification. A solution of sodium iodide (10 equiv.) and acetonitrile (30 mL) were de-
gased for 0.5 h. The hydroxyl compound was then added and the reaction mixture heated 
under reflux for 2.5 h. The mixture was cooled to room temperature and then concentrated 
to dryness. Purification was carried out by flash column chromatography eluting with 
dichloromethane/ethyl acetate (9:1) to give the desired compounds.  
Methyl isoquinolin-1-one-3-carboxylate 6791 
 
NH
O
67
CO2Me
 
 
Methyl 2-iodobenzoate (5.00 g, 19.0 mmol) and methyl-2-acetamidoacrylate (4.10 g, 28.0 
mmol) were dissolved in acetonitrile (150 mL).  Palladium(II) acetate (0.40 g, 1.90 mmol), 
tetrabutylammonium chloride (4.20 g, 15.0 mmol) and sodium hydrogencarbonate (4.00 g, 
47.0 mmol) were added to reaction mixture and heated under reflux overnight.  The 
reaction mixture was cooled to room temperature and concentrated in vacuo.  The reaction 
was diluted with water (200 mL) and subsequently extracted with ethyl acetate (200 mL).  
The organic phase was washed with water (3 × 200 mL), dried (MgSO4) and the ethyl 
acetate layer was removed under reduced pressure.  The product was purified by flash 
column chromatography using a graduated eluent of ethyl acetate/petroleum ether to give 
methyl isoquinoline-1-one-3-carboxylate 67 as a white solid (2.50 g, 65%). mp 146–
147 °C (lit.,91 mp 158–159 °C);  δH (400 MHz, CDCl3) 4.00 (3H, s, CH3), 7.39 (1H, s, 4-H), 
7.62–7.77 (3H, m, Ar H), 8.46 (1H, d, J 8.0 Hz, Ar H), 9.10 (1H, br s, NH);  δC (100 MHz, 
CDCl3) 53.2 (CH3), 111.4 (CH), 127.7 (C), 128.0 (CH), 128.2 (CH), 128.4 (C), 129.5 (CH), 
133.1 (CH), 136.0 (C), 161.7 (C), 162.3 (C); m/z (EI) 203.0578 (M+. C11H9NO3 requires 
203.0582), 143 (15%), 82 (100), 46 (36). 
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Methyl 1-bromoisoquinoline-3-carboxylate 4542 
 
N
Br
45
CO2Me
 
 
Methyl isoquinolin-1-one-3-carboxylate 67 (1.70 g, 8.30 mmol), phosphorous oxybromide 
(7.10 g, 2.50 mmol) and anhydrous potassium carbonate (3.50 g, 2.50 mmol) were added 
to acetonitrile (150 mL). The solution was heated under reflux for 1.5 h.  The reaction 
mixture was cooled to room temperature and concentrated under reduced pressure to form 
a oil.  The residue was cautiously dispersed in water (50 mL) and the insoluble material 
was filtered, washed with water, dried (MgSO4) and recrystallized from ethyl acetate.  
Methyl 1-bromoisoquinoline-3-carboxylate 45 was obtained as a light brown solid (1.60 g, 
71%). mp 122–124 °C (lit.,42 mp 125 °C); δH (400 MHz, CDCl3) 4.10 (3H, s, CH3), 7.83–
7.87 (2H, m, Ar H), 7.97–8.01 (1H, m, Ar H), 8.38–8.41 (1H, m, Ar H), 8.56 (1H, s, 4-H); 
δC (100 MHz, CDCl3) 53.1 (CH3), 124.6 (CH), 128.7 (CH), 129.1 (CH), 130.4 (C), 131.1 
(CH), 132.0 (CH), 136.8 (C), 141.0 (C), 145.5 (C), 165.1 (C); m/z (EI) 264.9742 (M+. 
C11H879BrNO2 requires 264.9738), 207 (100), 127 (83), 100 (11), 49 (37). 
 
Methyl 1-(2-Chlorophenyl)isoquinoline-3-carboxylate 4642 
 
N
46
CO2Me
Cl
 
 
The reaction was carried out according to general procedure 1 using methyl 1-
bromoisoquinoline-3-carboxylate 45 (0.20 g, 0.75 mmol) and 2-chlorophenylboronic acid 
(0.15 g, 0.98 mmol) and gave methyl 1-(2-chlorophenyl)isoquinoline-3-carboxylate 46 as a 
yellow solid (0.15g, 67%). mp 150–152 °C; δH (400 MHz, CDCl3) 4.10 (3H, s, CH3), 
7.34–7.47 (4H, m, Ar H), 7.56–7.62 (2H, m, Ar H), 7.70–7.74 (1H, m, Ar H),  7.98 (1H, d, 
J 8.0 Hz, Ar H), 8.61 (1H, s, 4-H);  δC (100 MHz, CDCl3) 53.1 (CH3), 124.3 (CH), 127.0 
(CH), 127.6 (CH), 128.4 (CH), 128.8 (C), 129.7 (2 × CH), 130.2 (CH), 131.0 (CH), 131.6 
(CH) 133.5 (C), 135.9 (C), 137.8 (C), 141.0 (C), 159.3 (C), 166.5 (C);  m/z (EI) 297.0558 
(M+. C17H1235ClNO2 requires 297.0557), 239 (100%), 203 (26), 43 (10).  
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1-(2-Chlorophenyl)isoquinoline-3-carboxylic acid 3442 
 
N
34
CO2H
Cl
 
 
The reaction was carried out according to general procedure 2 using methyl 1-(2-
chlorophenyl)isoquinoline-3-carboxylate 46 (1.05 g, 3.50 mmol) and sodium hydroxide 
(0.56 g, 14.0 mmol) and gave 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid 34 as a 
white solid (0.95 g, 96%). mp 188–189 °C (lit.,42 mp 191 °C); δH (400 MHz, CDCl3) 7.45–
7.56 (3H, m, Ar H), 7.60–7.62 (1H, m, Ar H), 7.70–7.79 (2H, m, Ar H), 7.84–7.88 (1H, m, 
Ar H), 8.12 (1H, d, J 8.4 Hz, Ar H), 8.74 (1H, s, 4-H);  δC (100 MHz, CDCl3) 122.8 (CH), 
127.0 (CH), 127.8 (CH), 128.9 (CH), 129.0 (C), 130.0 (CH), 130.3 (CH), 130.6 (CH), 
131.3 (CH), 131.7 (CH), 133.3 (C), 136.6 (C), 136.7 (C), 138.6 (C), 157.9 (C), 164.9 (C); 
m/z (CI) 284.0475 (MH+. C16H1135ClNO2 requires 284.0478), 250 (13), 248 (8). 
 
1-(2-Chlorophenyl)isoquinoline-3-N-sec-butylcarboxamide 7192 
 
N
Cl
71
N
H
O
 
 
The reaction was carried out according to general procedure 3 using 1-(2-
Chlorophenyl)isoquinoline-3-carboxylic acid 34 (0.10 g, 0.35 mmol) and sec-butylamine 
(1.1 mL, 10.5 mmol) and gave 1-(2-chlorophenyl)isoquinoline-3-N-sec-butylcarboxamide 
71 as a white solid (0.11 g, 90%). mp 124–126 °C (lit.,92 mp 124.5–125.5 °C); δH (400 
MHz, CDCl3) 0.94–1.00 (3H, m, CHCH2CH3), 1.26 (3H, d, J 8.0 Hz, NCHCH3), 1.57–
1.65 (2H, m, CH2CH3), 4.10–4.23 (1H, m, NCH), 7.46–7.53 (2H, m, Ar H), 7.57–7.61 (2H, 
m, Ar H), 7.67–7.70 (1H, m, Ar H), 7.75 (1H, ddd, J 8.0, 6.8, 1.2 Hz, Ar H), 8.05 (2H, d, J 
8.0 Hz, Ar H), 8.67 (1H, s, 4-H); δC (100 MHz, CDCl3) 10.6 (CH3), 20.5 (CH3), 29.8 
(CH2), 46.8 (CH), 120.2 (CH), 126.7 (CH), 127.3 (CH), 128.2 (C), 128.5 (CH), 129.8 (CH), 
129.9 (CH), 130.0 (CH), 130.7 (CH) 131.5 (CH), 133.5 (C), 136.7 (C), 137.9 (C), 142.9 
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(C), 157.2 (C), 164.0 (C); m/z (CI) 339.1259 (MH+. C20H2035ClN2O requires 339.1264), 
305 (10%), 113 (19), 85 (64), 69 (100). 
 
1-(2-Chlorophenyl)isoquinoline-3-N-methyl-N-sec-butylcarboxamide (PK11195) 32 
 
N
Cl
32
N
O
 
 
The reaction was carried out according to general procedure 4 using 1-(2-
chlorophenyl)isoquinoline-3-N-sec-butylcarboxamide 71 (0.08 g, 0.23 mmol) and methyl 
iodide (0.23 mL, 3.70 mmol) and gave 1-(2-chlorophenyl)isoquinoline-3-N-methyl-N-sec-
butylcarboxamide (PK11195) 32 as a white solid (0.07 g, 84%). NMR spectra showed a 
2:1 mixture of rotamers, only signals for the major rotamer is recorded. δH (400 MHz, 
DMSO-d6) 0.70 (3H, t, J 7.2 Hz, CH2CH3), 1.10–1.16 (3H, m, NCHCH3), 1.49–1.60 (2H, 
m, CH2CH3), 2.85 (3H, s, NCH3), 3.67–3.83 (1H, m, NCHCH3), 7.52–7.62 (4H, m, Ar H), 
7.67–7.70 (2H, m, Ar H), 7.85 (1H, t, J 7.6 Hz, Ar H), 8.07–8.13 (1H, m, Ar H), 8.17 (1H, 
d, J 8.0 Hz Ar H); δC (100 MHz, DMSO-d6) 10.8 (CH3), 18.3 (CH3), 26.5 (CH2), 49.7 
(CH3), 54.9 (CH), 119.5 (CH), 126.2 (C), 126.3 (CH), 127.2 (CH), 127.7 (CH), 128.7 (CH), 
129.5 (CH) 130.5 (CH), 131.0 (CH), 131.4 (CH), 132.1 (C), 136.1 (C), 137.4 (C), 147.9 
(C), 157.0 (C), 168.9 (C);  m/z (CI) 352.1336 (M+. C21H2135ClN2O requires 352.1342), 239 
(95%), 203 (65), 176 (24), 86 (100). 
 
Methyl 1-(2-Bromophenyl)isoquinoline-3-carboxylate 72 
 
N
72
CO2Me
Br
 
 
The reaction was carried out according to general procedure 1 using methyl 1-
bromoisoquinoline-3-carboxylate 45 (1.90 g, 7.15 mmol) and 2-bromoboronic acid (1.90 g, 
9.29 mmol) and gave methyl 1-(2-bromophenyl)isoquinoline-3-carboxylate 72 as a yellow 
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solid (1.20 g, 60%). mp 160–161 °C; νmax/cm–1 (neat) 2939 (CH), 1715 (CO), 1562, 1450, 
1292, 675; δH (400 MHz, CDCl3) 4.05 (3H, s, CH3), 7.35–7.40 (1H, m, Ar H), 7.48 (2H, d, 
J 4.4 Hz, Ar H) 7.65–7.66 (2H, m, Ar H), 7.71 (1H, d, J 7.6 Hz, Ar H), 7.77–7.79 (1H, m, 
Ar H), 8.04 (1H, d, J 8.0 Hz, Ar H), 8.67 (1H, s, 4-H);  δC (100 MHz, CDCl3) 53.1 (CH3), 
121.5 (C), 122.6 (CH), 125.9 (CH), 126.0 (CH), 126.8 (CH), 127.0 (C), 128.0 (CH), 128.6 
(CH), 129.4 (CH), 129.9 (CH), 131.2 (CH), 134.3 (C), 138.1 (C), 139.2 (C), 158.8 (C), 
164.8 (C);  m/z (EI) 341.0058 (M+. C17H1279BrNO2 requires 341.0051), 283 (53), 203 (31), 
83 (100), 47 (25). 
 
1-(2-Bromophenyl)isoquinoline-3-carboxylic acid 73 
 
N
73
CO2H
Br
 
 
The reaction was carried out according to procedure 2 using methyl 1-(2-
bromophenyl)isoquinoline-3-carboxylate 72 (1.50 g, 4.38 mmol) and sodium hydroxide 
(0.57 g, 14.2 mmol) and gave 1-(2-bromophenyl)isoquinoline-3-carboxylic acid 73 as a 
white solid (1.30 g, 91%); mp 178–179 °C; νmax/cm–1 (neat) 2619 (CH), 1695 (CO), 1427, 
1257, 906, 729; δH (400 MHz, CDCl3) 7.43–7.48 (2H, m, Ar H), 7.52–7.56 (1H, m, Ar H), 
7.70–7.81 (3H, m, Ar H), 7.84–7.88 (1H, m, Ar H), 8.12 (1H, d, J 8.4 Hz, Ar H), 8.74 (1H, 
s, 4-H);  δC (100 MHz, CDCl3) 120.9 (C), 121.0 (C), 125.7 (CH), 126.0 (CH), 127.0 (CH), 
127.1 (CH), 128.5 (CH), 129.0 (CH), 129.4 (CH), 130.0 (CH), 131.4 (CH), 135.0 (C) 
136.7 (C), 136.8 (C), 157.3 (C), 163.1 (C);  m/z (CI) 326.9891 (MH+. C16H1079BrNO2 
requires 326.9895), 283 (100%), 204 (92), 83 (47). 
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1-(2-Bromophenyl)isoquinoline-3-N-sec-butylcarboxamide 74  
 
N
N
H
O
Br
74  
 
The reaction was carried out according to general procedure 3 using 1-(2-
bromophenyl)isoquinoline-3-carboxylic acid 73 (0.30 g, 0.90 mmol) and sec-butylamine 
(2.76 mL, 27.4 mmol) and gave 1-(2-bromophenyl)isoquinoline-3-N-sec-butylcarboxamide 
74 as a white solid (0.21 g, 60%). mp 112–114 °C; νmax/cm–1 (KBr) 3384 (NH), 2966 (CH), 
1666 (CO), 1509, 1379, 758; δH (400 MHz, CDCl3) 0.96 (3H, t, J 7.4 Hz, CHCH2CH3), 
1.26 (3H, d, J 6.6 Hz, NCHCH3), 1.53–1.64 (2H, m, CH2CH3), 4.14–4.21 (1H, m, NCH), 
7.40–7.54 (2H, m, Ar H), 7.57–7.61 (1H, m, Ar H), 7.67–7.70 (1H, m, Ar H), 7.73–7.80 
(2H, m, Ar H), 8.05 (2H, d, J 8.0 Hz, Ar H), 8.67 (1H, s, 4-H); δC (100 MHz, CDCl3) 10.6 
(CH3), 20.5 (CH3), 29.9 (CH2), 46.8 (CH), 120.2 (CH), 123.2 (C), 127.2 (CH), 127.3 (CH), 
128.1 (C), 128.6 (CH), 128.8 (CH), 130.2 (CH), 130.7 (CH) 131.5 (CH), 133.2 (CH), 
136.8 (C), 139.8 (C), 142.9 (C), 158.4 (C), 164.1 (C);  m/z (CI) 383.0757 (MH+. 
C20H2079BrN2O requires 383.0759), 303 (18%), 196 (32), 71 (100). 
 
1-(2-Bromophenyl)isoquinoline-3-N-methyl-N-sec-butylcarboxamide 63  
 
N
N
O
Br
63  
 
The reaction was carried out according to general procedure 4 using 1-(2-
bromophenyl)isoquinoline-3-N-sec-butylcarboxamide 74 (0.18 g, 0.47 mmol) and methyl 
iodide (0.47 mL, 7.52 mmol) and gave 1-(2-bromophenyl)isoquinoline-3-N-methyl-N-sec-
butylcarboxamide 63 as a yellow oil (0.17 g, 91%). NMR spectra showed a 3:1 mixture of 
rotamers, only signals for the major rotamer is recorded. νmax/cm–1 (neat) 2968 (CH), 1622 
(CO), 1472, 1091, 909; δH (400 MHz, CDCl3) 0.97–1.00 (3H, m, CHCH2CH3), 1.17–1.28 
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(3H, m, NCHCH3), 1.52–1.66 (2H, m, CH2CH3), 2.97 (3H, s, NCH3), 3.89–3.95 (1H, m, 
NCHCH3), 7.36–7.45 (3H, m, Ar H), 7.53–7.64 (2H, m, Ar H), 7.71–7.75 (2H, m, Ar H), 
7.94–8.06 (2H, m, Ar H); δC (100 MHz, CDCl3) 11.1 (CH3), 18.5 (CH3), 27.4 (CH2), 50.4 
(CH3), 55.7 (CH), 120.0 (CH), 120.4 (CH), 120.7 (CH), 122.8 (C), 127.3 (CH), 128.2 (CH), 
130.1 (CH), 130.7 (CH), 131.3 (CH), 132.8 (CH), 136.6 (C), 139.8 (C), 148.3 (C), 159.0 
(C), 169.4 (C), 170.1 (C);  m/z (CI) 397.0916 (MH+. C21H2179BrN2O requires 397.0915), 
317 (87), 284 (3). 
 
1-(2-Iodophenyl)isoquinoline-3-N-methyl-3-N-sec-butylcarboxamide 61 
 
N
I
61
N
O
 
 
A Schlenk tube was charged with copper iodide (0.01 g, 0.02 mmol) and sodium iodide 
(0.10 g, 0.64 mmol), evacuated and backfilled with argon.  N,N-Dimethylethylenediamine 
(0.01 g, 0.03 mmol) and 1-(2-bromophenyl)isoquinoline-3-N-methyl-N-sec-
butylcarboxamide 63 (0.13 g, 0.32 mmol) were dissolved in butan-1-ol (6 mL) and added 
to the Schlenk tube.  The Schlenk tube was sealed with a Teflon valve and the reaction 
mixture stirred at 120 °C for 24 h.  The reaction had not gone to completion therefore more 
equivalents of copper iodide (0.01 g, 0.02 mmol), sodium iodide (0.10 g, 0.64 mmol) and 
N,N-dimethylethylenediamine (0.01 g, 0.03 mmol) were added and left for another 72 h.  
The reaction was diluted with water, extracted with ethyl acetate (3 × 20 mL), dried 
(MgSO4) and concentrated to dryness. The product was purified by flash column 
chromatography, using a graduated eluent with petroleum ether/ethyl acetate to give 1-(2-
Iodophenyl)isoquinoline-3-N-methyl-3-N-sec-butylcarboxamide 61 as a yellow oil (0.09 g, 
63%). NMR spectra showed a 3:1 mixture of rotamers, only signals for the major rotamer 
is recorded. νmax/cm–1 (NaCl) 2966 (CH), 1629 (CO), 1464, 1242, 754; δH (400 MHz, 
CDCl3) 0.74–0.84 (3H, m, CH2CH3), 1.23 (3H, t, J 6.4 Hz, NCHCH3), 1.49–1.68 (2H, m, 
CH2CH3), 2.98 (3H, s, NCH3), 3.91–4.04 (1H, m, NCHCH3), 7.18–7.22 (1H, m, Ar H), 
7.33–7.42 (1H, m, Ar H), 7.47–7.57 (3H, m, Ar H), 7.71–7.74 (1H, m, Ar H), 7.94–8.06 
(3H, m, Ar H); δC (100 MHz, CDCl3) 11.1 (CH3), 18.6 (CH3), 26.3 (CH3) 27.4 (CH2), 55.8 
(CH), 97.6 (C), 119.9 (CH), 120.5 (CH), 127.1 (CH), 127.4 (CH), 128.2 (CH), 128.3 (CH), 
130.2 (CH) 130.8 (CH), 132.8 (C), 136.7 (C), 139.1 (CH), 142.8 (C), 148.1 (C), 161.7 (C), 
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170.2 (C);  m/z (FAB) 445.0775 (MH+. C21H22IN2O requires 445.0777), 397 (21%), 330 
(33), 203 (19), 88 (25). 
 
Butyl 1-(2-iodophenyl)isoquinoline-3-carboxylate 75 
 
N
O
O
I
75  
 
A Schlenk tube was charged with copper iodide (0.01 g, 0.03 mmol) and sodium iodide 
(0.18 g, 1.17 mmol), evacuated and backfilled with argon.  N,N-Dimethylethylenediamine 
(0.01 g, 0.03 mmol) and methyl 1-(2-bromophenyl)isoquinoline-3-carboxylate 72 (0.20 g, 
0.58 mmol) were dissolved in butan-1-ol (7 mL) and added to the Schlenk tube.  The 
Schlenk tube was sealed with a Teflon valve and the reaction mixture stirred at 135 °C for 
18 h.  The reaction had not gone to completion therefore more equivalents of copper iodide 
(0.01 g, 0.03 mmol), sodium iodide (0.18 g, 1.17 mmol) and N,N-dimethylethylenediamine 
(0.01 g, 0.03 mmol) were added and left for another 18 h.  The reaction was diluted with 
water, extracted with ethyl acetate (3 × 20 mL), dried (MgSO4) and concentrated to 
dryness. The product was purified by flash column chromatography, using a graduated 
eluent with petroleum ether/ethyl acetate to give butyl 1-(2-iodophenyl)isoquinoline-3-
carboxylate 75 as yellow oil (0.13 g, 52%). νmax/cm–1 (NaCl) 2957 (CH), 1712 (CO), 1465, 
1239, 1098, 758;  δH (400 MHz, CDCl3) 0.99 (3H, t, J 7.4 Hz, CH2CH2CH3), 1.46–1.60 
(2H, m, CH2CH2CH3), 1.80–1.87 (2H, m, CH2CH2CH3), 4.47 (2H, td, J 6.8, 1.6 Hz, 
OCH2), 7.17–7.21 (1H, m, Ar H), 7.43–7.52 (2H, m, Ar H), 7.62–7.66 (2H, m, Ar H), 
7.71–7.80 (1H, m, Ar H), 7.90 (1H, d, J 8.4 Hz, Ar H), 8.05 (1H, d, J 8.4 Hz, Ar H), 8.62 
(1H, s, 4-CH); δC (100 MHz, CDCl3) 12.4 (CH3), 17.5 (CH2), 29.3 (CH2), 64.2 (CH2), 96.7 
(C), 122.4 (CH), 126.1 (CH), 126.7 (CH),  127.0 (CH), 128.1 (CH), 128.7 (CH), 129.3 
(CH), 130.1 (CH), 134.5 (C), 137.7 (C), 138.2 (CH), 139.6 (C), 141.9 (C), 161.2 (C), 164.3 
(C); m/z (EI) 431.0388 (M+. C20H18INO2 requires 431.0382), 358 (14), 331 (100), 203 (59).  
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1-(2-Iodophenyl)isoquinoline-3-carboxylic acid 60 
 
N
60
CO2H
I
 
 
The reaction was carried out according to general procedure 2 using butyl 1-(2-
iodophenyl)isoquinoline-3-carboxylate 75 (0.18 g, 0.41 mmol) and sodium hydroxide 
(0.06 g, 1.67 mmol) and gave 1-(2-iodophenyl)isoquinoline-3-carboxylic acid 60 as a 
yellow oil (0.14 g, 89%); mp 174–176 °C; νmax/cm–1 (NaCl) 2923 (CH), 2902 (CH), 1719 
(CO), 1379, 1101, 752; δH (400 MHz, CDCl3) 7.26–7.29 (1H, m, Ar H), 7.41–7.45 (1H, m, 
Ar H), 7.51–7.58 (1H, m, Ar H), 7.71–7.80 (2H, m, Ar H), 7.86 (1H, t, J 6.4 Hz, Ar H), 
8.07 (1H, d, J 8.0 Hz, Ar H), 8.13 (1H, d, J 8.0 Hz, Ar H), 8.75 (1H, s, 4-H);  δC (100 MHz, 
CDCl3) 97.4 (C), 122.7 (CH), 127.8 (CH), 128.1 (CH), 128.9 (CH), 130.2 (CH), 130.6 
(CH), 131.7 (CH), 131.8 (CH), 133.1 (C), 136.6 (CH), 137.2 (C), 138.0 (C), 139.6 (C), 
142.2 (C), 161.3 (C); m/z (EI) 374.9760 (M+. C16H10INO2 requires 374.9756), 331 (10%), 
204 (19), 134 (25), 83 (100), 44 (60). 
 
1-(2-Iodophenyl)isoquinoline-3-N-sec-butylcarboxamide 
 
N
I
N
H
O
 
 
The reaction was carried out according to general procedure 3 using 1-(2-
iodophenyl)isoquinoline-3-carboxylic acid 60 (0.13 g, 0.34 mmol) and sec-butylamine 
(1.05 mL, 10.4 mmol) and gave 1-(2-iodophenyl)isoquinoline-3-N-sec-butylcarboxamide 
as a colourless oil (0.10 g, 74%). νmax/cm–1 (NaCl) 3377 (NH), 2964 (CH), 1669 (CO), 
1619, 1515, 1017, 733; δH (400 MHz, CDCl3) 0.87–0.92 (3H, m, CHCH2CH3 ), 1.17–1.20 
(3H, m, NCHCH3), 1.51–1.58 (2H, m, CH2CH3), 4.05–4.16 (1H, m, NCHCH3), 7.14–7.17 
(1H, m, Ar H), 7.34–7.39 (1H, m, Ar H), 7.44–7.53 (2H, m, Ar H), 7.58–7.61 (1H, m, Ar 
H), 7.66–7.72 (1H, m, Ar H), 7.97–8.01 (2H, m, Ar H), 8.59 (1H, s, 4-H); δC (100 MHz, 
CDCl3) 8.6 (CH3), 18.5 (CH3), 27.7 (CH2), 44.7 (CH), 96.1 (C), 118.1 (CH), 121.1 (CH), 
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125.4 (C), 125.9 (CH), 126.5 (CH), 128.1 (CH), 128.7 (C) 129.5 (CH), 131.1 (CH), 134.9 
(CH), 137.7 (CH), 140.7 (C), 141.2 (C), 158.5 (C), 162.1 (C); m/z (FAB) 431.0623 (MH+. 
C20H20IN2O requires 431.0620), 383 (20%), 330 (42), 203 (23), 148 (31). 
 
1-(2-Iodophenyl)isoquinoline-3-N-methyl-3-N-sec-butylcarboxamide 61 
 
N
I
61
N
O
 
 
The reaction was carried out according to general procedure 4 using 1-(2-
iodophenyl)isoquinoline-3-N-sec-butylcarboxamide (0.10 g, 0.23 mmol) and methyl iodide 
(0.22 mL, 3.73 mmol) and gave 1-(2-iodophenyl)isoquinoline-3-N-methyl-3-N-sec-
butylcarboxamide 61 as an yellow oil (0.05 g, 48%). NMR spectra showed a 3:1 mixture of 
rotamers, only signals for the major rotamer is recorded. νmax/cm–1 (NaCl) 2966 (CH), 1629 
(CO), 1464, 1242, 754; δH (400 MHz, CDCl3) 0.74–0.84 (3H, m, CH2CH3), 1.23 (3H, t, J 
6.4 Hz, NCHCH3), 1.49–1.68 (2H, m, CH2CH3), 2.98 (3H, s, NCH3), 3.91–4.04 (1H, m, 
NCHCH3), 7.18–7.22 (1H, m, Ar H), 7.33–7.42 (1H, m, Ar H), 7.47–7.57 (3H, m, Ar H), 
7.71–7.74 (1H, m, Ar H), 7.94–8.06 (3H, m, Ar H); δC (100 MHz, CDCl3) 11.1 (CH3), 
18.6 (CH3), 26.3 (CH3) 27.4 (CH2), 55.8 (CH), 97.6 (C), 119.9 (CH), 120.5 (CH), 127.1 
(CH), 127.4 (CH), 128.2 (CH), 128.3 (CH), 130.2 (CH) 130.8 (CH), 132.8 (C), 136.7 (C), 
139.1 (CH), 142.8 (C), 148.1 (C), 161.7 (C), 170.2 (C);  m/z (FAB) 445.0775 (MH+. 
C21H22IN2O requires 445.0777), 397 (21%), 330 (33), 203 (19), 88 (25). 
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1-(2-(Trimethylstannyl)phenyl)isoquinoline-3-N-methyl-3-N-sec-butylcarboxamide 64 
 
N
N
O
SnMe3
64  
 
1-(2-Bromophenyl)isoquinoline-3-N-methyl-N-sec-butylcarboxamide 63 (0.10 g, 0.25 
mmol) and toluene (15 mL) were de-gased for 0.5 h.  Hexamethylditin (0.10 mL, 0.50 
mmol) and tetrakis(triphenylphosphine)palladium (0.01 g, 0.09 mmol) were added to the 
reaction mixture and heated under reflux for 48 h.  The black mixture was diluted with 
dichloromethane (15 mL), filtered and the solvent removed by rotary evaporation.  The 
product was purified by flash column chromatography using graduated eluent with 
petroleum ether > petroleum ether/ethyl acetate (50:50) to give 1-(2-
(trimethylstannyl)phenyl)isoquinoline-3-N-methyl-N-sec-butylcarboxamide 64 as a yellow 
oil (0.02 g, 13%). NMR spectra showed a 3:1 mixture of rotamers, only signals for the 
major rotamer is given here. νmax/cm–1 (NaCl) 2967 (CH), 1636 (CO), 1459, 1090, 757; δH 
(400 MHz, CDCl3) 0.04 (9H, s, Sn(CH3)3), 0.88 (3H, t, J 7.3 Hz, CHCH2CH3), 1.28 (3H, d, 
J 6.5 Hz, NCHCH3), 1.44–1.57 (2H, m, CH2CH3), 3.13 (3H, s, NCH3), 3.88–4.05 (1H, m, 
NCHCH3), 7.60–7.65 (2H, m, Ar H), 7.70–7.74 (2H, m, Ar H), 7.86–7.91 (2H, m, Ar H), 
8.06–8.10 (2H, m, Ar H), 8.17 (1H, d, J 8.4 Hz, 4-H);  δC (100 MHz, CDCl3) 8.1 (3 × CH3), 
11.2 (CH3), 18.4 (CH3), 26.8 (CH3), 27.4 (CH2), 55.7 (CH), 119.4 (C), 119.5 (CH), 127.0 
(C), 127.5 (CH), 127.6 (CH), 127.9 (CH), 129.7 (CH), 130.1 (CH), 130.5 (CH), 136.8 
(CH), 136.9 (CH), 145.5 (C), 148.3 (C), 148.5 (C), 162.2 (C), 169.3 (C); m/z (CI) 483.1458 
(MH+. C24H31N2O118Sn requires 483.1458), 479 (43%), 467 (32), 463 (13), 319 (6), 165 (4).  
Ethyl 3-methyl-4-hydroxyquinoline-2-carboxylate 8193 
N
OH
81
CO2Et
 
To a solution of aniline 83 (2.25 mL, 24.7 mmol) and diethyl oxalpropionate 82 (4.57 mL, 
24.7 mmol) in cyclohexane (200 mL) was added p-toluenesulfonic acid (0.03 g, 0.17 
mmol) and the mixture heated under reflux under an argon atmosphere at 120 °C using a 
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Dean-Stark condenser for 48 h. The reaction mixture was cooled to room temperature, 
filtered, washed with hexane and the solvent of the combined filtrate removed under 
reduced pressure. To this crude oil product was added polyphosphoric acid (20.0 g) and the 
mixture was stirred at 120 °C for 1 h to form a dark brown substance. The substance was 
cooled to room temperature and 2.4 M sodium carbonate solution (100 mL) was added 
slowly to quench the excess acid and precipitated the product as a yellow solid. The 
mixture was filtered, followed by dissolving in chloroform and hot filtering to remove 
insoluble impurities. Purification by flash column chromatography using a graduated 
eluent of petroleum ether > petroleum ether/ethyl acetate (50:50) afforded ethyl 3-methyl-
4-hydroxyquinoline-2-carboxylate 81 as a yellow solid (3.14 g, 53%). mp 176–178 °C; 
νmax/cm–1 (KBr) 3395 (OH), 2973 (CH), 1736 (CO), 1520, 1476, 1231, 763; δH (400 MHz, 
CDCl3) 1.48 (3H, t, J 7.2 Hz, OCH2CH3), 2.49 (3H, s, 3-CH3), 4.52 (2H, q, J 7.2 Hz, 
OCH2CH3), 7.31–7.37 (2H, m, Ar H), 7.62 (1H, ddd, J 8.4, 5.5, 1.5 Hz, Ar H), 8.35 (1H, d, 
J 8.4 Hz, Ar H), 9.18 (1H, s, OH); δC (100 MHz, CDCl3) 11.7 (CH3), 14.2 (CH3), 63.3 
(CH2), 117.5 (CH), 122.8 (C), 123.7 (C), 123.8 (CH), 126.6 (CH), 132.7 (CH), 132.8 (C), 
138.3 (C), 164.4 (C), 179.7 (C); m/z (EI) 231.0897 (M+. C13H13NO3 requires 231.0895), 
202 (100%), 157 (98), 129 (46), 84 (41).  
Ethyl 3-methyl-4-bromoquinoline-2-carboxylate 80 
80
N
Br
CO2Et
 
To a solution of ethyl 3-methyl-4-bromoquinoline-2-carboxylate 81 (4.55 g, 19.6 mmol) in 
anhydrous acetonitrile (250 mL) was added phosphorous oxybromide (16.9 g, 59.1 mmol) 
and anhydrous potassium carbonate (8.16 g, 59.1 mmol). The solution was heated under 
reflux for 2 h. The reaction mixture was cooled to room temperature and concentrated 
under reduced pressure to form an oil. Water (100 mL) was added to the residue and 
subsequently extracted with ethyl acetate (100 mL). The ethyl acetate layer was removed 
under reduced pressure to form a brown oil from which ethyl 3-methyl-4-bromoquinoline-
2-carboxylate precipitated as a brown solid 80 (4.85 g, 84%). mp 48–50 °C; νmax/cm–1 
(KBr) 2983 (CH), 1714 (CO), 1479, 1272, 759; δH (400 MHz, CDCl3) 1.48 (3H, t, J 7.1 Hz, 
OCH2CH3), 2.72 (3H, s, 3-CH3), 4.55 (2H, q, J 7.1 Hz, OCH2CH3), 7.68 (1H, ddd, J 8.3, 
6.9, 1.4 Hz, Ar H), 7.75 (1H, ddd, J 8.3, 6.9, 1.4 Hz, Ar H), 8.18 (1H, d, J 8.3 Hz, Ar H), 
8.25 (1H, d, J 8.3 Hz Ar H); δC (100 MHz, CDCl3) 14.2 (CH3), 19.9 (CH3), 62.5 (CH2), 
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126.8 (CH), 128.5 (C), 129.3 (CH), 129.5 (C), 129.9 (CH), 130.1 (CH), 137.7 (C), 145.6 
(C), 150.8 (C), 166.2 (C); m/z (EI) 293.0053 (M+. C13H1279BrNO2 requires 293.0051), 264 
(39%), 221 (73), 140 (100), 114 (21), 84 (81).  
Ethyl 3-methyl-4-bromophenylquinoline-2-carboxylate 91 
91
N CO2Et
Br
 
The reaction was carried out according to general procedure 1 using ethyl 3-methyl-4-
bromoquinoline-2-carboxylate 80 (3.70 g, 12.5 mmol) and bromophenylboronic acid (3.28 
g, 16.4 mmol) and gave ethyl 3-methyl-4-bromophenylquinoline-2-carboxylate 91 as a 
white solid (3.47 g, 75%). mp 88–90 °C; νmax/cm–1 (KBr) 2987 (CH), 1719 (CO), 1468, 
1370, 1244, 1072, 754; δH (400 MHz, CDCl3) 1.49 (3H, t, J 7.2 Hz, OCH2CH3), 2.29 (3H, 
s, 3-CH3), 4.55 (2H, q, J 7.2 Hz, OCH2CH3), 7.18–7.24 (2H, m, Ar H), 7.36–7.41 (1H, m, 
Ar H), 7.45–7.52 (2H, m, Ar H), 7.69 (1H, ddd, J 8.3, 6.7, 1.4 Hz, Ar H), 7.78 (1H, d, J 8.5 
Hz, Ar H), 8.21 (1H, d, J 8.5 Hz, Ar H); δC (100 MHz, CDCl3) 14.3 (CH3), 16.5 (CH3), 
62.2 (CH2), 123.4 (C), 125.4 (CH), 127.0 (C), 127.5 (C), 127.8 (CH), 128.1 (CH), 129.2 
(CH), 130.0 (CH), 130.1 (CH), 130.8 (CH), 133.1 (CH), 137.7 (C), 145.7 (C), 147.4 (C), 
151.4 (C), 167.7 (C); m/z (EI) 369.0360 (M+. C19H1679BrO2 requires 369.0364), 342 (11%), 
297 (70), 216 (100), 189 (31), 82 (49). 
3-Methyl-4-bromophenylquinoline-2-carboxylic acid 93 
93
N CO2H
Br
 
The reaction was carried out according to general procedure 2 using ethyl 3-methyl-4-
bromophenylquinoline-2-carboxylate 91 (2.53 g, 6.84 mmol) and sodium hydroxide (0.41 
g, 10.3 mmol) and gave 3-methyl-4-bromophenylquinoline-2-carboxylic acid 93 as a white 
solid (2.16  g, 92%). mp 133–134 °C; νmax/cm–1 (KBr) 3479 (OH), 2932 (CH), 1747 (CO), 
1470, 1375, 1230, 1023, 766; δH (400 MHz, CDCl3) 2.62 (3H, s, 3-CH3), 7.18–7.20 (1H, d, 
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J 7.5 Hz, Ar H), 7.26–7.28 (1H, m, Ar H), 7.40–7.44 (1H, m, Ar H), 7.49–7.61 (2H, m, Ar 
H), 7.75–7.82 (2H, m, Ar H), 7.69 (1H, d, J 8.4 Hz, Ar H), 7.78 (1H, d, J 8.5 Hz, Ar H), 
8.21 (1H, d, J 8.5 Hz, Ar H); δC (100 MHz, CDCl3) 17.0 (CH3), 123.4 (C), 125.8 (CH), 
126.5 (C), 127.9 (CH), 128.8 (CH), 129.0 (C), 129.2 (CH), 129.5 (CH), 130.1 (CH), 130.7 
(CH), 133.2 (CH), 137.3 (C), 143.8 (C), 144.8 (C), 150.0 (C), 164.4 (C); m/z (EI) 341.0054 
(M+. C17H1279BrO2 requires 341.0051), 342 (11%), 297 (13), 262 (28), 216 (99), 189 (23), 
108 (11), 63 (4). 
Ethyl 3-methyl-4-phenylquinoline-2-carboxylate 9471 
94
N CO2Et
 
The reaction was carried out according to general procedure 1 using ethyl 3-methyl-4-
bromoquinoline-2-carboxylate 80 (3.40 g, 11.6 mmol) and phenylboronic acid (2.64 g, 
21.7 mmol) and gave ethyl 3-methyl-4-phenylquinoline-2-carboxylate 94 as a white solid 
(3.33 g, 99%). mp 110–112 °C (lit.,71 mp 114–115 °C); νmax/cm–1 (KBr) 2972 (CH), 1723 
(CO), 1488, 1372, 1245, 1065, 768; δH (400 MHz, CDCl3) 1.48 (3H, t, J 7.2 Hz, 
OCH2CH3), 2.32 (3H, s, 3-CH3), 4.55 (2H, q, J 7.2 Hz, OCH2CH3), 7.23–7.27 (2H, m, Ar 
H), 7.37–7.56 (5H, m, Ar H), 7.67 (1H, ddd, J 8.3, 6.7, 1.4 Hz, Ar H), 8.19 (1H, d, J 8.3 
Hz, Ar H); δC (100 MHz, CDCl3) 14.3 (CH3), 16.8 (CH3), 62.1 (CH2), 126.0 (CH), 126.2 
(C), 127.7 (CH), 128.1 (CH), 128.2 (C), 128.7 (2 × CH), 129.0 (CH), 129.2 (2 × CH), 
129.8 (CH), 136.7 (C), 145.6 (C), 148.7 (C), 151.5 (C), 167.4 (C); m/z (CI) 292.1336 
(MH+. C19H18NO2 requires 292.1338), 220 (48%), 137 (3), 113 (9), 85 (19).  
3-Methyl-4-phenylquinoline-2-carboxylic acid 96 
96
N CO2H
 
The reaction was carried out according to general procedure 2 using ethyl 3-methyl-4-
phenylquinoline-2-carboxylate 94 (1.97 g, 6.77 mmol) and sodium hydroxide (0.62 g, 15.4 
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mmol) and gave 4-phenyl-3-methylquinoline-2-carboxylic acid 96 as a white solid (1.66 g, 
92%). mp 130–132 °C; νmax/cm–1 (KBr) 3437 (OH), 2931 (CH), 1722 (CO), 1649 (C=C), 
1590, 1364, 1317, 768; δH (400 MHz, CDCl3) 2.65 (3H, s, 3-CH3), 7.23–7.25 (2H, m, Ar 
H), 7.43 (1H, d, J 8.3 Hz, Ar H), 7.50–7.60 (4H, m, Ar H), 7.75 (1H, ddd, J 8.3, 6.9, 1.2 
Hz, Ar H), 8.14 (1H, d, J 8.3 Hz, Ar H); δC (100 MHz, CDCl3) 17.4 (CH3), 126.5 (CH), 
128.4 (CH), 128.8 (2 × CH), 129.0 (CH), 129.1 (CH), 129.2 (2 × CH), 129.7 (C), 129.8 
(CH), 130.2 (C), 136.4 (C), 143.6 (C), 144.2 (C), 151.4 (C), 164.4 (C); m/z (CI) 264.1027 
(MH+. C17H14NO2 requires 264.1025), 220 (19%), 188 (3), 85 (27).  
3-Methyl-4-phenylquinoline-2-N-sec-butylcarboxamide 9762 
N
N
H
O
97  
The reaction was carried out according to general procedure 3 using 3-methyl-4-
phenylquinoline-2-carboxylic acid 96 (1.21 g, 4.61 mmol) and sec-butylamine (6.90 mL, 
68.4 mmol) and gave 3-methyl-4-phenylquinoline-2-N-sec-butylcarboxamide 97 as a white 
solid (1.02 g, 70%). mp 152–154 °C (lit.,62 mp 157–158 °C); νmax/cm–1 (KBr) 3282 (NH), 
2967 (CH), 1639 (CO), 1535, 1443, 1156, 761; δH (400 MHz, CDCl3) 1.03 (3H, t, J 7.4 Hz, 
CHCH2CH3), 1.33 (3H, d, J 6.6 Hz, CHCH3), 1.61–1.75 (2H, m, CH2CH3), 2.56 (3H, s, 3-
CH3), 4.08–4.20 (1H, m, CHCH3), 7.21–7.25 (2H, m, Ar H), 7.35 (1H, d, J 8.3 Hz, Ar H), 
7.40–7.55 (3H, m, Ar H), 7.65 (1H, ddd, J 8.3, 6.8, 1.4 Hz, Ar H), 7.90 (1H, d, J 8.3 Hz, 
Ar H), 8.09 (1H, d, J 8.3 Hz, Ar H); δC (100 MHz, CDCl3) 10.6 (CH3), 17.6 (CH3), 20.5 
(CH3), 29.9 (CH2), 46.8 (CH), 126.1 (CH), 127.5 (CH), 127.9 (CH), 128.5 (C), 128.6 (2 × 
CH), 128.7 (CH and C), 129.3 (2 × CH), 129.4 (CH), 137.2 (C), 144.6 (C), 149.4 (C), 
150.1 (C), 166.2 (C); m/z (CI) 319.1809 (MH+. C21H23N2O requires 319.1810), 220 (19%), 
202 (5), 148 (6), 113 (16), 85 (77).  
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3-Methyl-4-phenylquinoline-2-N-methyl-N-sec-butylcarboxamide 9562  
N
N
O
95  
The reaction was carried out according to general procedure 4 using 3-methyl-4-
phenylquinoline-2-N-sec-butyl-carboxamide 97 (0.90 g, 2.84 mmol) and methyl iodide 
(1.53 mL, 24.6 mmol) and gave 3-methyl-4-phenylquinoline-2-N-methyl-N-sec-
butylcarboxamide 95 as a dark orange solid (0.77 g, 82%). NMR spectra showed a 3:1 
mixture of rotamers, only signals for the major rotamer is recorded. mp 114–117 °C (lit.,62 
mp 117–118 °C); νmax/cm–1 (KBr) 2963 (CH), 1628 (CO), 1465, 1072, 771; δH (400 MHz, 
CDCl3) 0.86 (3H, t, J 7.3 Hz, CH2CH3), 1.24 (3H, d, J 6.6 Hz, CHCH3), 1.55–1.70 (2H, m, 
CH2CH3), 2.23 (3H, s, 3-CH3), 3.05 (3H, s, NCH3), 3.42–3.53 (1H, m, CHCH3), 7.25–7.31 
(2H, m, Ar H), 7.38–7.44 (2H, m, Ar H), 7.47–7.57 (3H, m, Ar H), 7.62–7.67 (1H, m, Ar 
H), 8.10 (1H, d, J 8.3 Hz, Ar H); δC (100 MHz, CDCl3) 11.3 (CH3), 16.4 (CH3), 18.6 (CH3), 
25.5 (CH3), 27.2 (CH2) 49.5 (CH) 125.3 (C), 125.9 (CH), 126.8 (2 × CH), 127.4 (C), 128.0 
(CH), 128.6 (CH), 128.7 (CH), 129.2 (2 × CH), 129.4 (CH), 136.8 (C), 145.8 (C), 148.0 
(C), 156.1 (C), 169.7 (C); m/z (EI) 332.1888 (M+. C22H24N2O requires 332.1889), 303 
(35%), 275 (22), 218 (89), 189 (25), 86 (100).  
3-Bromomethyl-4-phenylquinoline-2-N-methyl-N-sec-butylcarboxamide 98  
N
N
O
Br
98  
To a stirred, degassed solution of 3-methyl-4-phenylquinoline-2-N-methyl-N-sec-
butylcarboxamide 95 (0.10 g, 0.30 mmol) in carbon tetrachloride (20 mL), was added N-
bromosuccinimide (0.06 g, 0.34 mmol) and dibenzoyl peroxide (0.01 g, 0.03 mmol) and 
the orange solution heated under reflux for 24 h. The reaction mixture was cooled to room 
temperature and a second portion of N-bromosuccinimide (0.06 g, 0.34 mmol) and 
dibenzoyl peroxide (0.01 g, 0.03 mmol) were added. The solution was heated under reflux 
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for a further 48 h. A third quota of N-bromosuccinimide (0.06 g, 0.34 mmol) and dibenzoyl 
peroxide (0.01 g, 0.03 mmol) was added after 48 h and the reaction heated under reflux for 
a final 24 h. The reaction mixture was cooled to room temperature, filtered and the solvent 
removed under reduced pressure. The crude product (orange oil) was purified by flash 
column chromatography using an graduated eluent of dichloromethane > 
dichloromethane/ethyl acetate (95:5) and afforded 3-bromomethyl-4-phenylquinoline-2-N-
methyl-N-sec-butylcarboxamide 98 as a white powder (0.06 g, 45%). NMR spectra showed 
a 2:1 mixture of rotamers, only signals for the major rotamer is recorded. mp 160–164 °C; 
νmax/cm–1 (KBr) 2966 (CH), 1630 (CO), 1483, 1396, 1045, 760; δH (400 MHz, CDCl3) 
1.08 (3H, t, J 7.4 Hz, CH2CH3), 1.32 (3H, d, J 6.8 Hz, CHCH3), 1.52–1.67 (2H, m, 
CH2CH3), 2.85 (3H, s, NCH3), 4.60 (1H, d, J 10.2 Hz, 3-CHHBr), 4.67 (1H, d, J 10.2 Hz, 
3-CHHBr), 4.83 (1H, sextet, J 6.8 Hz, CHCH3), 7.38–7.48 (4H, m, Ar H), 7.52–7.60 (3H, 
m, Ar H), 7.72 (1H, ddd, J 8.3, 6.7, 1.5 Hz, Ar H), 8.07–8.14 (1H, m, Ar H); δC (100 MHz, 
CDCl3) 11.2 (CH3), 17.1 (CH3), 26.6 (CH2), 27.8 (CH2), 30.5 (CH3), 50.2 (CH), 126.3 (C), 
126.8 (2 × CH), 127.5 (CH), 128.6 (2 × CH), 128.7 (CH), 129.1 (CH), 129.2 (CH), 129.5 
(CH), 134.9 (C), 135.0 (C), 146.4 (C), 149.4 (C), 156.0 (C), 168.4 (C); m/z (EI) 410.0995 
(M+. C22H2379BrN2O requires 410.0994), 330 (27%), 217 (57), 189 (28), 86 (100).  
3-Iodomethyl-4-phenylquinoline-2-N-methyl-N-sec-butylcarboxamide 65  
N
N
O
I
65  
To a stirred solution of 18-crown-6 (0.02 g, 0.06 mmol) in acetonitrile (40 mL) was added 
sodium iodide (0.47 g, 3.16 mmol) and the colourless solution stirred for 1 h at room 
temperature. To this, a solution of 3-bromomethyl-4-phenylquinoline-2-N-methyl-N-sec-
butylcarboxamide 98 (0.13 g, 0.32 mmol) in acetonitrile (10 mL) was added and the 
resulting cloudy mixture stirred at room temperature for 24 h. Water (10 mL) was added 
and the mixture was extracted using chloroform and the organic layer was dried (MgSO4). 
The chloroform was removed under reduced pressure to form a colourless oil which was 
subsequently purified by flash column chromatography using an graduated eluent of 
dichloromethane > dichloromethane/ethyl acetate (70:30). This afforded 3-iodomethyl-4-
phenylquinoline-2-N-methyl-N-sec-butylcarboxamide 65 as a brown solid (0.11 g, 74%). 
NMR spectra showed a 2:1 mixture of rotamers, only signals for the major rotamer is 
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recorded. mp 150–152 °C; νmax/cm–1 (KBr) 2963 (CH), 1628 (CO), 1483, 1091, 1044, 759; 
δH (400 MHz, CDCl3) 1.10 (3H, t, J 7.4 Hz, CHCH2CH3), 1.34 (3H, d, J 6.8 Hz, CHCH3), 
1.56–1.68 (2H, m, CH2CH3), 2.89 (3H, s, NCH3), 4.53 (1H, d, J 9.1 Hz, 3-CHHI), 4.67 
(1H, d, J 9.1 Hz, 3-CHHI), 4.87 (1H, sextet, J 6.8 Hz, CHCH3), 7.32–7.37 (1H, m, Ar H), 
7.39–7.47 (3H, m, Ar H), 7.52–7.60 (3H, m, Ar H), 7.67–7.73 (1H, m, Ar H), 8.09 (1H, t, J 
8.8 Hz, Ar H); δC (100 MHz, CDCl3) 10.9 (CH3), 16.7 (CH3), 26.3 (CH2), 27.5 (CH2), 30.3 
(CH3), 49.8 (CH), 126.2 (CH), 127.0 (CH), 127.1 (CH), 127.5 (C), 128.0 (C), 128.2 (CH), 
128.4 (2 × CH and C), 129.2 (2 × CH), 129.5 (CH), 129.6 (C) 145.6 (C), 148.2 (C), 168.0 
(C); m/z (EI) 458.0854 (M+. C22H23IN2O requires 458.0855), 331 (55%), 301 (10), 216 
(86), 189 (22), 151 (13), 86 (100).  
3-Methyl-4-phenylquinoline-2-N-diethylcarboxamide 99 
 
N
N
O
99
 
 
The reaction was carried out according to general procedure 3 using 3-methyl-4-
phenylquinoline-2-carboxylic acid 96 (0.50 g, 1.90 mmol) and diethylamine (5.9 mL, 57.0 
mmol) and gave 3-methyl-4-phenylquinoline-2-N-diethylcarboxamide 99 as a colourless 
oil (0.51 g 88%); νmax/cm–1 (NaCl) 2970 (CH), 1624 (CO), 1442, 1265, 763; δH (400 MHz, 
CDCl3) 1.17 (3H, t, J 7.2 Hz, CH2CH3), 1.34 (3H, t, J 7.2 Hz, CH2CH3), 2.22 (3H, s, 3-
CH3), 3.24 (2H, q, J 7.2 Hz, CH2CH3), 3.67 (2H, q, J 7.2 Hz, CH2CH3), 7.27 (2H, d, J 6.8 
Hz, Ar H), 7.39–7.40 (2H, m,  Ar H), 7.46–7.56 (3H, m, Ar H), 7.62–7.66 (1H, m, Ar H), 
8.11 (1H, d, J 8.4 Hz, Ar H); δC (100 MHz, CDCl3) 12.9 (CH3), 14.0 (CH3), 16.0 (CH3), 
39.3 (CH2), 42.9 (CH2), 125.0 (C), 126.0 (CH), 126.8 (CH), 128.1 (CH), 128.6 (2 × CH), 
128.8 (CH), 129.0 (C), 129.2 (2 × CH), 129.4 (CH), 136.6 (C), 145.8 (C), 147.9 (C), 156.1 
(C), 168.8 (C);  m/z (EI) 318.1736 (M+. C21H22N2O requires 318.1732), 247 (56%), 219 
(100), 189 (12), 72 (73), 44 (25). 
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3-Methyl-4-phenylquinoline-2-N-benzylcarboxamide  
 
N
N
H
O
 
 
The reaction was carried out according to general procedure 3 using 3-methyl-4-
phenylquinoline-2-carboxylic acid 96 (0.50 g, 1.90 mmol) and benzylamine (6.24 mL, 57.0 
mmol) and gave 3-methyl-4-phenylquinoline-2-N-benzylcarboxamide as a yellow oil (0.40 
g, 60%); νmax/cm–1 (NaCl) 3392 (NH), 2925 (CH), 1671 (CO), 1454, 1253, 766; δH (400 
MHz, CDCl3) 2.58 (3H, s, 3-CH3), 3.64 (1H, s, NH), 4.71 (2H, s, NHCH2), 7.19–7.23 (2H, 
m, Ar H), 7.25–7.30 (2H, m, Ar H) 7.33–7.42 (5H, m, Ar H), 7.44–7.54 (3H, m,  Ar H), 
7.61 (1H, ddd, J 8.4, 6.8, 1.6 Hz, Ar H), 8.03 (1H, d, J 8.4 Hz, Ar H); δC (100 MHz, 
CDCl3) 17.5 (CH3), 43.5 (CH2), 126.1 (CH), 126.9 (C), 127.4 (CH), 127.7 (CH), 128.0 
(CH), 128.6 (4 × CH), 128.8 (CH), 128.9 (CH), 129.5 (4 × CH), 137.1 (C), 138.4 (C), 
138.5 (C), 144.6 (C), 149.6 (C), 149.7(C), 166.6 (C);  m/z (EI) 352.1578 (M+. C24H20N2O 
requires 352.1576), 309 (25%), 219 (100), 91 (35). 
 
3-Methyl-4-phenylquinoline-2-N-phenethylcarboxamide  
 
N
N
H
O
 
 
The reaction was carried out according to general procedure 3 using 3-methyl-4-
phenylquinoline-2-carboxylic acid 96 (0.50 g, 1.90 mmol) and phenethylamine (7.10 mL, 
57.0 mmol) and  gave 3-methyl-4-phenylquinoline-2-N-phenethylcarboxamide as a yellow 
oil (0.51 g, 74%); νmax/cm–1 (NaCl) 3392 (NH), 2929 (CH), 1670 (CO), 1486, 1213, 765; 
δH (400 MHz, CDCl3) 2.41 (3H, s, 3-CH3), 2.87 (2H, t, J 7.1 Hz, PhCH2), 3.61–3.69 (2H, 
m, NHCH2), 7.04 (2H, d, J 8.0 Hz, Ar H), 7.10–7.13 (1H, m, Ar H) 7.19–7.27 (5H, m, Ar 
H), 7.32–7.39 (3H, m, Ar H), 7.46 (1H, t, J 8.0 Hz, Ar H), 7.84 (1H, d, J 8.0 Hz, Ar H), 
8.17 (1H, br t, J 5.2 Hz, Ar H); δC (100 MHz, CDCl3) 16.9 (CH3), 35.2 (CH2), 40.3 (CH2), 
123.1 (CH), 125.0 (CH), 125.4 (CH), 126.5 (CH), 126.9 (CH), 127.0 (CH), 127.3 (4 × CH), 
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127.7 (2 × CH), 128.6 (2 × CH), 128.9 (C), 136.3 (C), 138.3 (C), 143.8 (C), 148.6 (C), 
149.3 (C), 165.1 (C), 166.1(C); m/z (EI) 366.1736 (M+. C25H22N2O requires 366.1732), 
275 (78%), 218 (100), 140 (14), 82 (52). 
 
3-Methyl-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide 101 
 
N
N
O
101  
 
The reaction was carried out according to general procedure 4 using 3-methyl-4-
phenylquinoline-2-N-benzylcarboxamide (0.30 g, 0.85 mmol) and methyl iodide (0.85 mL, 
13.6 mmol) and gave 3-methyl-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide 101 
as a yellow oil (0.25 g, 80%). NMR spectra showed a 1:1 mixture of rotamers, only signals 
for one rotamer is recorded; νmax/cm–1(NaCl) 2925 (CH), 1643 (CO), 1454, 1263, 765; δH 
(400 MHz, CDCl3) 2.24 (3H, s, 3-CH3), 2.83 (3H, s, NCH3), 4.48 (2H, s, NHCH2), 7.22–
7.31 (4H, m, Ar H), 7.34–7.41 (4H, m, Ar H) 7.44–7.55 (4H, m, Ar H), 7.62–7.67 (1H, m, 
Ar H), 8.12 (1H, d, J 8.4 Hz, Ar H); δC (100 MHz, CDCl3) 15.0 (CH3), 34.3 (CH3), 53.5 
(CH2), 123.9 (C), 124.9 (CH), 125.9 (CH), 126.6 (CH), 126.8 (CH), 127.0 (2 × CH), 127.4 
(4 × CH), 127.8 (2 × CH), 127.9 (C), 128.1 (CH), 128.3 (CH), 135.2 (C), 135.6 (C), 144.7 
(C), 147.1 (C), 154.5 (C), 168.3 (C); m/z (EI) 366.1733 (M+. C25H22N2O requires 
366.1732), 219 (14%), 120 (12), 82 (100). 
 
3-Methyl-4-phenylquinoline-2-N-methyl-N-phenethylcarboxamide 103 
 
N
N
O
103
 
The reaction was carried out according to general procedure 4 using 3-methyl-4-
phenylquinoline-2-N-benzylcarboxamide (0.30 g, 0.85 mmol) and methyl iodide (1.03 mL, 
16.6 mmol) and gave 3-methyl-4-phenylquinoline-2-N-methyl-N-phenethylcarboxamide 
  115
103 as a yellow oil (0.36 g, 91%). NMR spectra showed a 1:1 mixture of rotamers, only 
signals for one rotamer is recorded. νmax/cm–1 (NaCl) 2928 (CH), 1643 (CO), 1486, 1054, 
765; δH (400 MHz, CDCl3) 2.84 (3H, s, 3-CH3), 3.10 (2H, t, J 7.6 Hz, PhCH2), 3.23 (3H, s, 
NCH3), 3.48 (2H, t, J 7.6 Hz, NCH2), 6.94 (1H, d, J 7.2 Hz, Ar H) 7.10–7.17 (2H, m, Ar 
H), 7.18–7.25 (2H, m, Ar H), 7.28–7.35 (2H, m, Ar H), 7.39–7.41 (2H, m, Ar H), 7.45–
7.54 (3H, m, Ar H), 7.61–7.68 (1H, m, Ar H), 8.12 (1H, t, J 9.2 Hz, Ar H); δC (100 MHz, 
CDCl3) 16.1 (CH3), 32.7 (CH3), 33.4 (CH2), 52.7 (CH2), 124.9 (C), 125.6 (C), 126.1 (CH), 
126.5 (CH), 126.6 (CH), 126.9 (CH), 127.1 (CH),  128.1 (CH), 128.6 (4 × CH), 128.9 (2 × 
CH), 129.3 (2 × CH), 136.6 (C), 138.7 (C), 145.8 (C), 148.1 (C), 155.9 (C), 169.2 (C);  m/z 
(EI) 380.1887 (M+. C26H24N2O requires 380.1889), 323 (28%), 289 (59), 218 (100), 134 
(29), 91 (20). 
Ethyl 2-chloromethyl-4-phenylquinoline-3-carboxylate 11169  
N
Cl
CO2Et
111  
2-Aminobenzophenone 110 (4.00 g, 20.3 mmol) and ethyl 4-chloroacetoacetate 109 (3.34 
g, 20.3 mmol) were placed in a sealed tube with N,N-dimethylformamide (40 mL). 
Chlorotrimethylsilane (10.3 mL, 81.1 mmol) was then added dropwise, the tube was sealed 
and heated to 100 oC overnight. After cooling, the reaction mixture was diluted with water, 
extracted with dichloronethane, dried (MgSO4) and concentrated to dryness. Purification 
was carried out using flash column chromatography eluting with petroleum ether/ethyl 
acetate to give ethyl 2-chloromethyl-4-phenylquinoline-3-carboxylate 111 as yellow 
crystals (5.67 g, 85%). mp 109–111 °C (lit.,69 mp 111–112 °C); νmax/cm–1 (KBr) 2980 
(CH), 1720 (CO), 1566, 1487, 1404, 1301, 1232, 768; δH (400 MHz, CDCl3) 0.92 (3H, t, J 
7.1 Hz, OCH2CH3), 4.04 (2H, q, J 7.1 Hz, OCH2CH3), 5.04 (2H, s, CH2Cl), 7.35–7.37 (2H, 
m, Ar H), 7.48–7.52 (4H, m, Ar H), 7.63 (1H, d, J 8.3 Hz, Ar H), 7.77 (1H, t, J 7.2 Hz, Ar 
H), 8.14 (1H, d, J 8.3 Hz, Ar H); δC (100 MHz, CDCl3) 13.5 (CH3), 45.9 (CH2), 61.6 (CH2), 
126.1 (C), 126.3 (C), 126.7 (CH), 127.8 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 129.3 (CH), 
129.6 (CH), 130.8 (CH), 135.7 (C), 147.4 (C), 148.2 (C), 153.1 (C), 167.7 (C); m/z (EI) 
325.0868 (M+. C19H1635ClNO2 requires 325.0870), 280 (67%), 262 (61), 217 (63), 176 (22), 
151(11), 84 (100).  
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9-Phenylfuro[3,4-b]quinolin-1(3H)-one 12271 
N
O
O
122  
Ethyl 2-chloromethyl-4-phenylquinoline-3-carboxylate 111 (7.00 g, 21.5 mmol) was 
dissolved in 6 M hydrochloric acid (100 mL) and ethanol (100 mL) and heated under 
reflux for 9 days. The reaction mixture was concentrated to dryness and diluted with water 
(100 mL), made alkaline with solid sodium carbonate (pH ~ 8–9) and extracted with 
chloroform (100 mL). The organic layer was dried (MgSO4) and concentrated under 
vacuum. Purification was carried out by flash column chromatography eluting, with 
petroleum ether/ethyl acetate to give 9-phenylfuro[3,4-b]quinolin-1(3H)-one 122 as a 
yellow solid (5.15 g, 91%). mp 197–199 °C (lit.,71 mp 203–204 °C); νmax/cm–1 (neat) 3043 
(CH), 1764 (CO), 1604, 1582, 1495,1443, 1136, 1030, 777; δH (400 MHz, CDCl3) 5.46 
(2H, s, CH2), 7.45–7.47 (2H, m, Ar H) 7.58–7.61 (4H, m, Ar H), 7.89–7.93 (2H, m, Ar H), 
8.21 (1H, d, J 8.3 Hz, Ar H); δC (100 MHz, CDCl3) 68.9 (CH2), 112.8 (C), 126.4 (C), 
126.7 (C), 127.4 (CH), 127.6 (2 × CH), 128.7 (CH), 128.8 (CH), 129.1 (2 × CH), 130.9 
(CH), 131.9 (CH), 150.6 (C), 150.8 (C), 162.9 (C), 167.2 (C); m/z (FAB) 262.0867 (MH+. 
C17H12NO2 requires 262.0868), 232 (11%), 204 (18), 147 (14), 109 (14), 69 (57), 57 (100).  
2,3-Bis(hydroxymethyl)-4-phenylquinoline 12371 
N
OH
OH
123  
9-Phenylfuro[3,4-b]quinolin-1(3H)-one 122 (1.95 g, 7.47 mmol) was added to 
tetrahydrofuran (100 mL) and cooled to 0 °C. Lithium aluminium hydride (30.0 mL, 1.0 M 
in tetrahydrofuran) was then added slowly and the reaction mixture stirred at room 
temperature. After 1 h, the reaction was quenched with 1 M hydrochloric acid (pH~2) and 
the mixture extracted with ethyl acetate (2 × 50 mL), dried (MgSO4) and concentrated 
under vacuum. The residue was then dissolved in methanol (100 mL) and 10% palladium 
on carbon (1.00 g) was added. The reaction mixture was stirred at room temperature 
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overnight. The catalyst was removed by filtration, washed with hot methanol and the 
filtrate was concentrated to dryness under vacuum to give 2,3-bis(hydroxymethyl)-4-
phenylquinoline 123 as a white solid (1.33 g, 67%). mp 166–169 °C (lit.,71 mp 175–
177 °C); νmax/cm–1 (neat) 3420 (OH), 2991 (CH), 1570, 1441, 1022, 1005, 765; δH (400 
MHz, CD3OD) 4.62 (2H, s, CH2), 5.12 (2H, s, CH2) 7.33–7.36 (2H, m, Ar H), 7.39–7.47 
(2H, m, Ar H), 7.53–7.58 (3H, m, Ar H), 7.72 (1H, ddd, J 8.4, 6.8, 1.6 Hz, Ar H), 8.10 (1H, 
d, J 8.4 Hz, Ar H); δC (100 MHz, CD3OD) 59.1 (CH2), 64.7 (CH2), 127.8 (CH), 127.9 
(CH), 128.6 (C), 129.4 (CH), 129.5 (2 × CH), 129.6 (CH), 130.1 (CH), 130.8 (2 × CH), 
130.9 (C), 137.3 (C), 147.4 (C), 150.4 (C), 160.9 (C); m/z (CI) 266.1180 (MH+. C17H16NO2 
requires 266.1181), 264 (30%), 246 (23), 218 (6), 116 (3), 85 (6).  
9-Phenylfuro[3,4-b]quinolin-3(1H)-one 10771 
N
O
O
107  
2,3-Bis(hydroxymethyl)-4-phenylquinoline 123 (0.10 g, 0.38 mmol) was dissolved in 
chloroform (20 mL). Activated manganese dioxide (1.02 g, 11.7 mmol) was then added 
and the reaction mixture stirred at room temperature for 1 h. The reaction mixture was 
filtered through Celite® and washed with chloroform (100 mL) to give 9-phenylfuro[3,4-
b]quinolin-3(1H)-one 107 as a white solid (0.08 g, 80%). mp 174–176 °C; νmax/cm–1 (neat) 
3061 (CH), 1768 (CO), 1581, 1369, 1344, 1153, 1051, 1009, 767; δH (400 MHz, CDCl3) 
5.41 (2H, s, CH2), 7.45–7.48 (2H, m, Ar H), 7.57–7.69 (4H, m, Ar H), 7.85 (1H, ddd, J 8.4, 
6.8, 1.2 Hz, Ar H), 7.91 (1H, d, J 9.0 Hz, Ar H), 8.43 (1H, d, J 8.4 Hz, Ar H); δC (100 
MHz, CDCl3) 67.9 (CH2), 125.9 (CH), 127.9 (C), 128.9 (CH), 129.4 (2 × CH), 129.5 (2 × 
CH), 129.6 (CH), 130.7 (CH), 131.4 (CH), 132.3 (C), 133.6 (C), 143.9 (C), 144.3 (C), 
150.7 (C), 168.8 (C); m/z (EI) 261.0788 (M+. C17H11NO2 requires 261.0790), 217 (23%), 
204 (100), 176 (14), 151 (9), 95 (9), 84 (18).  
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3-Hydroxymethyl-4-phenylquinoline-2-N-diethylcarboxamide 12529 
N
OH
N
O
125  
The reaction was carried out according to general procedure 5 using 9-phenylfuro[3,4-
b]quinolin-3(1H)-one 107 (0.30 g, 1.15 mmol), diethylamine (0.12 g, 1.61 mmol) and 
trimethylaluminum (0.75 mL, 1.61 mmol) and gave 3-hydroxymethyl-4-phenylquinoline-
2-N-diethylcarboxamide 125 as yellow oil (0.25 g, 65%). νmax/cm–1 (neat) 3414 (OH), 2976 
(CH), 1614 (CO), 1485, 1269, 1068, 765; δH (400 MHz, CDCl3) 1.19 (3H, t, J 7.1 Hz, 
NCH2CH3), 1.28 (3H, t, J 7.1 Hz, NCH2CH3), 3.34 (2H, q, J 7.1 Hz, NCH2CH3), 3.60 (2H, 
q, J 7.1 Hz, NCH2CH3), 4.03 (1H, t, J 6.1 Hz, CH2OH), 4.32 (2H, d, J 6.1 Hz, CH2OH), 
7.36–7.49 (7H, m, Ar H), 7.64 (1H, ddd, J 8.4, 6.8, 1.6 Hz, Ar H), 8.04 (1H, d, J 8.4 Hz, 
Ar H); δC (100 MHz, CDCl3) 11.2 (CH3), 12.5 (CH3), 38.7 (CH2), 42.1 (CH2), 58.1 (CH2), 
124.1 (CH), 125.3 (C), 125.8 (C), 126.8 (2 × CH), 127.2 (C), 127.7 (CH), 128.1 (CH), 
128.2 (CH), 129.1 (2 × CH), 133.6 (CH), 144.5 (C), 147.6 (C), 153.4 (C), 168.1 (C); m/z 
(CI) 335.1759 (MH+. C21H23N2O2 requires 335.1760), 334 (54%), 317 (26), 262 (32), 234 
(6), 209 (4), 74 (26).  
3-Hydroxymethyl-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide 12494  
N
OH
N
O
124  
The reaction was carried out according to general procedure 5 using 9-phenylfuro[3,4-
b]quinolin-3(1H)-one 107 (0.30 g, 1.15 mmol), N-benzylmethylamine (0.20 g, 1.60 mmol) 
and trimethylaluminium (0.37 mL, 0.74 mmol) and gave 3-hydroxymethyl-4-
phenylquinoline-2-N-methyl-N-benzylcarboxamide 124 as a yellow oil (0.26 g, 59%). 
NMR spectra showed a 1:1 mixture of rotamers, only signals for one rotamer is recorded.  
νmax/cm–1 (neat) 3408 (OH), 2933 (CH), 1620 (CO), 1485, 1397, 1152, 1057, 729; δH (400 
MHz, CDCl3), 3.19 (3H, s, NCH3), 4.10 (1H, t, J 7.1 Hz, CH2OH), 4.44 (2H, d, J 7.1 Hz, 
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CH2OH), 4.73 (2H, s, NCH2Ph), 7.28–7.33 (4H, m, Ar H), 7.38–7.55 (8H, m, Ar H), 7.72–
7.76 (1H, m, Ar H), 8.09 (1H, d, J 8.4 Hz, Ar H); δC (100 MHz, CDCl3) 28.4 (CH3), 53.8 
(CH2), 58.5 (CH2), 125.5 (C), 126.3 (CH), 126.5 (CH), 126.6 (CH), 127.0 (CH), 127.2 (4 × 
CH), 127.4 (CH), 128.2 (CH), 128.5 (4 × CH), 129.4 (C), 133.9 (C), 135.1 (C), 144.9 (C), 
148.2 (C), 153.3 (C), 169.1 (C); m/z (CI) 383.1758 (MH+. C25H23N2O2 requires 383.1760), 
367 (19%), 336 (48), 262 (82), 219 (31), 178 (21), 122 (100), 91 (24).  
3-Hydroxymethyl-4-phenylquinoline-2-N-methyl-N-phenethylcarboxamide 126  
N
OH
N
O
126  
The reaction was carried out according to general procedure 5 using 9-phenylfuro[3,4-
b]quinolin-3(1H)-one 107 (0.30 g, 1.15 mmol), N-methylphenethylamine (0.20 g, 1.49 
mmol) and trimethylaluminium (0.37 mL, 0.74 mmol) and gave 3-hydroxymethyl-4-
phenylquinoline-2-N-methyl-N-phenethyl carboxamide 126 as yellow oil (0.24 g, 53%). 
NMR spectra showed a 1:1 mixture of rotamers, only signals for one rotamer is recorded.  
νmax/cm–1 (KBr) 3422 (OH), 2927 (CH), 1617 (CO), 1487, 1120, 1054, 1010, 701; δH (400 
MHz, CDCl3) 3.08 (2H, t, J 7.4 Hz, NCH2CH2Ph), 3.27 (3H, s, NCH3), 3.80 (1H, t, J 7.4 
Hz, NCH2CH2Ph), 3.93–3.97 (3H, m, CH2OH), 4.08 (1H, br s, CH2OH), 6.94 (1H, dd, J 
7.6, 2.0 Hz, Ar H), 7.07–7.15 (2H, m, Ar H), 7.32–7.37 (2H, m, Ar H), 7.40–7.43 (2H, m, 
Ar H), 7.47–7.56 (5H, m, Ar H), 7.72–7.77 (1H, m, Ar H), 8.15 (1H, d, J 14.4, 8.0 Hz, Ar 
H); δC (100 MHz, CDCl3) 33.4 (CH3), 34.6 (CH2), 52.8 (CH2), 59.3 (CH2), 126.6 (CH), 
126.7 (CH), 127.0 (CH), 127.5 (CH), 127.6 (CH), 127.7 (C), 128.4 (2 × CH), 128.6 (4 × 
CH), 129.0 (C), 129.4 (CH), 129.8 (2 × CH), 135.2 (C), 138.0 (C), 145.8 (C), 149.3 (C), 
154.4 (C), 170.0 (C); m/z (CI) 397.1917 (MH+. C26H25N2O2 requires 397.1916), 381 (49%), 
367 (42), 290 (94), 264 (92), 220 (42), 164 (22), 136 (100).  
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3-Iodomethyl-4-phenylquinoline-2-N-diethylcarboxamide 127 
N
I
N
O
127  
The reaction was carried out according to general procedure 6 using 3-hydroxymethyl-4-
phenylquinoline-2-N-diethylcarboxamide 125 (0.16 g, 0.48 mmol) and oxalyl chloride 
(0.77 mL, 10.5 mmol), followed by sodium iodide (0.43 g, 2.83 mmol) and  gave 3-
iodomethyl-4-phenylquinoline-2-N-diethylcarboxamide 127 as yellow oil (0.12 g, 56%). 
νmax/cm–1 (neat) 2978 (CH), 1626 (CO), 1560, 1481, 1267, 1067, 702; δH (400 MHz, 
CDCl3) 1.33–1.43 (6H, m, 2 × NCH2CH3), 3.30 (2H, q, J 7.2 Hz, NCH2CH3), 3.69 (2H, q, 
J 7.2 Hz, NCH2CH3), 4.61 (2H, s, CH2I), 7.33–7.36 (1H, m, Ar H), 7.40–7.47 (3H, m, Ar 
H), 7.51–7.60 (3H, m, Ar H), 7.69 (1H, ddd, J 8.4, 6.8, 1.2 Hz, Ar H), 8.09 (1H, d, J 8.4 
Hz, Ar H); δC (100 MHz, CDCl3) 0.0 (CH2), 12.4 (CH3), 13.4 (CH3), 39.3 (CH2), 43.9 
(CH2), 126.6 (CH), 127.4 (CH), 127.7 (C), 128.5 (2 × CH and C), 128.6 (2 × CH), 128.7 
(CH), 129.6 (CH), 129.9 (CH), 135.1 (C), 145.8 (C), 148.4 (C), 155.3 (C), 167.9 (C); m/z 
(FAB) 445.0782 (MH+. C21H22IN2O requires 445.0777), 401 (11%), 327 (22), 317 (98), 
281 (56), 217 (38), 148 (5), 85 (8).  
3-Iodomethyl-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide 1285 
N
I
N
O
128  
The reaction was carried out according to general procedure 6 using 3-hydroxymethyl-4-
phenylquinoline-2-N-methyl-N-benzylcarboxamide 124 (0.10 g, 0.26 mmol) and oxalyl 
chloride (0.40 mL, 5.76 mmol), followed by sodium iodide (0.08 g, 0.5 mmol) and gave 3-
iodomethyl-4-phenylquinoline-2-N-methyl-N-benzylcarboxamide 128 as a yellow oil (0.05 
g, 39%). NMR spectra showed a 2:1 mixture of rotamers, only signals for the major 
rotamer is recorded. νmax/cm–1 (neat) 2962 (CH), 1631 (CO), 1485, 1260, 1052, 699; δH 
(400 MHz, CDCl3) 2.98 (3H, s, NCH3), 4.65 (2H, s, CH2I) 4.96 (2H, s, NCH2Ph), 7.30–
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7.37 (2H, m, Ar H), 7.39–7.48 (5H, m, Ar H), 7.53–7.60 (4H, m, Ar H), 7.64–7.73 (2H m, 
Ar H), 8.12 (1H, d, J 8.3 Hz, Ar H); δC (100 MHz, CDCl3) 0.3 (CH2), 36.6 (CH3), 55.7 
(CH2), 126.7 (CH), 127.9 (CH), 128.2 (C), 128.4 (C), 128.6 (2 × CH), 128.7 (4 × CH), 
128.8 (2 × CH), 129.0 (CH), 129.6 (CH), 129.7 (CH), 130.2 (CH), 135.2 (C), 136.5 (C), 
146.0 (C), 148.7 (C), 155.0 (C), 168.6 (C); m/z (FAB) 493.0765 (MH+. C25H22IN2O 
requires 493.0777), 365 (8%), 327 (7), 281 (28), 222 (14), 208 (19), 148 (38), 75 (100).  
3-Iodomethyl-4-phenylquinoline-2-N-methyl-N-phenethylcarboxamide 129 
N
I
N
O
129  
The reaction was carried out according to general procedure 6 using 3-hydroxymethyl-4-
phenylquinoline-2-N-methyl-N-phenethylcarboxamide 126 (0.04 g, 0.12 mmol) and oxalyl 
chloride (0.18 mL, 2.38 mmol), followed by sodium iodide (0.11 g, 0.70 mmol) and gave 
3-iodomethyl-4-phenylquinoline-2-N-methyl-N-phenethylcarboxamide 129 as yellow oil 
(0.02 g, 53%). NMR spectra showed a 1:1 mixture of rotamers, only signals for one 
rotamer is recorded. νmax/cm–1 (neat) 2962 (CH), 1636 (CO), 1561, 1486, 1394, 1261, 1055, 
701; δH (400 MHz, CDCl3) 3.08 (3H, s, NCH3), 3.15 (2H, t, J 8.8 Hz, NCH2CH2Ph), 3.87-
3.91 (2H, m, NCH2CH2Ph), 4.61 (2H, s, CH2I), 7.09–7.11 (1H, m, Ar H), 7.14–7.27 (2H, 
m, Ar H), 7.33–7.49 (6H, m, Ar H), 7.52–7.61 (3H, m, Ar H), 7.71–7.77 (1H, m, Ar H), 
8.10 (1H, dd, J 14.4, 8.0 Hz, Ar H); δC (100 MHz, CDCl3) 0.1 (CH2), 34.6 (CH2), 37.4 
(CH3), 49.5 (CH2), 126.3 (CH), 126.6 (CH), 127.5 (CH), 127.8 (C), 128.5 (4 × CH), 128.6 
(2 × CH), 128.7 (2 × CH), 128.9 (CH), 129.3 (CH), 129.9 (CH), 130.0 (C), 134.9 (C), 
138.5 (C), 145.6 (C), 148.3 (C), 154.8 (C), 168.1 (C); m/z (FAB) 507.0927 (MH+. 
C26H24IN2O requires 507.0933), 415 (6%), 397 (83), 323 (6), 287 (12), 217 (53), 135 (35), 
107 (28), 75 (17).  
 
 
 
 
  122
3-Methyl-4-phenylquinoline-2-N-(3-iodobenzyl)carboxamide 130 
N
N
H
O
I
130  
The reaction was carried out according to general procedure 3 using 3-methyl-4-
phenylquinoline-2-carboxylic acid 96 (0.25 g, 0.95 mmol) and 3-iodobenzylamine (0.63 
mL, 4.75 mmol) and gave 3-methyl-4-phenylquinoline-2-N-(3-iodobenzyl)carboxamide 
130 as a yellow oil (0.36 g, 80%); νmax/cm–1 (NaCl) 3380 (NH), 2927 (CH), 1670 (CO), 
1485, 1257, 764; δH (400 MHz, CDCl3) 2.61 (3H, s, 3-CH3), 4.66 (2H, d, J 6.0 Hz, NCH2), 
7.09 (1H, t, J 8.0 Hz, Ar H), 7.22–7.26 (2H, m, Ar H), 7.35–7.45 (3H, m, Ar H), 7.49–7.56 
(3H, m, Ar H), 7.61–7.67 (2H, m, Ar H), 7.78 (1H, s, Ar H), 8.06 (1H, d, J 8.0 Hz, Ar H), 
8.58 (1H, br t, J 6.0 Hz, NH); δC (100 MHz, CDCl3) 17.6 (CH3), 42.8 (CH2), 94.7 (C), 
126.2 (CH), 127.1 (CH), 127.8 (CH), 128.1 (CH), 128.7 (2 × CH), 128.8 (C), 129.0 (CH), 
129.3 (2 × CH), 129.4 (CH and C), 130.4 (CH), 136.5 (CH) 136.7 (CH), 137.1 (C), 141.1 
(C), 144.6 (C), 149.2 (C), 149.8 (C), 166.6 (C); m/z (CI) 479.0617 (MH+. C24H20IN2O 
requires 479.0620), 391 (8%), 353 (100), 263 (4), 220 (14), 136 (5), 79 (14).  
3-Methyl-4-phenylquinoline-2-N-(4-iodobenzyl)carboxamide 132 
N
N
H
O
I
132  
The reaction was carried out according to general procedure 3 using 3-methyl-4-
phenylquinoline-2-carboxylic acid 96 (0.25 g, 0.95 mmol) and 4-iodobenzylamine (0.63 
mL, 4.75 mmol) and gave 3-methyl-4-phenylquinoline-2-N-(4-iodobenzyl)carboxamide 
132 as a yellow oil (0.24 g, 53%). νmax/cm–1 (NaCl) 3378 (NH), 2927 (CH), 1670 (CO), 
1513, 1484, 1006, 761; δH (400 MHz, CDCl3) 2.46 (3H, s, 3-CH3), 4.51 (2H, d, J 6.0 Hz, 
NCH2), 7.04 (2H, d, J 8.0 Hz, Ar H), 7.09 (2H, d, J 8.0 Hz, Ar H), 7.22–7.24 (1H, m, Ar 
H) 7.28–7.32 (1H, m, Ar H), 7.36–7.49 (3H, m, Ar H), 7.50–7.54 (3H, m, Ar H), 7.91 (1H, 
d, J 8.0 Hz, Ar H), 8.53 (1H, br t, J 6.0 Hz, NH); δC (100 MHz, CDCl3) 17.7 (CH3), 43.1  
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(CH2), 92.8 (C), 126.3 (CH), 128.0 (CH), 128.7 (2 × CH), 128.9 (CH and C), 129.3 (CH), 
129.5 (CH), 129.8 (2 × CH), 130.9 (C), 131.8 (C), 137.2 (C), 137.8 (4 × CH), 138.4 (C), 
144.6 (C), 149.7 (C), 167.0 (C); m/z (EI) 478.0545 (M+. C24H19IN2O requires 478.0542), 
435 (8%), 351 (3), 308 (3), 232 (10), 219 (100), 189 (6), 91 (13).  
3-Methyl-4-phenylquinoline-2-N-methyl-N-(3-iodobenzyl)carboxamide 131 
N
N
O
I
131  
The reaction was carried out according to general procedure 4 using 3-methyl-4-
phenylquinoline-2-N-(3-iodobenzyl)carboxamide 130 (0.22 g, 0.46 mmol) and methyl 
iodide (0.46 mL, 7.36 mmol) and gave 3-methyl-4-phenylquinoline-2-N-methyl-N-(3-
iodobenzyl)carboxamide 131 as a yellow oil (0.17 g, 76%). NMR spectra showed a 1:1 
mixture of rotamers, only signals for one rotamer is recorded. νmax/cm–1 (NaCl) 2963 (CH), 
1640 (CO), 1485, 1260, 1019, 799; δH (400 MHz, CDCl3) 2.16 (3H, s, 3-CH3), 2.75 (3H, s, 
NCH3), 4.73 (2H, s, NCH2), 7.06 (1H, t, J 7.8 Hz, Ar H), 7.17–7.20 (2H, m, Ar H), 7.24 
(1H, d, J 7.8 Hz, Ar H), 7.30–7.37 (2H, m, Ar H), 7.41–7.48 (3H, m, Ar H), 7.53–7.63 (2H, 
m, Ar H), 7.69–7.74 (1H, m, ArH), 8.05 (1H, d, J 7.8 Hz Ar H); δC (100 MHz, CDCl3) 
16.1 (CH3), 35.6 (CH3), 49.7 (CH2), 94.6 (C), 125.1 (C), 125.6 (CH), 126.1 (CH), 127.2 
(CH), 127.7 (CH), 128.1 (2 × CH), 128.7 (CH), 129.0 (2 × CH), 129.3 (CH), 129.4 (CH), 
130.5 (C), 136.6 (C), 136.7 (CH), 136.9 (C), 137.2 (CH), 145.9 (C), 148.4 (C), 155.4 (C), 
169.5 (C); m/z (EI) 492.0700 (M+. C25H21IN2O requires 492.0699), 435 (18%), 266 (3), 
275 (3), 246 (22), 219 (100), 189 (6), 119 (7), 90 (7).  
3-Methyl-4-phenylquinoline-2-N-methyl-N-(4-iodobenzyl)carboxamide 133 
N
N
O
I
133  
The reaction was carried out according to general procedure 4 using 3-methyl-4-
phenylquinoline-2-N-(4-iodobenzyl)carboxamide 132 (0.14 g, 0.29 mmol) and methyl 
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iodide (0.30 mL, 4.69 mmol) and gave 3-methyl-4-phenylquinoline-2-N-methyl-N-(4-
iodobenzyl)carboxamide 133 as a colourless oil (0.13 g, 90%). NMR spectra showed a 1:1 
mixture of rotamers, only signals for one rotamer is recorded. νmax/cm–1 (neat) 2926 (CH), 
1644 (CO), 1485, 1399, 1052, 765; δH (400 MHz, CDCl3) 2.14 (3H, s, 3-CH3), 2.73 (3H, s, 
NCH3), 4.71 (2H, s, NCH2), 7.00 (1H, d, J 8.1 Hz, Ar H), 7.11–7.17 (3H, m, Ar H) 7.30–
7.33 (2H, m, Ar H), 7.39–7.46 (3H, m, Ar H), 7.54–7.61 (3H, m, Ar H), 8.03 (1H, d, J 8.1 
Hz, Ar H); δC (100 MHz, CDCl3) 15.0 (CH3), 34.4 (CH3), 48.8 (CH2), 92.2 (C), 123.9 (C), 
126.1 (CH), 127.0 (CH), 127.1 (2 × CH), 128.1 (2 × CH), 128.3 (C), 128.8 (CH), 129.4 (2 
× CH), 130.7 (CH), 130.8 (CH), 135.0 (C), 135.5 (C), 136.9 (2 × CH), 144.9 (C), 147.3 (C), 
154.4 (C), 168.5 (C); m/z (CI) 493.0778 (MH+. C25H22IN2O requires 493.0777), 445 (6%), 
409 (6), 367 (100), 309 (7), 277 (4), 220 (8).  
3-Hydroxymethyl-4-phenylquinoline-2-N-dimethylcarboxamide 142 
N
OH
N
O
142  
The reaction was carried out according to general procedure 5 using 9-phenylfuro[3,4-
b]quinolin-3(1H)-one 107 (0.15 g, 0.57 mmol) and dimethylamine (0.38 mL, 0.75 mmol) 
and trimethylaluminium (0.38 mL, 0.75 mmol) and gave 3-hydroxymethyl-4-
phenylquinoline-2-N-dimethylcarboxamide 142 as yellow oil (0.11 g, 60%). δH (400 MHz, 
CDCl3) 3.05 (3H, s, NCH3), 3.17 (3H, s, NCH3), 4.00-4.06 (1H, m, CH2OH), 4.34 (2H, s, 
CH2OH), 7.33–7.48 (7H, m, Ar H), 7.62–7.66 (1H, m, Ar H), 8.03 (1H, d, J 8.4 Hz, Ar H); 
δC (100 MHz, CDCl3) 37.5 (CH3), 39.2 (CH3), 67.9 (CH2), 125.8 (CH), 127.6 (CH), 128.5 
(2 × CH), 128.9 (CH), 129.4 (2 × CH), 130.7 (CH), 131.5 (CH), 133.5 (C), 135.2 (C), 
144.3 (C), 146.1 (C), 150.7 (C), 154.7 (C), 170.0 (C);  m/z (CI) 307.1444 (MH+. 
C19H19N2O2 requires 307.1447), 262 (100%), 220 (19), 137 (4), 71 (25) 
 
 
 
 
  125
3-Hydroxymethyl-4-phenylquinoline-2-N-morpholincarboxamide 143 
N
OH
N
O
143
O
 
The reaction was carried out according to general procedure 5 using 9-phenylfuro[3,4-
b]quinolin-3(1H)-one 107 (0.07 g,  0.27 mmol) and morpholine (0.03 mL, 0.75 mmol) and 
trimethylaluminium (0.03 mL, 0.34 mmol) and gave 3-hydroxymethyl-4-phenylquinoline-
2-N-morpholincarboxamide 143 as yellow oil (0.08 g, 86%). δH (400 MHz, CDCl3) 3.55–
3.57 (2H, m, NCH2CH2O), 3.66–3.69 (2H, m, NCH2CH2O), 3.78–3.83 (2H, m, 
NCH2CH2O), 3.87–3.90 (2H, m, NCH2CH2O), 4.03 (2H, d, J 6.5 Hz, CH2OH), 7.32–7.37 
(2H, m, Ar H), 7.42–7.51 (5H, m, Ar H),7.62–7.69 (1H, m, Ar H), 8.04 (1H, d, J 8.4 Hz, 
Ar H). 
3-Iodomethyl-4-phenylquinoline-2-N-dimethylcarboxamide 138 
N
I
N
O
138  
The reaction was carried out according to general procedure 6 using 3-hydroxymethyl-4-
phenylquinoline-2-N-dimethylcarboxamide 142 (0.10 g, 0.31 mmol) and oxalyl chloride 
(0.52 mL, 7.18 mmol), followed by sodium iodide (0.20 g, 1.4 mmol) and gave 3-
iodomethyl-4-phenylquinoline-2-N-dimethylcarboxamide 138 as yellow oil (0.01 g, 15%). 
νmax/cm–1 (neat) 2927 (CH), 1625 (CO), 1485, 1390, 1168, 1058, 757; δH (400 MHz, 
CDCl3) 3.09 (3H, s, NCH3), 3.26 (3H, s, NCH3) 4.61 (2H, s, CH2I), 7.36–7.48 (4H, m, Ar 
H), 7.55–7.61 (3H, m, Ar H), 7.69–7.74 (1H, m, Ar H), 8.09 (1H, d, J 8.4, Hz, Ar H); δC 
(100 MHz, CDCl3) 0.0 (CH2), 35.0 (CH3), 39.2 (CH3), 126.5 (CH), 127.5 (CH), 128.1 (C), 
128.4 (2 × CH and C), 128.5 (2 × CH), 128.6 (CH), 129.2 (CH), 130.0 (CH), 134.9 (C), 
145.6 (C), 148.4 (C), 155.0 (C), 168.2 (C); m/z (CI) 417.0459 (MH+. C19H18IN2O requires 
417.0464), 291 (100%), 220 (5), 137 (10).   
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3-Iodomethyl-4-phenylquinoline-2-N-morpholinecarboxamide 139 
N
I
N
O
O
139  
The reaction was carried out according to general procedure 6 using 3-hydroxymethyl-4-
phenylquinoline-2-N-morpholinecarboxamide 143 (0.10 g, 0.31 mmol) and oxalyl chloride 
(0.30 mL, 4.17 mmol), followed by sodium iodide (0.12 g, 0.82 mmol) and gave 3-
iodomethyl-4-phenylquinoline-2-N-morpholinecarboxamide 139 as yellow oil (0.01 g, 
21%). νmax/cm–1 (neat) 2847 (CH), 1628 (CO), 1617, 1468, 1246, 1011, 765; δH (400 MHz, 
CDCl3) 3.57 (2H, t, J 4.8 Hz, NCH2CH2O), 3.85 (2H, t, J 4.8 Hz, NCH2CH2O), 3.90–4.00 
(4H, m, 2 × NCH2CH2O), 4.58 (2H, s, CH2I), 7.35–7.41 (3H, m, Ar H), 7.44–7.48 (1H, m, 
Ar H), 7.53–7.61 (3H, m, Ar H), 7.72 (1H, ddd, J 8.2, 5.6, 1.2 Hz, Ar H), 8.09 (1H, d, J 8.2 
Hz, Ar H); δC (100 MHz, CDCl3) 0.0 (CH2), 42.0 (CH2), 47.4 (CH2), 66.1 (CH2), 66.3 
(CH2), 126.5 (CH), 127.6 (CH), 128.3 (CH), 128.5 (C), 128.5 (2 × CH and C), 128.6 (2 × 
CH), 129.3 (CH), 130.0 (CH), 134.7 (C), 145.0 (C), 148.2 (C), 153.8 (C), 166.6 (C); m/z 
(FAB) 459.0571 (MH+. C21H20IN2O2 requires 459.0570), 410 (75%), 365 (95), 331 (100), 
262 (42), 126 (25). 
Ethyl 4-hydroxylquinoline-2-carboxylate 15095 
N
OH
150
CO2Et
 
Aniline 83 (4.30 mL, 47.5 mmol), diethyl oxalacetate 151 (10.0 g, 47.5 mmol), and p-
toluenesulfonic acid (9.05 g, 47.5 mmol) were dissolved in cyclohexane (300 mL) and the 
solution heated under Dean-Stark conditions for 40 h. The reaction mixture was cooled to 
room temperature and the solvent removed under reduced pressure. To the residual crude 
oil, polyphosphoric acid (21.0 g, 214 mmol) was added and the mixture heated at 120 °C 
for 1 h, forming a dark brown oil. This substance was cooled to room temperature and a 
20% aqueous sodium carbonate solution (800 mL) was added slowly to quench the excess 
acid and precipitate the product as a brown solid. The mixture was filtered and the solid 
dissolved in dichloromethane (50 mL). Water (50 mL) was added and the organic layer 
  127
extracted with dichloromethane (3 × 40 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The resulting dark brown solid was recrystallised 
from ethyl acetate and hexane to give ethyl 4-hydroxylquinoline-2-carboxylate 150 as a 
light brown solid (3.90 g, 40%). mp 198–200 °C (lit.,95 mp 213 °C); νmax/cm–1 (neat) 2924 
(CH), 1739 (CO), 1562, 1519, 1268; δH (400 MHz, CDCl3) 1.42 (3H, t, J 7.1 Hz, 
OCH2CH3), 4.46 (2H, q, J 7.1 Hz, OCH2CH3), 7.01 (1H, s, Ar H), 7.38 (1H, t, J 7.4 Hz, Ar 
H), 7.50 (1H, d, J 8.3 Hz, Ar H), 7.66 (1H, ddd, J 8.3, 6.8, 1.2 Hz, Ar H), 8.35 (1H, d, J 8.3 
Hz, Ar H), 9.43 (1H, br s, OH); δC (100 MHz, CDCl3) 14.1 (CH3), 63.3 (CH2), 111.6 (CH), 
118.4 (CH), 124.5 (CH), 126.3 (CH), 126.4 (C), 133.1 (CH), 136.6 (C), 139.1 (C), 163.0 
(C), 179.7 (C); m/z (EI) 217.0741 (M+ . C12H11NO3 requires 217.0739), 189 (6%), 171 (19), 
143 (100), 115 (24), 89 (20).  
Ethyl 4-bromoquinoline-2-carboxylate 14996 
N
Br
CO2Et
149  
Ethyl 4-hydroxylquinoline-2-carboxylate 150 (1.50 g, 6.90 mmol), phosphorous 
oxybromide (5.94 g, 20.7 mmol) and anhydrous potassium carbonate (2.87 g, 20.7 mmol) 
were dissolved in anhydrous acetonitrile (100 mL). The mixture was then heated to 92 °C 
under argon for 2 h, followed by cooling to room temperature and removal of the solvent 
under reduced pressure to form a brown solid. Water (200 mL) was added and the mixture 
extracted with ethyl acetate (100 mL). The organic layer was washed with water (3 × 150 
mL) and then dried (MgSO4). The solvent was removed under reduced pressure to give 
ethyl 4-bromoquinoline-2-carboxylate 149 as a dark brown solid (1.64 g, 85%). mp 91–
92 °C (lit.,96 mp 91–92 °C); νmax/cm–1 (neat) 2993 (CH), 1712 (CO), 1365, 1195, 756; δH 
(400 MHz, CDCl3) 1.50 (3H, t, J 7.1 Hz, OCH2CH3), 4.57 (2H, q, J 7.1 Hz, OCH2CH3), 
7.76 (1H, ddd, J 8.4, 7.0, 1.4 Hz, Ar H), 7.85 (1H, ddd, J 8.4, 7.0, 1.4 Hz, Ar H), 8.25 (1H, 
d, J 8.4 Hz, Ar H), 8.32 (1H, d, J 8.4 Hz, Ar H), 8.48 (1H, s, Ar H); δC (100 MHz, CDCl3) 
14.4 (CH3), 62.6 (CH2), 125.0 (CH), 126.6 (CH), 128.8 (C), 129.9 (CH), 131.1 (CH), 131.3 
(CH), 135.2 (C), 147.9 (C), 148.0 (C), 164.3 (C); m/z (EI) 280.9873 (M+. C12H1081BrNO2 
requires 280.9875), 281 (12%), 234 (13), 207 (100), 127 (60), 100 (14).  
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Ethyl 4-bromophenylquinoline-2-carboxylate 152 
N CO2Et
Br
152  
The reaction was carried out according to general procedure 1 using ethyl 4-
bromoquinoline-2-carboxylate 149 (1.50 g, 5.37 mmol) and 2-bromophenylboronic acid 
(1.40 g, 6.98 mmol) and gave ethyl 4-bromophenylquinoline-2-carboxylate 152 as a light 
yellow solid (1.35 g, 71%). mp 77–79 °C; νmax/cm–1 (neat) 2980 (CH), 1739 (CO), 1468, 
1266, 1140, 795, 736; δH (400 MHz, CDCl3) 1.37 (3H, t, J 7.2 Hz, OCH2CH3), 4.42–4.49 
(2H, m, OCH2CH3), 7.19–7.25 (2H, m, Ar H), 7.35 (1H, t, J 7.2 Hz Ar H), 7.42–7.48 (2H, 
m, Ar H), 7.63–7.70 (2H, m, Ar H), 7.99 (1H, s, Ar H), 8.28 (1H, d, J 8.4 Hz, Ar H); δC 
(100 MHz, CDCl3) 14.4 (CH3), 62.3 (CH2), 121.6 (CH), 123.0 (C), 125.7 (CH), 127.5 
(CH), 127.7 (CH), 128.7 (C), 129.8 (CH), 131.1 (2 × CH), 131.4 (CH), 133.1 (CH), 138.3 
(C), 147.8 (C), 147.9 (C), 148.7 (C), 165.5 (C); m/z (CI) 358.0264 (MH+. C18H1581BrNO2 
requires 358.0268), 356 (92%), 276 (100), 263 (13). 
4-Bromophenylquinoline-2-carboxylic acid 148 
N CO2H
Br
148  
The reaction was carried out according to general procedure 2 using ethyl 4-
bromophenylquinoline-2-carboxylate 152 (1.35 g, 3.79 mmol) and sodium hydroxide (0.23 
g, 5.69 mmol) and gave 4-bromophenylquinoline-2-carboxylic acid 148 as a light yellow 
solid (1.05 g, 84%). mp 68–70 °C;  νmax/cm–1 (neat) 2899 (CH), 1725 (CO), 1592, 1232, 
760, 728; δH (400 MHz, CDCl3) 7.33 (1H, dd, J 7.2, 1.6 Hz Ar H), 7.39–7.43 (1H, m, Ar 
H), 7.48–7.52 (1H, m, Ar H), 7.60–7.67 (2H, m, Ar H), 7.78 (1H, dd, J 8.0, 1.4 Hz, Ar H), 
7.86 (1H, ddd, J 8.4, 6.4, 1.4  Hz, Ar H), 8.20 (1H, s, Ar H), 8.24 (1H, d, J 8.4 Hz, Ar H); 
δC (100 MHz, CDCl3) 119.9 (CH), 122.8 (C), 126.2 (CH), 127.6 (CH), 128.6 (C), 129.3 
(CH), 129.8 (CH), 130.5 (CH), 130.9 (CH), 131.0 (CH), 133.2 (CH), 137.8 (C), 145.4 (C), 
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146.1 (C), 150.5 (C), 164.1 (C); m/z (EI) 326.9899 (M+. C16H1079BrNO2 requires 326.9895), 
283 (100%), 204 (95), 176 (45), 101 (20), 44 (21). 
4-Bromophenylquinoline-2-N-diethylcarboxamide 154 
N
Br
N
O
154  
The reaction was carried out according to general procedure 3 using 4-
bromophenylquinoline-2-carboxylic acid 148  (0.30 g, 0.90 mmol) and diethylamine (0.50 
mL, 4.50 mmol) and gave 4-bromphenylquinoline-2-N-diethylcarboxamide 154 as a light 
yellow solid (0.28 g, 80%). mp 111–113 °C; νmax/cm–1 (neat) 2943 (CH), 1620 (CO), 1550, 
1489, 1273, 771; δH (400 MHz, CDCl3) 1.25 (3H, t, J 7.2 Hz, NCH2CH3), 1.33 (3H, t, J 7.2 
Hz, NCH2CH3), 3.41–3.57 (2H, m, NCH2), 3.66 (2H, qd, J 6.8, 1.6 Hz, NCH2), 7.34–7.39 
(2H, m, Ar H), 7.44–7.48 (1H, m, Ar H), 7.51–7.52 (2H, m, Ar H), 7.55 (1H, s, Ar H), 
7.73–7.77 (2H, m, Ar H), 8.18 (1H, d, J 8.4 Hz, Ar H); δC (100 MHz, CDCl3) 13.0 (CH3), 
14.1 (CH3), 40.5 (CH2), 43.5 (CH2), 120.8 (CH), 123.0 (C), 125.8 (CH), 126.5 (C), 127.5 
(2 × CH), 129.9 (2 × CH), 130.1 (CH), 131.3 (CH), 133.0 (CH), 138.4 (C), 147.0 (C), 
148.3 (C), 154.4 (C), 168.6 (C); m/z (EI) 383.0761 (MH+. C20H3079BrN2O requires 
383.0759), 303 (100%), 265 (39), 204 (5), 69 (33).  
4-Bromophenylquinoline-2-N-morpholincarboxamide 155 
N
Br
N
O
O
155  
The reaction was carried out according to general procedure 3 using 4-
bromphenylquinoline-2-carboxylic acid 148  (0.30 g, 0.90 mmol) and morpholine (0.43 
mL, 4.50 mmol) and gave 4-bromphenylquinoline-2-N-morpholincarboxamide 155 as a 
yellow oil (0.21 g, 57%). νmax/cm–1 (neat) 2970 (CH), 1620 (CO), 1473, 1249, 1111, 771; 
δH (400 MHz, CDCl3) 3.74–3.91 (8H, m, NCH2CH2O), 7.36–7.41 (2H, m, Ar H), 7.46–
7.50 (1H, m, Ar H), 7.54–7.57 (2H, m, Ar H), 7.65 (1H, s, Ar H), 7.76–7.80 (2H, m, Ar H), 
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8.17 (1H, d, J 8.4 Hz, Ar H); δC (100 MHz, CDCl3) 42.9 (CH2), 47.9 (CH2), 66.9 (CH2), 
67.1 (CH2), 121.5 (CH), 123.0 (C), 125.9 (CH), 126.7 (C), 127.5 (CH), 127.9 (CH), 120.1 
(CH), 130.2 (2 × CH), 131.3 (CH), 133.0 (CH), 138.2 (C), 146.9 (C), 148.7 (C), 152.8 (C), 
167.4 (C); m/z (EI) 396.0468 (M+. C20H1779BrN2O2 requires 396.0473), 312 (8%), 283 (92), 
203 (88), 176 (24), 82 (100), 47 (19).  
4-Bromophenylquinoline-2-N-dimethylcarboxamide 153 
N
Br
N
O
153  
The reaction was carried out according to general procedure 3 using 4-
bromphenylquinoline-2-carboxylic acid 148  (0.40 g, 1.20 mmol) and dimethylamine (3.00 
mL, 6.00 mmol) and gave 4-bromphenylquinoline-2-N-dimethylcarboxamide 153 as a light 
yellow solid (0.25 g, 58%). mp 156–158 °C; νmax/cm–1 (neat) 2931 (CH), 1627 (CO), 1504, 
1396, 1257, 771; δH (400 MHz, CDCl3) 3.20 (6H, s, NCH3), 7.36–7.41 (2H, m, Ar H), 
7.44–7.48 (1H, m, Ar H), 7.50–7.53 (2H, m, Ar H), 7.60 (1H, s, Ar H), 7.74–7.90 (2H, m, 
Ar H), 8.18 (1H, d, J 8.4 Hz, Ar H); δC (100 MHz, CDCl3) 35.8 (CH3), 39.2 (CH3), 121.1 
(CH), 123.0 (C), 125.8 (CH), 126.5 (C), 127.5 (CH), 127.7 (CH), 129.5 (CH), 130.0 (CH), 
130.1 (CH), 131.3 (CH), 133.0 (CH), 138.0 (C), 146.9 (C), 148.5 (C), 153.8 (C), 168.9 (C); 
m/z (EI) 354.0366 (M+. C18H1579BrN2O requires 354.0368), 283 (72%), 203 (68), 176 (27), 
82 (100).  
4-Iodophenylquinoline-2-N-dimethylcarboxamide 145 
N
I
N
O
145  
A Schlenk tube was charged with copper iodide (0.01 g, 0.03 mmol) and sodium iodide 
(0.17 g, 1.13 mmol), evacuated and backfilled with argon.  N,N-dimethylethylenediamine 
(6.00 μL, 0.06 mmol) and 4-bromophenylquinoline-2-N-dimethylcarboxamide 153 (0.20 g, 
0.56 mmol) were dissolved in butan-1-ol (6 mL) and added to the Schlenk tube.  The 
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Schlenk tube was sealed with a Teflon valve and the reaction mixture stirred at 135 °C for 
72 h.  The reaction had not gone to completion therefore more equivalents of copper iodide 
(0.01 g, 0.03 mmol), sodium iodide (0.17 g, 1.13 mmol) and N,N-dimethylethylenediamine 
(6.00 μL, 0.06 mmol) were added and left for another 96 h.  The reaction was diluted with 
water, extracted with ethyl acetate (3 × 20 mL), dried (MgSO4) and concentrated to 
dryness. Purification was carried out by flash column chromatography, eluting with 
petroleum ether/ethyl acetate to give 4-iodophenylquinoline-2-N-dimethylcarboxamide 145 
as light yellow solid (0.06 g, 27%). mp 137–139 °C; νmax/cm–1 (neat) 2927 (CH), 1628 
(CO), 1505, 1397, 1087, 761; δH (400 MHz, CDCl3) 3.21 (6H, s, NCH3), 7.34–7.39 (2H, m, 
Ar H), 7.45–7.49 (1H, m, Ar H), 7.51–7.56 (2H, m, Ar H), 7.60 (1H, m, Ar H), 7.75–7.80 
(2H, m, Ar H), 7.62–7.60 (1H, dt, J 8.4, 1.0 Hz, Ar H); δC (100 MHz, CDCl3) 36.2 (CH3), 
39.3 (CH3), 121.1 (CH), 123.0 (C), 125.8 (CH), 126.5 (C),  127.5 (CH), 127.7 (CH), 129.8 
(2 × CH), 130.0 (CH), 131.2 (CH), 133.0 (CH), 138.2 (C), 146.8 (C), 148.4 (C), 153.8 (C), 
168.9 (C); m/z (FAB) 403.0311 (MH+. C18H16IN2O requires 403.0307), 335 (100%), 284 
(22), 203 (43), 162 (22), 75 (26). 
 
2-Iodo-4,5-dimethoxybenzoic acid 18797 
 
MeO
MeO
I
CO2H
187  
3,4-Dimethoxybenzoic acid 186 (5.00 g, 27.4 mmol), diacetoxyiodobenzene (0.90 g, 3.00 
mmol) and diiodine (0.90 g, 3.57 mmol) were added to a stirred solution of acetic acid 
(40.0 mL) and acetic anhydride (40.0 mL).  Sulfuric acid (5.00 mL) was then added slowly 
and the reaction mixture stirred at room temperature for 2.5 h.  Aqueous sodium sulfite 
(5%, 200 mL) was added to destroy excess diacetoxyiodobenzene and the unreacted 
diiodine was buffered with ammonium carbonate to neutralise the sulfuric acid.  The 
reaction mixture was filtered, the precipitate washed with water, air-dried and re-
crystallized using ethyl acetate.  2-Iodo-4,5-dimethoxybenzoic acid 187 was obtained as a 
light yellow solid (5.02 g, 60%). mp 193–195 °C (lit.,97 mp 204–205 °C);  νmax /cm–1 (neat) 
2990 (CH), 1688 (CO), 1508, 1269, 554; δH (400 MHz, CDCl3) 3.92 (3H, s, OCH3), 3.94 
(3H, s, OCH3), 7.45 (1H, s, Ar H), 7.64 (1H, s, Ar H); δC (100 MHz, CDCl3) 56.1 (CH3), 
56.4 (CH3), 85.8 (C), 114.7 (CH), 124.2 (CH), 124.3 (C), 148.7 (C), 152.7 (C), 170.4 (C);  
m/z (EI) 307.9550 (M+. C9H9IO4 requires 307.9546), 292 (29%), 236 (5), 138 (11), 82 (68).  
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Methyl 2-iodo-4,5-dimethoxybenzoate 18598 
 
MeO
MeO
I
CO2Me
185  
2-Iodo-4,5-dimethoxybenzoic acid 187 (4.50 g, 14.6 mmol) and thionyl chloride (2.6 mL, 
36.5 mmol) was added to methanol (60 mL) and heated under reflux for 18 h.  Next, the 
solvent was then removed and a solution of sodium hydrogen carbonate (100 mL) added to 
quench the reaction.  The product was extracted with ethyl acetate, dried (MgSO4) and 
concentrated under vacuum. Purification was carried out by flash column chromatography 
eluting, with petroleum ether/ethyl acetate to give methyl 2-iodo-4,5-dimethoxybenzoate 
185 as a white solid (4.31 g, 92%). mp: 98–100 °C (lit.,98 mp 105–107 °C);  νmax /cm–1 
(neat) 2955 (CH), 1718 (CO), 1506, 1107, 1024, 545; δH (400 MHz, CDCl3) 3.90 (3H, s, 
OCH3), 3.91 (3H, s, OCH3), 3.92 (3H, s, OCH3), 7.39 (1H, s, Ar H), 7.45 (1H, s, Ar H); δC 
(100 MHz, CDCl3) 51.7 (CH3), 55.5 (CH3), 55.7 (CH3), 84.1 (C), 113.3 (CH), 123.1 (CH), 
125.4 (C), 148.1 (C), 151.3 (C), 165.3 (C);  m/z (CI) 322.9779 (MH+. C10H12IO4 requires 
322.9780), 279 (5%), 197 (100), 183 (28), 113 (15), 85 (65). 
 
Methyl 1,2-dihydro-6,7-dimethoxyisoquinoline-3-carboxylate 183 
 
NH
O
MeO
MeO
CO2Me
183
 
Methyl 2-iodo-4,5-dimethoxybenzoate 185 (0.20 g, 0.60 mmol) and methyl-2-
acetamidoacrylate (0.13 g, 0.90 mmol) in acetonitrile (20 mL) was heated for 5 mins.  
Then palladium(II) acetate (0.02 g, 0.06 mmol), tetrabutylammonium chloride (0.14 g, 
0.50 mmol) and sodium hydrogen carbonate (0.13 g, 1.55 mmol) were added to the 
reaction mixture and heated under reflux overnight.  After 48 h, more palladium(II) acetate 
(0.02 g, 0.06 mmol) was added and heated under reflux for a further 48 h.  The reaction 
mixture was cooled to room temperature, diluted with water and extracted with ethyl 
acetate.  The organic phase was dried over MgSO4 and concentrated in vacuo.  Purification 
was carried out by flash column chromatography eluting with ethyl acetate/petroleum ether 
to give methyl 1,2-dihydro-6,7-dimethoxyisoquinoline-3-carboxylate 183 as a brown solid 
(0.10 g, 61%). mp 223–224 °C;  νmax /cm–1 (neat) 2956 (CH), 1732 (CO), 1512, 1259, 742; 
δH (400 MHz, CDCl3) 3.98 (3H, s, OCH3), 4.02 (3H, s, OCH3), 4.04 (3H, s, OCH3), 7.09 
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(1H, s, Ar H), 7.39 (1H, s, Ar H), 7.82 (1H, s, Ar H), 9.14 (1H, br s, NH); δC (100 MHz, 
CDCl3) 53.1 (CH3), 56.2 (CH3), 56.4 (CH3), 107.8 (CH), 108.0 (CH), 111.2 (CH), 122.7 
(C), 126.3 (C), 131.2 (C), 151.2 (C), 153.7 (C), 161.1 (C), 162.3 (C);  m/z (EI) 263.0798 
(M+. C13H13NO5 requires 263.0794), 248 (15%), 203 (17), 160 (22), 91 (16), 83 (35). 
 
Methyl 1-bromo-6,7-dimethoxyisoquinoline-3-carboxylate 188 
 
N
MeO
MeO
Br
CO2Me
188  
Methyl 1,2-dihydro-6,7-dimethoxyisoquinoline-3-carboxylate 183 (0.15 g, 0.57 mmol), 
potassium carbonate (0.63 g, 4.56  mmol), phosphorous oxybromide (1.30 g, 0.56 mmol) 
in dry acetonitrile (20 mL) were heated under reflux for 18 h. The reaction mixture was 
cooled to room temperature, and then concentrated in vacuo.  The residue was cautiously 
dispersed in water (20 mL) and the insoluble material was filtered, washed with water, 
dried and recrystallized using ethyl acetate. Methyl 1-bromo-6,7-dimethoxyisoquinoline-3-
carboxylate 188 was obtained as a light brown solid (0.13 g, 70%). mp: 192–194 °C;  νmax 
/cm–1 (neat) 2953 (CH), 1712 (CO), 1508, 1209, 713; δH (400 MHz, CDCl3) 4.03 (3H, s, 
OCH3), 4.07 (3H, s, OCH3), 4.11 (3H, s, OCH3), 7.14 (1H, s, Ar H), 7.57 (1H, s, Ar H), 
8.39 (1H, s, Ar H); δC (100 MHz, CDCl3) 52.9 (CH3), 56.4 (CH3), 56.5 (CH3), 106.4 (CH), 
107.1 (CH), 123.1 (CH), 126.6 (C), 133.3 (C), 139.8 (C), 142.7 (C), 153.0 (C), 154.0 (C), 
165.3 (C); m/z (CI) 326.0021 (MH+. C13H1379BrNO4 requires 326.0028), 300 (6), 248 (100), 
182 (7), 97 (31), 71 (91). 
 
4-(Benzyloxycarbonylamino)butanoic acid 19299  
 
N
H
O
O OH
O
192
4
3
2
1
 
γ-Aminobutyric acid 191 (3.00 g, 29.1 mmol) and 2 M sodium hydroxide (15.0 mL, 30.3 
mmol) were stirred in an ice bath.  Further, 2 M sodium hydroxide (15.0 mL, 30.3 mmol) 
and benzyl chloroformate (4.40 mL, 30.8 mmol) were added simultaneously to the stirred 
mixture.  The reaction mixture was stirred in an ice bath for 1 h and then at room 
temperature for an additional 1 h.  The reaction mixture was extracted with diethyl ether (3 
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× 50 mL), the aqueous layer acidified with 6 M hydrochloric acid (pH~3) and cooled in an 
ice bath.  The crystals formed were then filtered under suction, washed with 0.1 M 
hydrochloric acid (5.00 mL) and air dried to give 4-(benzyloxycarbonylamino)butanoic 
acid 192 as a white solid (7.06 g, 100%). mp 60–62 °C (lit.,99 mp 65–67 °C);  δH (400 MHz, 
CDCl3) 1.71–1.77 (2H, m, 3-H2), 2.30 (2H, t, J 7.2 Hz, 2-H2), 3.15 (2H, q, J 6.4 Hz, 4-H2), 
5.00 (2H, s, CH2Ph), 6.12 (1H, br s, NH), 7.21-7.30 (5H, m, Ar H); δC (100 MHz, CDCl3) 
25.0 (CH2), 31.2 (CH2), 40.3 (CH2), 66.9 (CH2), 128.1 (CH), 128.2 (2 × CH), 128.6 (2 × 
CH), 136.5 (C), 156.6 (C), 178.4 (C); m/z (EI) 237.1001 (M+. C12H15NO4 requires 
237.0999), 198 (3%), 165 (2), 108 (75), 91 (100), 79 (22).  
N-(3,4-Dimethoxyphenethyl)-4-(benzyloxycarbonylamino)butanamide 193 
 
NHO
N
H
O
O4
3
2
MeO
MeO
1
193  
 
4-(Benzyloxycarbonylamino)butanoic acid 192 (5.00 g, 21.1 mmol), 2-(3-4-
dimethoxyphenyl)ethylamine 173 (3.85 mL, 23.2 mmol) and 4-(dimethylamino)pyridine 
(0.25 g, 2.10 mmol) were stirred in dichloromethane (100 mL) at 0 °C.  Ethyl 3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (4.45 g,  23.2 mmol) was added and the 
reaction stirred for 2 h and then at room temperature overnight.  The mixture was 
concentrated in vacuo and the residue dissolved in ethyl acetate (100 mL) and water (100 
mL).  The organic layer was washed with water (3 × 100 mL), dried (MgSO4) and the 
filtrate concentrated in vacuo to give N-(3,4-dimethoxyphenethyl)-4-
(benzyloxycarbonylamino)butanamide 193 as a white solid (7.47 g, 89%). mp 84–86 °C; 
νmax/cm–1(neat) 3304 (NH), 2931 (CH), 1681 (CO), 1516, 1139, 669; δH (400 MHz, 
CDCl3) 1.77–1.84 (2H, m, 3-H2), 2.17 (2H, t, J 6.8 Hz, 2-H2), 2.76 (2H, t, J 7.0 Hz, 
PhCH2CH2), 3.18–3.22 (2H, m, 4-H2), 3.46–3.50 (2H, m, PhCH2CH2), 3.85 (6H, s, 2 × 
OCH3), 5.08 (3H, br s, CH2Ph, NH), 5.93 (1H, br s, NH), 6.72 (2H, m, Ar H), 6.79 (1H, d, 
J 8.4 Hz, Ar H), 7.34 (5H, s, Ar H); δC (100 MHz, CDCl3) 26.1 (CH2), 33.7 (CH2), 35.3 
(CH2), 40.3 (CH2), 40.8 (CH2), 55.9 (CH3), 60.0 (CH3), 66.7 (CH2), 111.3 (CH), 111.9 
(CH), 120.7 (CH), 128.1 (CH), 128.2 (CH), 128.6 (2 × CH), 131.4 (C), 136.5 (C), 147.7 
(C), 149.1 (C), 156.9 (C), 172.5 (C); m/z (EI) 400.2003 (M+. C22H28N2O5 requires 
400.1998), 292 (9%), 164 (99), 107 (24), 91 (75), 79 (25). 
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1-(Benzyloxycarbonylaminopropyl)-3-(3,4-dihydro-6,7-dimethoxyisoquinolin-1-yl) 
197 
 
N
MeO
MeO
N
H
O
O
1'
2'
3'
4
3
197  
3,4-Dimethoxyphenethyl 4-(benzyloxycarbonylamino)butanamide 193 (0.30 g, 0.75 
mmol) and  phosphorous oxychloride (5.00 mL) and heated under reflux for 18 h.  The 
reaction mixture was concentrated in vacuo and then cold 2 M sodium hydroxide (20.0 
mL) was added and subsequently extracted with dichloromethane (20.0 mL).  The organic 
phase was washed with water (3 × 20 mL), dried (MgSO4) and the dichloromethane layer 
was concentrated in vacuo. 1-(Benzyloxycarbonylaminopropyl)-3-(3,4-dihydro-6,7-
dimethoxyisoquinolin-1-yl) 197 was obtained as an yellow oil (0.21 g, 73%). νmax /cm–1 
(neat) 3325 (NH), 2935 (CH), 1714 (CO), 1514, 1257, 738; δH (400 MHz, CDCl3) 1.70–
1.78 (2H, m, 2’-H2), 2.22 (2H, t, J 7.6 Hz, 1’-H2), 2.85 (2H, t, J 7.1 Hz, 4-H2), 3.45 (2H, t, 
J 7.6 Hz, 3’-H2), 3.61 (2H, t, J 7.1 Hz, 3-H2), 3.73 (3H, s, OCH3), 3.77 (3H, s, OCH3), 5.17 
(2H, s, CH2Ph), 6.69–6.72 (2H, m, Ar H), 7.22–7.30 (3H, m, Ar H), 7.35–7.38 (2H, m, Ar 
H); δC (100 MHz, CDCl3) 19.5 (CH2), 26.7 (CH2), 37.2 (CH2), 47.2 (CH2), 54.7 (CH2), 
55.8 (CH3), 60.0 (CH3), 67.1 (CH2), 111.1 (CH), 112.6 (CH), 120.8 (CH), 128.1 (2 × CH), 
128.1 (C), 128.5 (2 × CH) 133.3 (C), 136.3 (C), 147.3 (C), 148.6 (C), 152.0 (C), 159.1 (C);  
m/z (FAB) 383.1961 (MH+. C22H27N2O4 requires 383.1971), 339 (10%), 250 (100), 243 
(96), 164 (95), 92 (52). 
 
3,4-Dimethoxy-β-nitrostyrene 20689 
 
MeO
MeO
NO2
206  
3,4-Dimethoxybenzaldehyde 202 (1.00 g, 6.00 mmol), nitromethane 203 (1.62 mL, 30.0 
mmol) and ammonium formate (0.46 g, 6.00 mmol) in toluene (20 mL) were heated under 
reflux for 18 h.  The resulting precipitate was separated and the filtrate was washed with 
water (2 × 20 mL), a saturated solution of sodium chloride (2 × 20 mL) and dried over 
MgSO4. 3,4-Dimethoxy-β-nitrostyrene 206 was obtained as a yellow solid (1.22 g, 97%). 
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mp 144–146 °C (lit.,89 mp 140–141 °C);  νmax /cm–1 (neat) 2831 (CH), 1597 (NO), 1481, 
1257, 964; δH (400 MHz, CDCl3) 3.93 (3H, s, OCH3), 3.95 (3H, s, OCH3), 6.92 (1H, d, J 
8.4 Hz Ar H), 7.01 (1H, s, Ar H), 7.18 (1H, d, J 8.4 Hz Ar H), 7.53 (1H, d, J 13.6 Hz 
CHCH), 7.97 (1H, d, J 13.6 Hz CHCH); δC (100 MHz, CDCl3) 56.0 (CH3), 56.2 (CH3), 
110.2 (CH), 111.4 (CH), 122.8 (C), 124.7 (CH), 135.2 (CH), 139.4 (CH) 149.6 (C), 152.8 
(C);  m/z (EI) 209.0689 (M+. C10H11NO4 requires 209.0688), 178 (7%), 162 (81), 119 (39), 
77 (59). 
3,4-Dimethoxy-α-methoxy-β-nitrostyrene 21089 
 
MeO
MeO
NO2
OMe
210  
3,4-Dimethoxy-β-nitrostryene 206 (0.50 g, 4.78 mmol) was stirred in methanol (5 mL) 
followed by the addition of 25% sodium methoxide (5 mL) and stirred for 2.5 h.  Next, 
glacial acetic acid (1 mL) was added and reaction stirred until a precipitate had formed. 
3,4-Dimethoxy-α-methoxy-β-nitrostyrene 210 was obtained as a yellow solid (0.48 g, 
84%). mp 106–108 °C (lit.,89 mp 104–106 °C); νmax/cm–1 (NaCl) 2937 (CH), 1593 (NO), 
1551, 1261, 808; δH (400 MHz, CDCl3) 3.27 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.91 (3H, 
s, OCH3) 4.39 (1H, dd, J 12.8, 3.2 Hz, CHH ), 4.60–4.65 (1H, m, CHOCH3), 4.89 (1H, dd, 
J 10.4, 3.6  Hz, CHH), 6.88–6.94 (3H, m, Ar H); δC (100 MHz, CDCl3) 56.0 (2 × CH3), 
57.0 (CH3), 79.9 (CH), 80.6 (CH2), 109.1 (CH), 111.3 (CH and C), 119.6 (CH), 128.3 (C), 
149.6 (C); m/z (EI) 241.0945 (M+. C11H15NO5 requires 241.0950), 209 (56%), 181 (100), 
151 (42). 
N-(3,4-Dimethoxyphenethyl)-4-(benzyloxycarbonylamino)butanamide 205 
 
 
NHO
N
H
O
O
32
MeO
MeO
1
OMe
205
3'
 
 
3,4-Dimethoxy-α-methoxy-β-nitrostyrene 210 (0.12 g, 0.50 mmol) was added to lithium 
aluminium hydride (1.50 mL, 1.50 mmol) in diethyl ether (10.0 mL). After 2 h, the 
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reaction was quenched with water and the diethyl ether layer, dried (MgSO4) and 
concentrated in vacuo to give 3,4-dimethoxy-β-methoxyphenethylamine 204. Next, 4-
(benzyloxycarbonylamino)butanoic acid 194 (0.10 g, 0.42 mmol), 3,4-dimethoxy-β-
methoxyphenethylamine 204 (0.10 g, 0.40 mmol) and 4-(dimethylamino)pyridine (0.01 g, 
0.04 mmol) were stirred in dichloromethane (5.00 mL) at 0 °C.  Ethyl 3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (0.13 g,  0.40 mmol) was then added 
and the reaction was stirred for 2 h and then at room temperature overnight.  The mixture 
was concentrated in vacuo and the residue dissolved in ethyl acetate (10 mL) and water (10 
mL).  The organic layer was washed with water (3 × 10 mL), dried (MgSO4) and the 
filtrate concentrated in vacuo to give 3,4-dimethoxyphenethyl 4-
(benzyloxycarbonylamino)butanamide 205 as a yellow oil (0.08 g, 37% over two steps); 
νmax/cm–1 (neat) 3366 (NH), 2931 (CH), 1654 (CO), 1515, 1261, 754; δH (400 MHz, 
CDCl3) 1.72–1.80 (2H, m, 2-H2), 2.14–2.17 (2H, m, 1-H2), 3.11–3.19 (5H, m, OCH3 and 3-
H2), 3.55–3.62 (1H, m, 3’-HH), 3.80 (6H, s, 2 × OCH3), 4.11–4.14 (1H, m, 3’-HH), 5.02 
(2H, s, CH2Ph), 5.11 (1H, br s, NH), 6.16 (1H, br s, NH), 6.75–6.77 (3H, m, Ar H), 7.23–
7.28 (5H, m, Ar H); δC (100 MHz, CDCl3) 24.9 (CH2), 32.7 (CH2), 39.4 (CH2), 44.7 (CH2), 
54.9 (2 × CH3), 55.6 (CH3), 65.6 (CH2), 81.0 (CH), 108.3 (CH), 109.9 (CH), 118.2 (CH), 
127.1 (CH), 127.5 (CH), 130.5 (C), 135.5 (C), 147.9 (C), 148.2 (C), 155.7 (C), 171.4 (C);  
m/z (CI) 431.2178 (MH+. C23H31N2O6 requires 431.2182), 399 (40%), 291 (100), 147 (31). 
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3.2 Radioligand binding methodology100 
Whole rat brains were obtained from male adult Sprague-Dawley rats and homogenised 
using a Polytron in ice-cold 50 mM Tris-base, pH 7.4. Homogenates were centrifuged at 
39100 g for 10 minutes at 4 °C and the resulting pellet was washed (2×) by centrifugation 
and resuspended. The final resuspension was stored at –50 °C until use.  
For determination of Ki values, triplicate aliquots of membrane suspensions (0.6–0.4 mg of 
protein) were incubated for 1.5 h at 4 °C in 50 mM Tris-base, pH 7.4, in the presence of 17 
concentrations of the competitor (range 3 pM–300 μM). Total incubation volume was 400 
μL, with only 1% ethanol. Non-specific binding was defined in the presence of 8 μM of 
[3H]-PK11195. Reactions were terminated by rapid filtration through Whatman GF/B glass 
fibre filters pre-soaked in 0.3% w/v polyethylenimine using a 24-well Brandel cell 
harvester. Filters received three rapid washes in ice-cold buffer and [3H] counts were 
determined by liquid scintillation analysis. Ki values were derived from nonlinear 
regression analysis using GraphPad Prism Version 4 (GraphPad Software Inc). 
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